WO2020032179A1 - Cd3陽性細胞の製造方法 - Google Patents
Cd3陽性細胞の製造方法 Download PDFInfo
- Publication number
- WO2020032179A1 WO2020032179A1 PCT/JP2019/031390 JP2019031390W WO2020032179A1 WO 2020032179 A1 WO2020032179 A1 WO 2020032179A1 JP 2019031390 W JP2019031390 W JP 2019031390W WO 2020032179 A1 WO2020032179 A1 WO 2020032179A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- positive
- agonist
- cell
- medium
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 49
- 210000004027 cell Anatomy 0.000 claims abstract description 685
- 238000000034 method Methods 0.000 claims abstract description 198
- 239000000556 agonist Substances 0.000 claims description 173
- 229940122738 CD3 agonist Drugs 0.000 claims description 118
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 106
- 108010056030 retronectin Proteins 0.000 claims description 105
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 101
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 101
- 239000000427 antigen Substances 0.000 claims description 100
- 108091007433 antigens Proteins 0.000 claims description 99
- 102000036639 antigens Human genes 0.000 claims description 99
- 230000027455 binding Effects 0.000 claims description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
- 108090000172 Interleukin-15 Proteins 0.000 claims description 55
- 102000003812 Interleukin-15 Human genes 0.000 claims description 50
- 239000012634 fragment Substances 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 238000012258 culturing Methods 0.000 claims description 41
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 39
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 108010067306 Fibronectins Proteins 0.000 claims description 31
- 102000016359 Fibronectins Human genes 0.000 claims description 31
- 108010002586 Interleukin-7 Proteins 0.000 claims description 30
- 102100021592 Interleukin-7 Human genes 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 27
- 230000004068 intracellular signaling Effects 0.000 claims description 24
- 230000004936 stimulating effect Effects 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 14
- 102000003810 Interleukin-18 Human genes 0.000 claims description 13
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 11
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 11
- 231100000617 superantigen Toxicity 0.000 claims description 11
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 10
- 102000013462 Interleukin-12 Human genes 0.000 claims description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 6
- 108010017987 CD30 Ligand Proteins 0.000 claims description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 4
- 239000003139 biocide Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 229940127174 UCHT1 Drugs 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 164
- 210000000170 cell membrane Anatomy 0.000 abstract description 9
- 239000002771 cell marker Substances 0.000 abstract description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 273
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 273
- 239000002609 medium Substances 0.000 description 154
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 97
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 97
- 108091008874 T cell receptors Proteins 0.000 description 96
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 93
- 108090000623 proteins and genes Proteins 0.000 description 88
- 230000000638 stimulation Effects 0.000 description 62
- 241000282414 Homo sapiens Species 0.000 description 50
- 230000003834 intracellular effect Effects 0.000 description 44
- 230000035755 proliferation Effects 0.000 description 44
- 230000014509 gene expression Effects 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 38
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 36
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 36
- 230000001472 cytotoxic effect Effects 0.000 description 36
- 238000012360 testing method Methods 0.000 description 36
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 31
- 229940088594 vitamin Drugs 0.000 description 31
- 229930003231 vitamin Natural products 0.000 description 31
- 235000013343 vitamin Nutrition 0.000 description 31
- 239000011782 vitamin Substances 0.000 description 31
- 238000012136 culture method Methods 0.000 description 29
- 150000003722 vitamin derivatives Chemical class 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 24
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 23
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 23
- 210000005259 peripheral blood Anatomy 0.000 description 23
- 239000011886 peripheral blood Substances 0.000 description 23
- 210000000130 stem cell Anatomy 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 21
- 239000012091 fetal bovine serum Substances 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 108700020467 WT1 Proteins 0.000 description 18
- 101150084041 WT1 gene Proteins 0.000 description 18
- 102100022748 Wilms tumor protein Human genes 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 238000012423 maintenance Methods 0.000 description 15
- 210000003071 memory t lymphocyte Anatomy 0.000 description 15
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 14
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 14
- -1 NANOG Proteins 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241001430294 unidentified retrovirus Species 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000007640 basal medium Substances 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000000539 dimer Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 210000004102 animal cell Anatomy 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000007758 minimum essential medium Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 9
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 102000043129 MHC class I family Human genes 0.000 description 8
- 108091054437 MHC class I family Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 102100033553 Delta-like protein 4 Human genes 0.000 description 7
- 241000588722 Escherichia Species 0.000 description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 7
- 108010075704 HLA-A Antigens Proteins 0.000 description 7
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000833 heterodimer Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 6
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 102000043131 MHC class II family Human genes 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 102000036693 Thrombopoietin Human genes 0.000 description 6
- 108010041111 Thrombopoietin Proteins 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 5
- 101150074155 DHFR gene Proteins 0.000 description 5
- 102100036462 Delta-like protein 1 Human genes 0.000 description 5
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 5
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 5
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 description 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 241000714474 Rous sarcoma virus Species 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 235000020776 essential amino acid Nutrition 0.000 description 5
- 239000003797 essential amino acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- 229960001471 sodium selenite Drugs 0.000 description 5
- 239000011781 sodium selenite Substances 0.000 description 5
- 235000015921 sodium selenite Nutrition 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 4
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 4
- 239000012826 P38 inhibitor Substances 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 4
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 description 4
- 229960002648 alanylglutamine Drugs 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical group 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229940123169 Caspase inhibitor Drugs 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 108020001019 DNA Primers Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 3
- 108010058607 HLA-B Antigens Proteins 0.000 description 3
- 108010052199 HLA-C Antigens Proteins 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102100034256 Mucin-1 Human genes 0.000 description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 239000000158 apoptosis inhibitor Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000013000 chemical inhibitor Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 229940065287 selenium compound Drugs 0.000 description 3
- 150000003343 selenium compounds Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 2
- JBNWDYGOTHQHOZ-UHFFFAOYSA-N 2-[5-[4-[(4-fluorophenyl)methyl]piperidine-1-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)N(CC1)CCC1CC1=CC=C(F)C=C1 JBNWDYGOTHQHOZ-UHFFFAOYSA-N 0.000 description 2
- XEOVWJYINDYNSM-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 XEOVWJYINDYNSM-UHFFFAOYSA-N 0.000 description 2
- BGIYKDUASORTBB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 BGIYKDUASORTBB-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 2
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 2
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 108700005092 MHC Class II Genes Proteins 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 2
- VSPFURGQAYMVAN-UHFFFAOYSA-N SB220025 Chemical compound NC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCNCC2)=N1 VSPFURGQAYMVAN-UHFFFAOYSA-N 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- MIJPAVRNWPDMOR-UHFFFAOYSA-N [2-(1,2-dihydroxyethyl)-3-hydroxy-5-oxo-2h-furan-4-yl] dihydrogen phosphate Chemical compound OCC(O)C1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 108010054176 apotransferrin Proteins 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- BVYZDBLMCKSKAT-UHFFFAOYSA-N 2,2,3,3-tetrahexyldecanoic acid Chemical compound CCCCCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)C(O)=O BVYZDBLMCKSKAT-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- RQVKVJIRFKVPBF-VWLOTQADSA-N 2-[[(2s)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C([C@H](N)CNC=1N(C(C(C=2C=C3C=CC=CC3=CC=2)=C(C=2C=CN=CC=2)N=1)=O)C)C1=CC=CC=C1 RQVKVJIRFKVPBF-VWLOTQADSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1-imidazolyl]-1-cyclohexanol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 238000009636 ATP test Methods 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032494 Clear cell adenocarcinoma of the ovary Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 108010072210 Cyclophilin C Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 description 1
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108010081208 RMFPNAPYL Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 101150031162 TM4SF1 gene Proteins 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100032802 Tetraspanin-8 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 108010022946 erythrogenic toxin Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001813 extracellular matrix secreting cell Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 201000001649 ovarian clear cell adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 101150024821 tetO gene Proteins 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Definitions
- the present invention provides a method for producing or expanding CD3-positive cells (or CD3-positive CD197-positive cells) comprising the step of culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.
- the present invention relates to a method and a kit for expanding CD3-positive cells.
- the present invention also relates to a method for maintaining CD3-positive cells as CD3-positive CD197-positive cells, including a step of stimulating a CD30 signal in CD3-positive cells, and a kit for maintaining CD3-positive cells as CD3-positive CD197-positive cells.
- Immunotherapy which has been shown to have a strong life-prolonging effect on cancers where conventional therapies fail, is becoming the mainstay of cancer treatment.
- CART therapy which transfers autologous T cells transfected with the anti-CD19 chimeric antigen receptor (CAR) gene, has shown a high complete remission rate for B-cell malignancies, and in 2017, B-cell acute lymphoblastic leukemia Two CART therapies for diffuse large B-cell lymphoma have been approved by the FDA. Many clinical trials are also underway for TCR-T cell therapy, which introduces a T cell receptor (TCR) gene that recognizes cancer cell antigens.
- TCR T cell receptor
- T-cell therapy using these patients' own (self) T cells involves T cell transport, genetic modification, cell culture, etc.
- off-the-shelf (all-in-one) allogeneic T-cell therapies is strongly sought after, because these processes make cost control and quality control more difficult, and they also lead to the loss of treatment opportunities for patients with advanced cancer.
- a CD8-positive Tc1 lymphocyte or a CD8-positive Tc2 lymphocyte is produced by contacting an anti-CD3 agonist antibody and an anti-CD30 agonist antibody with a T cell population.
- Patent Document 1 or obtaining a T cell population from a cancer patient, and contacting the T cell population with an anti-CD3 agonist antibody, an anti-CD28 antibody, and a VEGF inhibitor to expand culture of tumor-specific T cells (Patent Document 2) has been reported.
- T cells derived from healthy persons or patients have a limited proliferative ability, and the number of genetically modified T cells that can be produced from T cells that can be recovered by a single apheresis is limited.
- CCR7 CD197
- a cell surface marker for naive cells and memory T cells transiently increases, but disappears in the next few days. has been reported (Non-Patent Document 1).
- T cell persistence is important for in vivo antitumor activity.
- CART which is a memory T cell
- a high in vivo antitumor effect can be achieved. It has been reported that it was recognized (Non-Patent Document 2). Therefore, when CD197 expression of a cell population obtained as a result of expanding T cells was low, it was not suitable for cancer treatment.
- T cells differentiated T cells
- pluripotent stem cells such as iPS cells and ES cells
- iPS cells differentiated T cells
- ES cells derived from pluripotent stem cells that can proliferate infinitely in theory, so that the genetic modification is theoretically unlimited T cells can be produced.
- the method of expanding iPS cells while maintaining pluripotency requires high cost and involves technical difficulties, so iPS cells are expanded in large quantities and differentiated T cells,
- the method for obtaining CD197-positive T cells has its limitations. As a result, there is a need for another approach to obtaining large numbers of T cells, especially CD197 positive T cells.
- An object of the present invention is to provide a method for producing or expanding CD3-positive cells in which CD3 which is a T-cell marker is expressed on the cell membrane in order to stably supply differentiated T cells, particularly CD197-positive T cells.
- the present invention provides a method and a kit for expansion culture. It is another object of the present invention to provide a method for maintaining CD197-positive T cells and a kit for maintaining CD197-positive T cells.
- the present inventors have conducted intensive studies to achieve the above object, and as a result, using a medium containing an anti-CD30 agonist antibody on a culture vessel having immobilized anti-CD3 agonist antibody and RetroNectin (registered trademark). It has been found that when CD8-positive T cells (iPS cell-derived CD8-positive T cells) obtained from iPS cells into which a TCR gene has been introduced are cultured, the T cells can be efficiently proliferated. Furthermore, it was confirmed that repeated growth of the iPS cell-derived CD8-positive T cells by the culture method did not affect the proliferation efficiency of T cells or antigen-specific cytotoxic activity.
- the expression ratio of CD197 was higher than when the anti-CD30 agonist antibody was not used, and the expanded T cells were found to be central memory T cells. It was found that it exists as a cell.
- iPS cell-derived CD8-positive T cells human peripheral blood-derived CD8-positive T cells and iPS cell-derived CD8-positive T cells transfected with anti-CD19-CAR gene (iPS cell-derived anti-CD19-CART cells)
- iPS cell-derived anti-CD19-CART cells iPS cell-derived anti-CD19-CART cells
- a method for producing CD3-positive cells comprising a step (I) of culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.
- the method of [1] or [2], wherein the CD3-positive cells are derived from pluripotent stem cells.
- the pluripotent stem cells are iPS cells.
- the CD3-positive cells are CD3-positive cells expressing a chimeric antigen receptor.
- the CD3-positive cells are CD3-positive CD8-positive cells.
- the CD3-positive CD8-positive cells are CD3-positive CD8-positive CD4-negative cells.
- the CD3-positive cells are ⁇ TCR-positive and / or ⁇ TCR-positive cells.
- CD3 / TCR complex agonist is a CD3 agonist and / or a TCR agonist.
- the CD3 agonist is an anti-CD3 agonist antibody or a binding fragment thereof.
- the anti-CD3 agonist antibody or a binding fragment thereof is an anti-CD3 agonist antibody or a binding fragment thereof produced from a UCHT1 clone.
- the TCR agonist is at least one selected from the group consisting of an anti-TCR antibody or a binding fragment thereof, an HLA / peptide complex or a multimer thereof, and an HLA / superantigen complex or a multimer thereof; The method according to [9].
- the immobilization of the anti-CD3 agonist antibody or the binding fragment thereof is performed by contacting the culture vessel with 1 ng / ml to 50,000 ng / ml of the anti-CD3 agonist antibody or the binding fragment thereof. ].
- Retronectin registered trademark
- the method according to any one of [1] to [14], wherein the fibronectin or its variant is Retronectin (registered trademark).
- the RetroNectin registered trademark
- the immobilization of the RetroNectin is performed by bringing 1 to 150 ⁇ g / mL of the RetroNectin (registered trademark) into contact with a culture vessel.
- the CD30 agonist is at least one selected from the group consisting of an anti-CD30 agonist antibody or a binding fragment thereof and a CD30 ligand or a binding fragment thereof. the method of. [19] The method according to [18], wherein the anti-CD30 agonist antibody or a binding fragment thereof is contained in a medium. [20] The method according to [19], wherein the concentration of the anti-CD30 agonist antibody or a binding fragment thereof in the medium is 1 ng / ml to 1000 ng / ml.
- a method for expanding CD3-positive cells comprising a step of culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.
- a kit for expanding CD3-positive cells comprising: (1) a culture vessel in which a CD3 / TCR complex agonist and fibronectin or a variant thereof are immobilized, and (2) a medium containing a CD30 agonist.
- a method for maintaining CD3-positive cells as CD3-positive CD197-positive cells comprising a step of stimulating a CD30 signal in the CD3-positive cells.
- a kit for maintaining CD3-positive cells as CD3-positive CD197-positive cells comprising a CD30 agonist.
- a chimeric antigen receptor comprising an antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the intracellular signaling domain comprises an intracellular signaling domain of CD30 or a variant thereof. body.
- a nucleic acid comprising a polynucleotide encoding the chimeric antigen receptor according to [35].
- a chimeric antigen receptor expression vector comprising the nucleic acid according to [36].
- a chimeric antigen receptor-expressing cell comprising the chimeric antigen receptor expression vector according to [37].
- the cell according to [38], wherein the cell expressing the chimeric antigen receptor is a CD3-positive cell.
- a medicament comprising the cell according to [38] or [39].
- the cell of [38] or [39] which is used for prevention or treatment of a tumor that expresses the antigen recognized by the chimeric antigen receptor of [35].
- [44] Use of the cell according to [38] or [39] for producing a prophylactic or therapeutic agent for a tumor that expresses an antigen recognized by the chimeric antigen receptor according to [35].
- T cells By culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist, T cells can be efficiently produced or expanded.
- CD3-positive cells produced or expanded by the above-described culture are CD197-positive cells, long-term efficacy can be expected when used in gene-modified T cell therapy.
- stimulating the CD30 signal of a CD3-positive cell the cell can be maintained as a CD197-positive cell for a long period of time.
- FIG. 3 is a diagram showing concentrations suitable for immobilization of an anti-CD3 agonist antibody and RetroNectin (registered trademark) measured by ELISA.
- FIG. 3 is a graph showing the number of iPSC-derived T cells (measured by ATP amount) on day 12 after stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark).
- FIG. 2 is a graph showing a proliferation curve of iPSC-derived T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) or anti-CD3 / CD28 beads.
- FIG. 3 is a diagram showing a proliferation curve for each stimulation frequency of iPSC-derived T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark).
- FIG. 3 is a diagram showing antigen-specific cytotoxic activity of iPSC-derived T cells proliferated by stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark).
- FIG. 2 is a graph showing the enhancement of proliferation of iPSC-derived T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) by addition of an anti-CD30 agonist antibody.
- the vertical axis indicates the number of cells, and the horizontal axis indicates the number of days elapsed from the day when the above-described stimulation was started.
- FIG. 14 is a diagram showing a proliferation curve of iPSC-derived T cells when the same stimulation (second stimulation) is performed again.
- the vertical axis indicates the number of cells, and the horizontal axis indicates the number of days elapsed from the day when the second stimulation was started.
- FIG. 3 is a view showing expression of CD45RA.
- FIG. 2 shows antigen-specific cytotoxic activity of iPSC-derived T cells proliferated by stimulation with immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) and anti-CD30 agonist antibody.
- FIG. 4 shows the proliferation curves of human peripheral blood-derived CD8 + T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin®, or immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody
- FIG. The vertical axis indicates the number of cells, and the horizontal axis indicates the number of days elapsed from the day when the above-described stimulation was started.
- FIG. 2 shows the expression of CD197 on the surface of human peripheral blood-derived CD8-positive T cell membrane after stimulation with anti-CD3 / CD28 beads containing various ILs and anti-CD30 antibodies.
- Human peripheral blood-derived CD8-positive T cells stimulated with anti-CD3 / CD28 beads containing various ILs and anti-CD30 antibodies were implanted intravenously into irradiated immunodeficient mice.
- FIG. 3 is a view showing the number of human CD8-positive T cells surviving therein.
- iPS-T iPS cell-derived T cells
- iPS-CART anti-CD19 iPS cell-derived anti-CD19-CART cells
- immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody It is a figure which shows a growth curve.
- the vertical axis indicates the number of cells, and the horizontal axis indicates the number of days elapsed from the day when the above-described stimulation was started.
- FIG. 4 shows the growth curves of iPS cell-derived anti-CD19-CART cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin®, or immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody
- the vertical axis indicates the number of cells, and the horizontal axis indicates the number of days elapsed from the day when the above-described stimulation was started.
- Immobilized anti-CD3 agonist antibody / RetroNectin®, or CD197 on iPS cell-derived anti-CD19-CART cell membrane stimulated by immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody It is a figure which shows an expression.
- FIG. 3 shows the cytotoxic activity of iPS cell-derived anti-CD19-CART cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) on CD19-expressing Raji cells by adding an anti-CD30 agonist antibody.
- FIG. 2 shows the cytotoxic activity of iPS cell-derived anti-CD19-CART cells containing a CD30-derived intracellular domain (iCD19-CD30-CART) on CD19-expressing Raji cells.
- FIG. 3 shows the cytotoxic activity of iPS cell-derived anti-CD19-CART cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) on CD19-expressing Raji cells by adding an anti-CD30 agonist antibody.
- FIG. 2 shows the cytotoxic activity of iPS cell-derived anti-CD19-CART cells containing a CD30-derived intracellular domain (iCD19-CD30-CART) on CD19-expressing Raji
- FIG. 3 is a diagram showing cell proliferation of ⁇ T cells (i ⁇ T cells) differentiated from non-T cell-derived iPS cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) by addition of an anti-CD30 agonist antibody. .
- the vertical axis indicates the cell growth rate, and the horizontal axis indicates the number of days elapsed from the day when the above-described stimulation was started.
- FIG. 4 shows cell proliferation of (iCAR ⁇ T cells) to anti-CD19-CAR ⁇ T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) by adding an anti-CD30 agonist antibody.
- FIG. 2 is a graph showing antigen-specific cytotoxic activity of iCD19CAR / IL-15 ⁇ T cells proliferated by stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark).
- FIG. 2 is a graph showing the effect of iCD19CAR / IL-15 ⁇ T cells proliferated by stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) to extend the survival days of human tumor-bearing mice expressing CD19.
- FIG. 2 is a graph showing antigen-specific cytotoxic activity of iCD19CAR / IL-15 ⁇ T cells proliferated by stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) to extend the survival days of human tumor-bearing mice expressing CD19.
- FIG. 2 is a diagram showing the antitumor effect of iCD19CAR / IL-15 ⁇ T cells proliferated by stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark).
- FIG. 2 is a diagram showing the concentrations suitable for immobilization of anti-CD3 agonist antibody (UCHT1) and RetroNectin (registered trademark), which were measured by ELISA.
- FIG. 4 is a graph showing the proliferation rate of iPSC-derived T cells on day 13 after stimulation with an immobilized anti-CD3 agonist antibody (UCHT1) / RetroNectin (registered trademark) and an anti-CD30 agonist antibody.
- expression of a gene means that mRNA is synthesized from a specific nucleotide sequence of the gene (also referred to as transcription or expression of mRNA) and that a protein is synthesized based on information of the mRNA ( (Also referred to as translation or protein expression), unless otherwise noted, “gene expression” or simply “expression” shall mean protein expression.
- “positive” means that the protein or mRNA is expressed in a detectable amount by a technique known in the art.
- the protein can be detected using an immunological assay using an antibody, for example, an ELISA method, an immunostaining method, a Western blot method, or flow cytometry.
- a target protein can be detected by expressing a reporter protein together with the protein and detecting the reporter protein.
- detecting the function of the relevant protein for example, if the relevant protein is a transcription factor, detect a gene whose expression controls the gene; if the relevant protein is an enzyme, detect a substrate or a product catalyzed by the relevant protein.
- the detection of mRNA can be performed using a nucleic acid amplification method and / or a nucleic acid detection method such as RT-PCR, microarray, biochip, and RNAseq.
- negative means that the expression level of the protein or mRNA is less than the lower limit of detection by all or any of the above-mentioned known methods.
- the lower limit of detection of protein or mRNA expression may vary depending on each technique.
- culturing refers to maintaining, growing (growing), and / or differentiating cells in an in vitro environment. “Cultivating” means maintaining, growing (growing), and / or differentiating cells outside the tissue or body, for example, in a cell culture dish or flask.
- expansion culture means culturing for the purpose of expanding a desired cell population and increasing the number of cells.
- the increase in the number of cells may be achieved as long as the increase due to the proliferation of cells exceeds the decrease due to death, and it is not necessary that all cells in the cell population proliferate.
- the increase in cell number is 1.1 times, 1.2 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times compared to before the start of expansion culture. , 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 300-fold, 500-fold, 1,000-fold, 3,000-fold, 5,000-fold, 10,000-fold, 100,000-fold, 1,000,000-fold or more.
- stimulation means that a certain substance binds to various receptors and activates a downstream signal pathway.
- enrich refers to increasing the amount of a particular component in a composition, such as a composition of cells
- enriched refers to a composition of cells
- a composition such as a cell population
- a composition can be enriched for a target cell type, such that the percentage of the target cell type is relative to the percentage of target cells present in the cell population before being enriched.
- Cell populations can also be enriched for target cell types by cell selection and sorting methods known in the art. Cell populations can also be enriched by certain sorting or selection processes described herein.
- the method of enriching a target cell population causes the cell population to be at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85% relative to the target cell population. , 90%, 95%, 97%, 98% or 99% enriched.
- cell population means two or more cells of the same type or different types.
- Cell population also means a mass of cells of the same or different types.
- the present invention comprises a step of culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist, a method for producing CD3-positive cells or a method for expanding culture (hereinafter referred to as the present invention). Production method or expansion culture method).
- the CD3 / TCR complex agonist and the CD30 agonist can stimulate the CD3 / TCR complex and CD30, respectively.
- CD3-positive cells to be cultured are not particularly limited as long as they express CD3 on the cell membrane.
- the CD3 positive cells are preferably CD3 positive CD8 positive cells (CD3 positive CD8 positive CD4 positive cells or CD3 positive CD8 positive CD4 negative cells), more preferably CD3 positive CD8 positive CD4 negative cells.
- Another preferable example of the CD3-positive cell is a CD3-positive CD4-positive cell (CD3-positive CD4-positive CD8-positive cell or CD3-positive CD4-positive CD8-negative cell).
- the CD3-positive cells to be cultured may be CD30-positive before culture, or may be differentiated into CD30-positive during culture.
- the CD3-positive cells are CD30-positive before culture
- the CD3-positive cells are preferably CD3-positive CD8-positive CD30-positive cells (CD3-positive CD8-positive CD4-positive CD30-positive cells or CD3-positive CD8-positive CD4-negative CD30-positive cells), more preferably CD3-positive CD8-positive CD4-negative CD30-positive cells.
- Another preferable example of the CD3-positive cell is a CD3-positive CD4-positive CD30-positive cell (CD3-positive CD4-positive CD8-positive CD30-positive cell or CD3-positive CD4-positive CD8-negative CD30-positive cell).
- CD3 positive cells obtained as a result of production or expansion culture are not particularly limited as long as they express CD3 on the cell membrane, and the production method or the expansion culture method of the present invention And the same cells as the CD3-positive cells cultured in the above.
- the CD3-positive cells produced or expanded are preferably further CD197-positive.
- the cells specifically include CD3-positive CD8-positive CD197-positive cells (CD3-positive CD8-positive CD4-positive CD197-positive cells or CD3-positive CD8-positive CD4 Negative CD197-positive cells), more preferably CD3-positive CD8-positive CD4-negative CD197-positive cells.
- the cells are CD3 + CD4 + CD30 + CD197 + cells (CD3 + CD4 + CD8 + CD30 + CD197 + cells or CD3 + CD4 + CD8 + CD30 + CD197 + cells).
- CD3-positive cells CD197-positive cells are classified as stem cell memory T cells or central memory T cells depending on the presence or absence of CD45RA, and are T cells with high self-proliferation ability that can supply effector T cells. Suitable for anti-tumor immunity.
- the produced or expanded cultured CD3-positive cells are preferably further CD197-positive and CD45RA-negative.
- the cells are specifically CD3 + CD8 + CD197 + CD45RA-negative cells (CD3 + CD8 + CD4 + CD197 + CD45RA-negative cells) Or CD3 positive CD8 positive CD4 negative CD197 positive CD45RA negative cells), more preferably CD3 positive CD8 positive CD4 negative CD197 positive CD45RA negative cells.
- the cells are CD3 + CD4 + CD30 + CD197 + CD45RA-negative cells (CD3 + CD4 + CD8 + CD30 + CD197 + CD45RA-negative cells or CD3 + CD4 + CD8-negative CD30 + CD197 + CD45RA-negative cells).
- CD197-positive CD45RA-negative cells are also particularly called central memory T cells.
- CD3 is a molecule that is expressed during T cell maturation and forms a larger complex (CD3 / TCR complex) with the T cell receptor (T cell receptor (TCR)), and is also known as a T cell marker. And a complex of four types of polypeptides of ⁇ , ⁇ , ⁇ , and ⁇ chains.
- TCR which forms a complex with CD3
- TCR ⁇ is a molecule that transmits a signal into T cells
- TCR ⁇ is one of ⁇ chain (TCR ⁇ ), ⁇ chain (TCR ⁇ ), ⁇ chain (TCR ⁇ ) and ⁇ chain (TCR ⁇ )
- the dimer include a heterodimer composed of TCR ⁇ and TCR ⁇ ( ⁇ TCR), a heterodimer composed of TCR ⁇ and TCR ⁇ ( ⁇ TCR), and a homodimer composed of the same TCR chain.
- ⁇ TCR a heterodimer composed of TCR ⁇ and TCR ⁇
- ⁇ TCR a heterodimer composed of TCR ⁇ and TCR ⁇
- CD8 is expressed in the process of maturation of T cells like CD3, and is expressed together with CD4 in the early stage of maturation, but only CD4 expression is lost upon differentiation into cytotoxic T cells.
- CD8 functions as a co-receptor of the CD3 / TCR complex, and is a molecule that recognizes MHC class I / antigen peptides.
- CD4 also functions as a co-receptor for the CD3 / TCR complex, but unlike CD8, is a molecule that recognizes MHC class II / antigen peptides.
- CD30 is known as a molecule expressed on activated lymphocytes (T cells and B cells), has six cyctein-rich-pseudo-repeat-motifs as extracellular domains, and stimulates NF ⁇ B signal as an intracellular domain. TNF receptor-related factor (TRAF) binding sequence.
- CD197 and CD45RA are naive T cells or stem cell memory T cells (CD197 positive, CD45RA positive), central memory T cells (CD197 positive, CD45RA negative), effector memory T cells (CD197 negative, CD45RA negative), effector It has been used as a marker molecule to distinguish T cells (CD197 negative, CD45RA positive).
- CD3-positive cells to be cultured may be cells collected from mammals or cells obtained by differentiating pluripotent stem cells, but preferably, It is a cell obtained by differentiating pluripotent stem cells.
- the CD3-positive cells are cells collected from a mammal, for example, after collecting peripheral blood mononuclear cells (PBMC) from the mammal by apheresis, an anti-CD3 antibody column or density gradient centrifugation is used. Thereby, CD3-positive cells can be isolated and recovered.
- PBMC peripheral blood mononuclear cells
- mammals for recovering CD3-positive cells human or non-human animals (eg, dog, cat, mouse, rat, hamster, guinea pig, rabbit, pig, cow, goat, horse, sheep, monkey, etc.) And humans are preferred.
- the pluripotent stem cells include embryonic stem cells (embryonic stem cells: ES cells) and induced pluripotent stem cells (induced pluripotent stem cells: iPS cells), embryonic tumor cells (EC cells), and embryonic germ stem cells (EG cells), preferably ES cells or iPS cells (more preferably human iPS cells).
- the pluripotent stem cells are ES cells, they can be prepared by a method known per se.
- a method for preparing ES cells for example, a method of culturing an inner cell mass in a blastocyst stage of a mammal (for example, see Manipulating the Mouse Embryo: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994)) ), A method of culturing early embryos produced by somatic cell nuclear transfer (Wilmut et al., Nature, 385, 810 (1997); Cibelli et al., Science, 280, 1256 (1998); Akira Iritani et al., Protein nucleic acid Enzyme, 44, 892 (1999); Bagisi et al., Nature Biotechnology, 17, 456 (1999); Wakayama et al., Nature, 394, 369 (1998); Wakayama et al., Nature Genetics, 22, 127 (1999) Wakayama et al., Pro
- ES cells can be obtained from a predetermined organization, and further, commercially available products can be purchased.
- human ES cell lines include: WiCell Research Institute, USA for H1, H7, H9, H13 and H14, ES Cell International, Australia for HES1-6, Cellartis AB, HUES1 to Sweden for SA002, SA181 and SA611. 17 is available from the US HUES Cell Facility, KhES-1 to KhES-5 are available from the Kyoto University Institute for Regenerative Medicine, and SEES1 to SEES7 are available from the National Center for Child Health and Development.
- the type of somatic cells and the source for collecting the somatic cells are the same as those for the following iPS cell production.
- iPS cells can be prepared by introducing a nuclear reprogramming substance into somatic cells.
- Somatic cells that can be used as starting materials for producing iPS cells may be any cells other than germ cells derived from mammals (eg, mouse or human).
- keratinized epithelial cells eg, keratinized epidermal cells
- mucosal epithelial cells eg, epithelial cells of the tongue surface layer
- exocrine gland epithelial cells eg, mammary gland cells
- hormone-secreting cells eg, adrenal medulla cells
- Cells for metabolism / storage eg, hepatocytes
- luminal epithelial cells that make up the interface eg, type I alveolar cells
- luminal epithelial cells of the endothelium eg, vascular endothelial cells
- transport Ciliated cells with function eg, airway epithelial cells
- extracellular matrix secreting cells eg, fibroblasts
- contractile cells eg, smooth muscle cells
- blood and immune system cells eg, T Lymphocytes
- sensory cells eg, rod cells
- autonomic nervous system neurons eg, cholinergic neurons
- the undifferentiated progenitor cells include, for example, tissue stem cells (somatic stem cells) such as adipose-derived stromal (stem) cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, and dental pulp stem cells.
- tissue stem cells such as adipose-derived stromal (stem) cells
- neural stem cells such as adipose-derived stromal (stem) cells
- hematopoietic stem cells such as mesenchymal stem cells, and dental pulp stem cells.
- the protein encoded by the reprogramming gene can also be introduced into somatic cells as a nuclear reprogramming substance (Cell Stem Cell, 4: 381-384 (2009), Cell Stem Cell, doi: 10.1016 / j. stem.2009.05.005 (2009)).
- somatic cells a nuclear reprogramming substance
- a combination of three factors of Oct3 / 4, ⁇ Sox2 and Klf4 is preferable.
- iPS cell colonies are based on drug resistance and reporter activity as indicators (Cell, ⁇ 126, 663-676 ⁇ (2006), Nature, 448, 313-317 (2007)) or by visual morphological observation (Cell, 131, ⁇ 861-872 ⁇ (2007)). Confirmation of iPS cells can be performed using the expression of various ES cell-specific genes and teratoma formation as indices.
- iPSCs iPSCs
- Yamanaka et al. Established iPSCs (Takahashi by introducing Oct4 / 4, Sox2, Klf4, and c-Myc four factors into mouse fibroblasts. K, Yamanaka S., Cell, (2006) 126: 663-676), and human cell-derived iPSCs (Takahashi K, Yamanaka S., et. al. Cell, (2007) 131: 861-872.)
- Nanog expression was selected as an index, and established Nanog-iPSCs (Okita, K., Ichisaka, T., and Yamanaka, S. (2007).
- IPSCs produced by c-Myc-free method (Nakagawa M, Yamanaka S., et al. Nature Biotechnology, (2008) 26, 101-106), IPSCs established by introducing six factors by the virus-free method (Okita K et al. Nat. Methods 2011 May; 8 (5): 409-12, Okita K et al. Stem Cells. 31 (3): 458- 66.) can also be used.
- iPSCs established by introducing the four factors OCT3 / 4, SOX2, NANOG, and LIN28 produced by Thomson et al. (Yu J., Thomson JA. Et al., Science (2007) 318: 1917-1920.
- the TCR expressed in the CD3-positive cells includes a dimer composed of two of TCR ⁇ , TCR ⁇ , TCR ⁇ and TCR ⁇ .
- a dimer composed of two of TCR ⁇ , TCR ⁇ , TCR ⁇ and TCR ⁇ a heterodimer composed of TCR ⁇ and TCR ⁇ ( ⁇ TCR), a heterodimer composed of TCR ⁇ and TCR ⁇ ( ⁇ TCR), and a homodimer composed of the same TCR chain.
- TCRs may be endogenous dimers or exogenous dimers, but are preferably dimers containing exogenous TCR ⁇ and exogenous TCR ⁇ .
- exogenous TCR refers to a heterodimer consisting of exogenous TCR ⁇ and exogenous TCR ⁇ , a heterodimer consisting of exogenous TCR ⁇ and exogenous TCR ⁇ , and / or an exogenous identical It is a homodimer composed of TCR chains.
- the pluripotent stem cell is a nucleic acid comprising a nucleotide sequence encoding endogenous TCR ⁇ and a nucleotide sequence encoding endogenous TCR ⁇ May be a pluripotent stem cell produced from a cell containing a nucleic acid containing Such cells include, for example, T cells (CD8 positive CD4 negative cells, CD8 negative CD4 positive cells, CD4 positive CD8 positive cells, etc.).
- the pluripotent stem cells encode a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇ and an exogenous TCR ⁇ It may be a cell containing a nucleic acid containing a base sequence.
- ⁇ exogenous TCR nucleic acid '' refers to a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇ , a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇ , a nucleotide sequence encoding an exogenous TCR ⁇ And / or a nucleic acid comprising a base sequence encoding exogenous TCR ⁇ .
- a method for introducing an exogenous TCR nucleic acid for example, a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇ and a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇
- an exogenous TCR nucleic acid for example, a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇ and a nucleic acid containing a nucleotide sequence encoding an exogenous TCR ⁇
- the following method can be used.
- a vector such as a virus, a plasmid, or an artificial chromosome can be introduced into pluripotent stem cells by a technique such as lipofection, liposome, or microinjection.
- the virus vector include a retrovirus vector, a lentivirus vector, an adenovirus vector, an adeno-associated virus vector, and a Sendai virus vector.
- the artificial chromosome vector include a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), and a bacterial artificial chromosome (BAC, PAC).
- a plasmid for mammalian cells can be used.
- the vector can contain control sequences such as a promoter, an enhancer, a ribosome binding sequence, a terminator, and a polyadenylation site so that an exogenous TCR can be expressed, and further, if necessary, a drug resistance gene ( For example, kanamycin resistance gene, ampicillin resistance gene, puromycin resistance gene, etc.), thymidine kinase gene, selection marker sequence such as diphtheria toxin gene, fluorescent protein, ⁇ -glucuronidase (GUS), reporter gene sequence such as FLAG, etc. .
- kanamycin resistance gene For example, ampicillin resistance gene, puromycin resistance gene, etc.
- thymidine kinase gene selection marker sequence such as diphtheria toxin gene, fluorescent protein, ⁇ -glucuronidase (GUS), reporter gene sequence such as FLAG, etc.
- SV40 promoter As promoters, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney mouse leukemia virus) LTR, HSV-TK (herpes simplex virus thymidine kinase) promoter, EF- ⁇ promoter, CAG Promoters and drug-responsive promoters are exemplified.
- the drug-responsive promoter is exemplified by a TRE promoter that expresses a gene in the presence of a corresponding drug (CMV minimum promoter having a Tet-responsive element having seven consecutive tetO sequences).
- a fusion protein with reverse ⁇ tetR (rtetR) and VP16AD is simultaneously expressed in the same cell, whereby gene expression is performed in the presence of a corresponding drug (for example, tetracycline or doxycycline).
- a corresponding drug for example, tetracycline or doxycycline.
- a vector that combines the expression of the TRE promoter and the fusion gene of rtetR and VP16AD in the same vector.
- a polycistronic expression mode in order to simultaneously express exogenous TCR ⁇ and exogenous TCR ⁇ , a polycistronic expression mode may be used.
- the gene encoding sequence may be linked by an IRES or foot and mouth disease virus (FMDV) 2A coding region.
- the vector contains an expression cassette (a gene expression unit containing a promoter, a gene sequence and a terminator) in order to remove a sequence encoding an exogenous TCR incorporated into a chromosome, if necessary.
- an expression cassette a gene expression unit containing a promoter, a gene sequence and a terminator
- the transposon sequence is not particularly limited, and piggyBac is exemplified.
- a loxP sequence or FRT sequence may be provided before and after the expression cassette for the purpose of removing the expression cassette.
- the exogenous TCR nucleic acid when the exogenous TCR nucleic acid is in the form of RNA, it may be introduced into pluripotent stem cells by a technique such as electroporation, lipofection, or microinjection.
- the CD3-positive cells to be cultured may also be cells expressing a chimeric antigen receptor.
- chimeric antigen receptor means a fusion protein containing an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
- the antigen-binding domain of CAR includes a short-chain antibody (scFv) in which the light (VL) and heavy (VH) chains of the variable region of an antibody are linked in series via a linker (eg, GS linker).
- the CD3-positive cell in which CAR has been expressed recognizes the antigen in the scFv region, and then transmits the recognition signal into the cell through the intracellular signaling domain.
- the antigen targeted by the CAR includes, for example, a tumor antigen, but is not limited thereto.
- the tumor antigen may be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA).
- TSA tumor-specific antigen
- TAA tumor-associated antigen
- Specific examples of such tumor antigens include differentiation antigens such as MART-1 / MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2, WT1, Glypican-3, MAGE- 1, MAGE-3, BAGE, GAGE-1, GAGE-2, tumor-specific multi-lineage antigens such as p15, fetal antigens such as CEA, p53, Ras, overexpressed oncogenes such as HER-2 / neu or Mutated tumor suppressor genes, unique tumor antigens resulting from chromosomal translocations such as BCR-ABL, E2A-PRL, H4-RET, I
- tumor antigens include CD19, CD20, EGP2, erB2,3,4, GD2, GD3, Mesothelin, PSMA, 8H9, Lewis-Y, MUC1, TSP-180, MAGE-4, MAGE-5, MAGE-6 , RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, ⁇ -catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, ⁇ -fetoprotein, ⁇ -HCG, BCA225, BTAA, CA 125, CA 15-3 / CA 27.29 / BCAA, CA 195, CA 242 , CA-50, CAM43, CD68 / P1, CO-029, FGF-5, G250, Ga733 / EpCAM, HTgp-175, M344, MA
- transmembrane domain of CAR for example, TCR ⁇ chain, ⁇ chain or ⁇ chain, CD28, CD3 ⁇ chain, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86
- a transmembrane domain derived from a molecule derived from the first intracellular signaling domain linked to the antigen-binding domain is preferably used.
- the transmembrane domain may also be derived from CD28.
- an artificially designed transmembrane domain may be used.
- the intracellular signaling domain of CAR for example, FcR ⁇ chain, FcR ⁇ chain, CD3 ⁇ chain, CD3 ⁇ chain, CD3 ⁇ chain, CD3 ⁇ chain, CD5, CD22, CD79a, CD79b and one or more selected from the group consisting of CD66d
- Examples include, but are not limited to, intracellular domains derived from proteins. Among these, an intracellular domain derived from the CD3 ⁇ chain is preferred.
- tyrosine phosphorylation of ITAM contained in the intracellular domain of the CD3 ⁇ chain is triggered, a series of responses such as an increase in intracellular Ca 2+ concentration and cytokine secretion are shown, and eventually cell division occurs and CD3 positive The cells exhibit cytotoxic activity as CTL.
- the intracellular signaling domain may further include an intracellular domain of a costimulatory molecule, such as CD27, CD28, 4-1BB (CD137), OX40, CD30, Intracellular domain of one or more proteins selected from the group consisting of CD40, PD-1, ICOS, lymphocyte function-related antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and CD83 But not limited thereto.
- intracellular domains derived from CD28, 4-1BB (CD137) and CD30 are preferred.
- CD28 can be bound to promote T cell proliferation by increasing IL-2 production.
- 4-1BB can promote differentiation into memory cells by suppressing apoptosis caused in the final stage of T cell activation.
- CD30 can further enhance the proliferation of CD3-positive cells with the CD3 antibody, and can be maintained as CD197-positive cells for a long period of time.
- the intensity and duration of CAR activity can be controlled (for example, Mol Ther. 2009; 17: 1453-1464.). If the intracellular signaling domain includes one or more intracellular domains, the order is not limited.
- a spacer may be incorporated between the antigen-binding domain and transmembrane domain of CAR, or between the intracellular signaling domain and transmembrane domain of CAR, and the spacer is generally 300 amino acids or less, preferably 10 amino acids. Peptides consisting of 100100 amino acids, most preferably 25-50 amino acids can be used. Specific examples include, but are not limited to, an IgG1-derived hinge region, and a peptide containing a part of the CH2CH3 region of immunoglobulin and CD3.
- a first-generation CAR in which a scFv and a CD3 ⁇ chain are bound via a spacer, the activation between the scFv and the CD3 ⁇ chain of the first-generation CAR is enhanced in order to enhance the ability to activate T cells.
- a second-generation CAR incorporating a transmembrane domain and an intracellular domain derived from CD28, and a co-stimulation different from CD28 between the intracellular domain of CD28 and the CD3CD chain of the second-generation CAR. Includes, but is not limited to, third generation CARs that incorporate the intracellular domain of the molecule (4-1BB or OX40).
- the CD3-positive cells to be cultured may be cells that further express CAR and a fusion protein of IL-15 and IL-15R ⁇ (IL-15 / IL-15R ⁇ ).
- the CAR expressed with IL-15 / IL-15R ⁇ may be similar to the CAR described above.
- IL-15 / IL-15R ⁇ means a fusion protein containing IL-15 and IL-15R ⁇ .
- IL-15R ⁇ usually expressed on antigen presenting cells binds to IL-15, and IL-15 receptor consisting of R ⁇ and ⁇ c on CD8 positive CD4 negative cells
- presenting -15 trans-presentation
- CD8-positive CD4-negative cells CD8-positive CD4-negative cells
- CD3-positive cells that express IL-15 / IL-15R ⁇ can transmit an IL-15 signal into other CD8-positive CD4-negative cells via the IL-15 receptor.
- IL-15 / IL-15R ⁇ can maintain the cytotoxic activity of CD8-positive CD4-negative cells, a continuous cytotoxic effect on cells targeted for CAR can be expected.
- IL-15 / IL-15R ⁇ may be a transmembrane protein or a secretory protein.
- IL-15R ⁇ is known to have a IL-15 binding domain of 1-65 amino acids from the N-terminus of the mature protein as a responsible region for binding to IL-15 (Wei X. et al., J. Immunol., 167: 277-282, 2001). Therefore, the transmembrane protein may be any protein that retains the IL-15 binding domain and the IL-15R ⁇ transmembrane domain.
- the secretory protein may be any protein that retains the IL-15 binding domain and lacks the transmembrane domain of IL-15R ⁇ .
- IL-15 / IL-15R ⁇ may incorporate a spacer between IL-15 and IL-15R ⁇ , and the spacer is generally 300 amino acids or less, preferably 10-100 amino acids, and most preferably 20-50 amino acids. Peptides consisting of amino acids can be used. Specific examples include, but are not limited to, GS linkers.
- IL-15 / IL-15R ⁇ is not particularly limited as long as it is a peptide in which IL-15 and IL-15R ⁇ are bound via a spacer, and specific examples include a peptide consisting of SEQ ID NO: 8.
- the IL-15 / IL-15R is not limited as long as it binds to an IL-15 receptor and can transmit an IL-15 signal into a cell.
- homology refers to an optimal alignment (preferably, the algorithm employs sequence alignment for optimal alignment) when two amino acid sequences are aligned using a mathematical algorithm known in the art. (Which can take into account the introduction of gaps in one or both)), the percentage (%) of identical and similar amino acid residues to all overlapping amino acid residues.
- Similar amino acids means amino acids similar in physicochemical properties, for example, aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn ), Basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids having hydroxyl groups (Ser, Thr), and amino acids with small side chains (Gly, Ala, Ser, Thr, Met) Amino acids classified into groups are included. It is expected that substitutions with such similar amino acids will not change the phenotype of the protein (ie, are conservative amino acid substitutions).
- a CAR nucleic acid and / or an IL-15 / IL-15R ⁇ nucleic acid are used.
- the method of introduction into cells eg, pluripotent stem cells
- the same method as the method of introducing a TCR nucleic acid can be used.
- the pluripotent stem cells are differentiated into CD3-positive cells according to a method known per se. be able to. Specific methods for differentiating pluripotent stem cells into CD3-positive cells are described, for example, in WO 2016/076415 and WO 2017/221975. Specific methods for differentiating pluripotent stem cells into CD3-positive cells include, for example, (1) a step of differentiating pluripotent stem cells into hematopoietic progenitor cells, and (2) differentiation of the hematopoietic progenitor cells into CD3-positive cells. May be included.
- hematopoietic progenitor cells means CD34-positive cells, and preferably CD34-positive cells. CD43-positive cells.
- hematopoietic progenitor cells and hematopoietic stem cells are not distinguished, and unless otherwise specified, represent the same cells.
- the method for differentiating hematopoietic progenitor cells from pluripotent stem cells is not particularly limited as long as they can be differentiated into hematopoietic progenitor cells.
- WO 2013/075222, WO 2016/076415 and Liu S. et al , ⁇ Cytotherapy, ⁇ 17 ⁇ (2015); 344-358 and the like and a method of culturing pluripotent stem cells in an induction medium for hematopoietic progenitor cells.
- the medium for inducing hematopoietic progenitor cells is not particularly limited, and a medium used for culturing animal cells can be prepared as a basal medium.
- a basal medium for example, Dulbecco's medium (eg, IMDM), Eagle's medium (eg, DMEM, EMEM, BME, MEM, ⁇ MEM), ham medium (eg, F10 medium, F12 medium), RPMI medium (eg, RPMI- 1640 medium, RPMI-1630 medium), MCDB medium (eg, MCDB104, 107, 131, 151, 153 medium), Fisher medium, 199 medium, medium for primate ES cells (culture medium for primate ES / iPS cells, reprocell Corporation), culture medium for mouse ES cells (TX-WES culture solution, Thrombo X), serum-free medium (mTeSR, Stemcell II Technology), ReproFF, StemSpan (registered trademark) SFEM, StemT
- the basal medium may contain serum or may be used without serum.
- the basal medium contains 10-20% serum (fetal bovine serum (FBS), human serum, horse serum) or serum substitutes (such as KSR), various amino acids such as insulin, various vitamins, L-glutamine, and non-essential amino acids 2, 2-mercaptoethanol, various cytokines (interleukins (IL-2, IL-7, IL-15, etc.), stem cell factor (SCF (Stem cell factor)), activin, etc.), various hormones, various growth factors (leukemia) Inhibitors (LIF), basic fibroblast growth factor (bFGF), TGF- ⁇ , etc.), various extracellular matrices, various cell adhesion molecules, antibiotics such as penicillin / streptomycin, puromycin, pH indicators such as phenol red And the like can be appropriately added.
- FBS fetal bovine serum
- human serum human serum
- serum substitutes such as KSR
- various amino acids such as insulin
- the basal medium may include, for example, vitamin Cs (eg, ascorbic acid), albumin, insulin, transferrin, selenium compounds (eg, sodium selenite), fatty acids, trace elements, 2-mercaptoethanol , Thioglycerol (eg, ⁇ -monothioglycerol (MTG)), lipid, L-alanyl-L-glutamine (eg, Glutamax®), growth factor, small molecule compound, antibiotic, antioxidant, pyruvin Acids, buffers, inorganic salts and the like may be included.
- vitamin Cs eg, ascorbic acid
- albumin e.g, insulin, transferrin, selenium compounds (eg, sodium selenite)
- fatty acids e.g, trace elements
- 2-mercaptoethanol e.g, Thioglycerol (eg, ⁇ -monothioglycerol (MTG)
- lipid eg, L-alanyl-L-glutamine (e
- vitamin Cs means L-ascorbic acid and its derivatives
- L-ascorbic acid derivatives mean those which become vitamin C by an enzymatic reaction in a living body.
- Ascorbic acid derivatives used in step (1) include vitamin C phosphate, glucoside ascorbate, ascorbyl ethyl, vitamin C ester, ascobyl tetrahexyldecanoate, ascobyl stearate and ascorbic acid-2-phosphate-6 palmitic acid.
- vitamin C phosphate eg, Ascorbic acid 2-phosphate
- phosphate-L-ascorbate such as sodium phosphate-L-ascorbate or Mg phosphate-L-ascorbate.
- phosphate-L-ascorbate such as sodium phosphate-L-ascorbate or Mg phosphate-L-ascorbate.
- the vitamin Cs are present in the culture in an amount corresponding to 5 ng / ml to 500 ng / ml (eg, 5 ng / ml, 10 ng / ml, 25 ng / ml, 50 ng / ml). , 100 ng / ml, 200 ng / ml, 300 ng / ml, 400 ng / ml, 500 ng / ml).
- the vitamin Cs are present in the culture in an amount corresponding to 5 ⁇ g / ml to 500 ⁇ g / ml (eg, 5 ⁇ g / ml, 10 ⁇ g / ml, 25 ⁇ g / ml, 50 ⁇ g / ml). ml, 100 ⁇ g / ml, 200 ⁇ g / ml, 300 ⁇ g / ml, 400 ⁇ g / ml, 500 ⁇ g / ml).
- the medium used in the step (1) is BMP4 (Bone morphogenetic protein 4), VEGF (vascular endothelial growth factor), SCF (Stem cell factor), TPO (thrombopoietin), FLT-3L (Flt3 Ligand), bFGF (basic fibroblast growth). factor), at least one cytokine selected from the group consisting of: More preferably, it is a culture to which BMP4, VEGF and bFGF are added, and further preferably, it is a culture to which BMP4, VEGF, SCF and bFGF are added.
- BMP4 is 5 ng / ml to 500 ng / ml
- VEGF is 5 ng / ml to 500 ng / ml
- SCF is 5 ng / ml to 500 ng / ml.
- TPO can be 3 ng / ml to 300 ng / ml
- FLT-3L can be 1 ng / ml to 100 ng / ml
- bFGF can be 5 ng / ml to 500 ng / ml.
- TGF ⁇ inhibitor may be added to the medium.
- TGF ⁇ inhibitor is a small molecule inhibitor that interferes with TGF ⁇ family signaling, for example, SB431542, SB202190 (or more, RK Lindemann et al., Mol. Cancer 2:20 (2003)), SB505124 (GlaxoSmithKline), NPC30345, SD093, SD908, SD208 (Scios), LY2109761, LY364947, LY580276 (Lilly Research Laboratories) and the like.
- the concentration in the medium is preferably 0.5 ⁇ M to 100 ⁇ M.
- ⁇ Culture of pluripotent stem cells may be adhesion culture or suspension culture.
- the culture may be performed using a culture vessel coated with an extracellular matrix component, or may be co-cultured with feeder cells.
- the feeder cells are not particularly limited, and include, for example, fibroblasts (mouse fetal fibroblasts (MEF), mouse fibroblasts (STO), etc.).
- the feeder cells are preferably inactivated by a method known per se, for example, irradiation with radiation (such as gamma rays) or treatment with an anticancer agent (such as mitomycin C).
- Extracellular matrix components include Matrigel (Niwa A, et al.
- fibrous proteins such as gelatin, collagen, elastin, and glucosaminoglycans such as hyaluronic acid and chondroitin sulfate.
- cell adhesion proteins such as proteoglycan, fibronectin, vitronectin and laminin.
- Suspension culture refers to culturing cells in a non-adhered state to a culture vessel, and is not particularly limited, but is artificially treated for the purpose of improving the adhesion to cells (for example, coating with an extracellular matrix or the like).
- Treatment or a treatment that artificially suppresses adhesion (eg, coating treatment with polyhydroxyethyl methacrylic acid (poly-HEMA) or a nonionic surface-active polyol (Pluronic @ F-127, etc.))
- poly-HEMA polyhydroxyethyl methacrylic acid
- Pluronic @ F-127, etc. nonionic surface-active polyol
- Hematopoietic progenitor cells can also be prepared from net-like structures (also referred to as ES-sac or iPS-sac) obtained by culturing pluripotent stem cells.
- the “net-like structure” is a three-dimensional sac-like (those with a space inside) structure derived from pluripotent stem cells, formed of an endothelial cell population, etc., and contains hematopoietic progenitor cells inside. It is a structure.
- the conditions of the culture temperature in step (1) are not particularly limited, but are preferably, for example, about 37 ° C to 42 ° C, and about 37 ° C to 39 ° C.
- those skilled in the art can appropriately determine the culture period while monitoring the number of hematopoietic progenitor cells and the like.
- the number of days is not particularly limited, for example, at least 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, It is 14 days or more, preferably 14 days.
- the long culture period is not usually a problem in the production of hematopoietic progenitor cells, but is preferably, for example, 35 days or less, more preferably 21 days or less.
- the culture may be performed under low oxygen conditions.
- the low oxygen conditions are exemplified by an oxygen concentration of 15%, 10%, 9%, 8%, 7%, 6%, 5% or less. Is done.
- Step of differentiating hematopoietic progenitor cells into CD3-positive cells The method of differentiating hematopoietic progenitor cells into CD3-positive cells is not particularly limited as long as hematopoietic progenitor cells can be differentiated into CD3-positive cells. And a method for culturing hematopoietic progenitor cells under the same culture conditions as those for inducing T cells from hematopoietic progenitor cells, such as those described in WO / 076415 or WO2017 / 221975.
- the medium for inducing differentiation into CD3-positive cells is not particularly limited, and a medium used for culturing animal cells can be prepared as a basal medium.
- a medium used for culturing animal cells can be prepared as a basal medium.
- the basal medium include those similar to those used in the above step (1).
- the medium may contain serum or may be used without serum.
- the basal medium includes, for example, vitamin Cs (eg, ascorbic acid), albumin, insulin, transferrin, selenium compounds (eg, sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thiol Glycerol (eg, ⁇ -monothioglycerol (MTG)), lipid, amino acid, L-glutamine, L-alanyl-L-glutamine (eg, Glutamax®) non-essential amino acids, vitamins, growth factors, low molecular compounds , Antibiotics (eg, penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, and the like.
- vitamin Cs eg, ascorbic acid
- albumin e.g, insulin, transferrin, selenium compounds (eg, sodium selenite)
- fatty acids e.g, trace elements
- 2-mercaptoethanol thiol Glycerol (eg, ⁇ -
- the concentration of vitamin Cs in the medium or culture is preferably between 5 ⁇ g / ml and 200 ⁇ g / ml.
- the vitamin Cs are present in the culture in an amount corresponding to 5 ⁇ g / ml to 500 ⁇ g / ml (eg, 5 ⁇ g / ml, 10 ⁇ g / ml, 25 ⁇ g / ml, 50 ⁇ g / ml).
- p38 inhibitor refers to a substance that inhibits the function of p38 protein (p38 MAP kinase), such as a chemical inhibitor of p38, a dominant negative mutant of p38 or a nucleic acid encoding the same. But not limited thereto.
- SB203580 (4- (4-fluorophenyl) -2- (4-methylsulfonylphenyl) -5- (4-pyridyl) -1H-imidazole), and the like Derivative, SB202190 (4- (4-fluorophenyl) -2- (4-hydroxyphenyl) -5- (4-pyridyl) -1H-imidazole) and its derivative, SB239063 (trans-4- [4- (4- Fluorophenyl) -5- (2-methoxy-4-pyrimidinyl) -1H-imidazol-1-yl] cyclohexanol) and its derivatives, SB220025 and its derivatives, PD169316, RPR200765A, AMG-548, BIRB-796, SCIO- Examples include, but are not limited to, 469, SCIO-323, VX-702, and FR167653.
- SB203580 (4- (4-fluorophenyl) -2- (4-methylsulfonylphenyl) -5- (4-pyridyl) -1H-imidazole) and its derivatives are preferred.
- Examples of the dominant negative mutant of p38 in step (2) include p38T180A in which the threonine at position 180 located in the DNA binding region of p38 is mutated to alanine, and tyrosine at position 182 of p38 in humans and mice that is mutated to phenylalanine. P38Y182F and the like.
- the p38 inhibitor is contained in the medium in the range of, for example, about 1 ⁇ M to about 50 ⁇ M.
- SB203580 is used as a p38 inhibitor, it can be contained in the medium in the range of 1 ⁇ M to 50 ⁇ M, 5 ⁇ M to 30 ⁇ M, and 10 ⁇ M to 20 ⁇ M.
- SDF-1 in step (2) is not only SDF-1 ⁇ or its mature form, but also isoforms such as SDF-1 ⁇ , SDF-1 ⁇ , SDF-1 ⁇ , SDF-1 ⁇ or SDF-1 ⁇ , or their mature forms. Or a mixture of these at any ratio.
- SDF-1 ⁇ is used.
- SDF-1 may be referred to as CXCL-12 or PBSF.
- SDF-1 may have one or several amino acids substituted, deleted, added and / or inserted in its amino acid sequence, as long as it has activity as a chemokine.
- SDF-1 in which such amino acid substitution, deletion, addition, and / or insertion is also referred to as “SDF-1 variant”).
- SDF-1 or the SDF-1 mutant a sugar chain may be substituted, deleted and / or added.
- SDF-1 mutant include, for example, at least four cysteine residues (in the case of human SDF-1 ⁇ , Cys30, Cys32, Cys55, and Cys71), and 90 amino acids relative to the natural amino acid sequence. % Or more, but is not limited to this amino acid mutation.
- the SDF-1 may be from a mammal, for example, a human or a non-human mammal, such as, for example, a monkey, a sheep, a cow, a horse, a pig, a dog, a cat, a rabbit, a rat, a mouse, and the like.
- a mammal for example, a human or a non-human mammal, such as, for example, a monkey, a sheep, a cow, a horse, a pig, a dog, a cat, a rabbit, a rat, a mouse, and the like.
- GenBank accession number: NP_954637 can be used as human SDF-1 ⁇
- NP_000600 can be used as SDF-1 ⁇ .
- SDF-1 may be a commercially available product, a purified product from nature, or a product produced by peptide synthesis or genetic engineering techniques. SDF-1 is contained in the medium in the range of, for example, about 10 ng / ml to about 100 ng / ml. Instead of SDF-1, an SDF-1 substitute having SDF-1 like activity can be used. Examples of such SDF-1 substitutes include CXCR4 agonists, and low molecular weight compounds having CXCR4 agonist activity may be added to the medium instead of SDF-1.
- cytokines selected from the group consisting of SCF, TPO (thrombopoietin), FLT-3L and IL-7 may be further added to the culture solution.
- concentrations are, for example, SCF is 10 ng / ml to 100 ng / ml, TPO is 10 ng / ml to 200 ng / ml, and IL-7 is 1 ng / ml to 100 ng / ml.
- FLT-3L is 1 ng / ml to 100 ng / ml.
- hematopoietic progenitor cells may be adhered or suspended.
- a culture vessel may be coated and used, or may be co-cultured with feeder cells or the like.
- feeder cells to be co-cultured include bone marrow stromal cell line OP9 cells (available from RIKEN BioResource Center).
- the OP9 cells are preferably OP9-DL4 cells or OP9-DL1 cells that constitutively express DLL4 or DLL1 (for example, Holmes R1 and Zuniga-Pflucker JC. Cold Spring Harb Protoc. 2009 (2)).
- the method may be carried out by appropriately adding DLL4 or DLL1 prepared separately or a fusion protein of DLL4 or DLL1 to Fc or the like to the medium.
- the culture is performed by appropriately replacing the feeder cells.
- Exchange of the feeder cells can be performed by transferring the target cells in culture onto feeder cells seeded in advance. The exchange may occur every 5 days, every 4 days, every 3 days, or every 2 days.
- hematopoietic progenitor cells are obtained by suspension culture of embryoid bodies, it is preferable to dissociate them into single cells and then carry out adhesion culture.
- the cells may be co-cultured with the feeder cells, the culture is preferably performed without using the feeder cells.
- adhesion culture as a coating agent for coating a culture vessel, for example, Matrigel (Niwa A, et al.
- PLos One, 6 (7): e22261, 2011) collagen, gelatin, laminin, Heparan sulfate proteoglycan, retronectin, DLL4 or DLL1, or a fusion protein (eg, DLL4 / Fc chimera) of DLL4 or DLL1 with an antibody Fc region (hereinafter, sometimes referred to as Fc), entactin, and / or Combinations are preferred, and a combination of retronectin and a fusion protein of DLL4 with Fc or the like is preferred.
- Fc antibody Fc region
- the culture temperature conditions are not particularly limited, but are preferably, for example, about 37 ° C. to about 42 ° C., and about 37 ° C. to about 39 ° C. Further, those skilled in the art can appropriately determine the culture period while monitoring the number of CD3-positive cells and the like. As long as CD3-positive cells are obtained, the number of days is not particularly limited, for example, at least 10 days or more, 12 days or more, 14 days or more, 16 days or more, 18 days or more, 20 days or more, 22 days or more, 23 days or more Yes, preferably 21 days. Further, it is preferably 90 days or less, more preferably 42 days or less.
- the cells obtained by the above steps include CD3-positive cells, and a specific method for differentiating pluripotent stem cells into CD3-positive cells may further include the following step (3).
- Examples of a method for obtaining (CD30-positive cells) include methods described in WO 2016/076415, WO 2017/221975, and the like.
- CD3-positive cells may be enriched using a similar method.
- the medium used for obtaining CD3-positive CD8-positive CD4-negative cells (or CD3-positive CD8-positive CD4-negative CD30-positive cells) or enriching for CD3-positive cells is not particularly limited, but may be used for culturing animal cells.
- the medium used can be prepared as a basal medium. Examples of the basal medium include those similar to those used in the above step (1).
- the medium may contain serum or may be used without serum.
- the basal medium includes, for example, vitamin Cs (eg, ascorbic acid), albumin, insulin, transferrin, selenium compounds (eg, sodium selenite), fatty acids, trace elements, 2-mercaptoethanol, thiol Glycerol (eg, ⁇ -monothioglycerol (MTG)), lipid, amino acid, L-glutamine, L-alanyl-L-glutamine (eg, Glutamax®) non-essential amino acids, vitamins, growth factors, low molecular compounds , Antibiotics (eg, penicillin, streptomycin), antioxidants, pyruvate, buffers, inorganic salts, cytokines, hormones, and the like.
- vitamin Cs eg, ascorbic acid
- albumin e.g, insulin, transferrin, selenium compounds (eg, sodium selenite)
- fatty acids e.g, trace elements
- 2-mercaptoethanol thiol Glycerol (eg,
- the concentration of vitamin Cs in the medium or culture is preferably from 5 ⁇ g / ml to 200 ⁇ g / ml.
- the vitamin Cs are present in the culture in an amount corresponding to 5 ⁇ g / ml to 500 ⁇ g / ml (eg, 5 ⁇ g / ml, 10 ⁇ g / ml, 25 ⁇ g / ml, 50 ⁇ g / ml).
- examples of the hormone include corticosteroids.
- the corticosteroid is a glucocorticoid or a derivative thereof, and examples thereof include cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclomethasone propionate. Preferably, it is dexamethasone.
- the corticosteroid is dexamethasone, its concentration in the medium is between 1 nM and 100 nM.
- the medium contains a CD3 / TCR complex agonist.
- the CD3 / TCR complex agonist is not particularly limited as long as it can specifically transmit at least a part of the CD3 / TCR complex to transmit a signal from the CD3 / TCR complex into a CD3-positive cell. Not done.
- CD3 / TCR complex agonists include, for example, CD3 agonists and / or TCR agonists.
- an anti-CD3 agonist antibody or a binding fragment thereof As a CD3 agonist, an anti-CD3 agonist antibody or a binding fragment thereof, and as a TCR agonist, an anti-TCR antibody or a binding fragment thereof, an MHC / antigen peptide complex or a multimer thereof, and a MHC / superantigen complex or a multimer thereof. At least one selected is given.
- the anti-CD3 agonist antibody includes both a polyclonal antibody and a monoclonal antibody, but is preferably a monoclonal antibody.
- the antibody may belong to any immunoglobulin class of IgG, IgA, IgM, IgD or IgE, but is preferably IgG.
- anti-CD3 agonist antibody examples include an antibody produced from the OKT3 clone (OKT3) and an antibody produced from the UCHT1 clone (UCHT1), and preferably UCHT1.
- OKT3 contains RYTMH (SEQ ID NO: 9), YINPSRGYTNYNQKFKD (SEQ ID NO: 10), and YYDDHYCLDY (SEQ ID NO: 11) as complementarity determining regions 1 to 3 of the heavy chain variable region
- the complementarity determining regions 1 to 3 of the light chain variable region include SASSSVSYMN (SEQ ID NO: 12), DTSKLAS (SEQ ID NO: 13), and QQWSSNPFT (SEQ ID NO: 14).
- OKT3 preferably also includes a heavy chain variable region including the amino acid sequence represented by SEQ ID NO: 21 and a light chain variable region including the amino acid sequence represented by SEQ ID NO: 22.
- UCHT1 contains GYSFTGYTMN (SEQ ID NO: 15), LINPYKGVST (SEQ ID NO: 16), SGYYGDSDWYFDV (SEQ ID NO: 17) as complementarity determining regions 1 to 3 of the heavy chain variable region, RASQDIRNYLN (SEQ ID NO: 18), YTSRLHS (SEQ ID NO: 19), and QQGNTLPWT (SEQ ID NO: 20) are included as the complementarity determining regions 1 to 3 of the light chain variable region.
- UCHT1 preferably contains a heavy chain variable region including the amino acid sequence represented by SEQ ID NO: 23 and a light chain variable region including the amino acid sequence represented by SEQ ID NO: 24.
- concentration of the anti-CD3 agonist antibody in the medium is, for example, 10 ng / ml to 1000 ng / ml, preferably 50 ng / ml to 800 ng / ml, and more preferably 250 ng / ml to 600 ng / ml. ml.
- examples of the cytokine include IL-2 and IL-7.
- the concentration in the medium is 10 U / ml to 1000 U / ml
- the concentration in the medium is 1 ng / ml to 1000 ng. / ml.
- the culture temperature conditions are not particularly limited, but are preferably, for example, about 37 ° C. to about 42 ° C., and about 37 ° C. to about 39 ° C. Further, those skilled in the art can appropriately determine the culture period while monitoring the number of CD3-positive cells and the like.
- the number of days is not particularly limited as long as CD3-positive cells can be obtained, and is, for example, at least 1 day, 2 days or more, 3 days or more, 4 days or more, 5 days or more, and preferably 6 days or more. Also, it is preferably 28 days or less, more preferably 14 days or less.
- CD3-positive cells cultured in the production method or the expansion culture method of the present invention can be obtained by differentiating pluripotent stem cells.
- the production method or the expansion culture method of the present invention comprises a step of culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist (hereinafter referred to as step (I) of the present invention). To).
- the CD3 / TCR complex agonist may be the same as the CD3 / TCR complex agonist used in the step (3).
- the CD3 / TCR complex agonist used in the step (I) of the present invention is an anti-CD3 agonist antibody or an anti-TCR antibody
- those polyclonal antibodies can be prepared, for example, by the following method. Can be produced.
- a polyclonal antibody against CD3 a mixture of CD3 or a partial peptide containing an epitope thereof (eg, ⁇ , ⁇ , ⁇ , or ⁇ chain) and complete or incomplete Freund's adjuvant (FCA or FIA) is sensitized.
- FCA or FIA complete or incomplete Freund's adjuvant
- a mixture of TCR or a partial peptide containing an epitope thereof eg, ⁇ , ⁇ , ⁇ , or ⁇ chain
- FCA or FIA complete or incomplete Freund's adjuvant
- Immunize mammals such as rabbits, mice, rats, goats, guinea pigs or hamsters (boost one or several times every 1 to 4 weeks after the initial immunization), and about 3 to 10 days after each booster
- the antibody titer of the partially collected blood serum is measured using a conventionally known antigen-antibody reaction, and the increase is confirmed.
- the polyclonal antibody can also be purified as a single immunoglobulin class using conventional separation techniques such as salting out such as ammonium sulfate fractionation, centrifugation, dialysis, and column chromatography.
- the monoclonal antibody is usually produced by cell fusion. It can be obtained from a hybridoma (fused cell). That is, as in the case of the polyclonal antibody, antibody-producing cells are isolated from a mammal immunized with a partial peptide containing CD3 or TCR or an epitope thereof, and the resultant is fused with myeloma cells to form a hybridoma. The hybridoma is produced by cloning the hybridoma and selecting a clone that produces an antibody showing specific affinity for CD3 or TCR as a marker antigen. In addition, antibody-producing cells generated by allowing CD3 to act on spleen cells or lymphocytes isolated in advance in a culture solution can also be used. In this case, human-derived antibody-producing cells can also be prepared.
- Hybridomas secreting monoclonal antibodies can be prepared according to the method of Koehler and Milstein (Nature, Vol. 256, pp. 495-497, 1975) and modifications thereof. That is, the monoclonal antibody is a spleen cell, a thymocyte, a lymph node cell, a peripheral lymphocyte, a myeloma cell or a tonsil cell obtained from the animal immunized as described above, and preferably produces an antibody contained in the spleen cell.
- a hybridoma obtained by fusion of the cell with a mammal preferably a homologous mouse, rat, guinea pig, hamster, rabbit or human, more preferably a mouse, rat or human myeloma cell (myeloma) Prepared.
- the culture can be carried out in vitro or in vivo in mammals such as mice, rats, guinea pigs, hamsters, rabbits, etc., preferably in mice or rats, more preferably in the abdominal cavity of mice. Can be obtained from animal ascites.
- myeloma cells used for cell fusion include, for example, mouse-derived myeloma (eg, P3-NSI-1-Ag4-1, P3-X63-Ag8-U1, P3-X63-Ag8-653, ⁇ SP2 / 0-Ag14 and BW5147). ), Rat-derived myeloma (eg, 210RCY3-Ag1.2.3, etc.), human-derived myeloma (eg, U-266AR1, GML500-6TG-A1-2, UC729-6, CEM-AGR, D1R11, CEM-T15, etc.) And the like.
- mouse-derived myeloma eg, P3-NSI-1-Ag4-1, P3-X63-Ag8-U1, P3-X63-Ag8-653, ⁇ SP2 / 0-Ag14 and BW5147.
- Rat-derived myeloma eg, 210RC
- Screening of a hybridoma clone producing a monoclonal antibody is carried out by culturing the hybridoma in, for example, a microtiter plate, and measuring the reactivity of the culture supernatant in the well in which proliferation has been performed for CD3 by radioimmunoassay, enzyme immunoassay, fluorescence immunoassay, and the like. It can be performed by measuring.
- the monoclonal antibody is isolated and purified by subjecting the antibody-containing culture supernatant or ascites produced by the method described above to affinity column chromatography such as ion exchange chromatography, an anti-immunoglobulin column or a protein G column. It can be carried out.
- the monoclonal antibody used in the step (I) of the present invention is not limited to the above-mentioned production method, and may be obtained by any method. Further, the monoclonal antibody usually has a sugar chain having a different structure depending on the type of mammal to be immunized, but the monoclonal antibody in the present invention is not limited by the structural difference of the sugar chain, and can be any mammal. It also encompasses monoclonal antibodies derived from them.
- anti-CD3 agonist antibodies or anti-TCR antibodies include natural antibodies such as the polyclonal antibodies and monoclonal antibodies (mAbs) described above, chimeric antibodies (humanized antibodies) that can be produced using genetic recombination techniques, and single-chain antibodies.
- binding fragments of these antibodies are included.
- An antibody-binding fragment means a partial region of the aforementioned antibody having specific binding activity, specifically, Fab, Fab ', F (ab') 2 , scAb, scFv, or scFv-Fc. Include.
- those skilled in the art can also produce a fusion antibody of an anti-CD3 agonist antibody or an anti-TCR antibody or a binding fragment thereof and another peptide or protein, or produce a modified antibody bound with a modifying agent.
- Other peptides and proteins used for fusion are not particularly limited as long as they do not reduce the binding activity of the antibody, and include, for example, human serum albumin, various tag peptides, artificial helix motif peptides, maltose binding protein, glutathione S transferase , Various toxins, and other peptides or proteins that can promote multimerization.
- the modifier used for the modification is not particularly limited as long as it does not reduce the binding activity of the antibody, and examples thereof include polyethylene glycol, sugar chains, phospholipids, liposomes, and low molecular weight compounds.
- the commercially available anti-CD3 agonist antibody is not particularly limited, and is, for example, an antibody (OKT3) produced from an OKT3 clone (anti-human CD3 functional grade purified (Clone: OKT3) (eBioscience)) and a UCHT1 clone.
- Antibody (UCHT1) CD3 antibody (Clone: UCHT1) (GeneTex)
- UCHT1 can be used.
- the MHC / antigen peptide complex is a CD3 / antigen peptide complex.
- the molecule is not particularly limited as long as it is specifically recognized by the CD3 / TCR complex of the positive cell and can transmit a signal into the CD3 positive cell.
- the MHC constituting the MHC / antigen peptide complex may be MHC class I or MHC class II, but is preferably MHC class I.
- the MHC class I forms a complex with the antigen peptide, is recognized by the CD3 / TCR complex and CD8, and outputs a signal into CD3-positive cells.
- the CD3 / TCR complex and CD8 There is no particular limitation as long as it is a molecule that transmits.
- MHC class I includes, for example, ⁇ chain (in humans, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F or HLA-G, in mice, H-2K, H-2D or dimers include consisting H-2L) and beta 2 microglobulin, preferably, HLA-a, HLA-B , HLA-C, HLA-E, the HLA-F, or HLA-G and beta 2 microglobulin a composed dimer, more preferably, it is a dimer consisting of HLA-a, HLA-B or HLA-C and beta 2 microglobulin.
- ⁇ chain in humans, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F or HLA-G, in mice, H-2K, H-2D or dimers include consisting H-2L) and beta 2 microglobulin, preferably, HLA-a, HLA-B , HLA-C, HLA-E, the HLA-F, or
- specific MHC class I includes, for example, HLA-A * 02: 01, HLA-A * 24: 02 or HLA-A * 01: 01 and the like.
- the present invention is not limited to these.
- the antigenic peptide is not particularly limited as long as it is a peptide presented by MHC class I.
- Antigen peptides presented to MHC class I include, for example, HER-2 / neu, MART-1, NY-ESO-1, Gp-100, MUC-1, p53, prostate specific antigen (PSA), hTERT, WT1, Examples include a peptide derived from survivin, CEA, MAGE-3, or a protein derived from a group of viruses strongly associated with the development of malignant tumor, and preferably a WT1-derived peptide.
- WT1-derived peptides include RMFPNAPYL (SEQ ID NO: 1), SLGEQQYSV (SEQ ID NO: 2) or CMTWNQMNL (SEQ ID NO: 3) (the modified peptide CYTWNQMNL (SEQ ID NO: 4)) and the like. .
- the MHC class II forms a complex with the antigen peptide, is recognized by the CD3 / TCR complex and CD4, and enters into the CD3-positive cell.
- MHC class II includes, for example, HLA-DR, HLA-DQ and HLA-DP for humans, H-2A or H-2B for mice, and ⁇ and ⁇ chains, respectively (eg, HLA-DR is It is a dimer composed of HLA-DRA which is an ⁇ -chain and HLA-DRB1) which is a ⁇ -chain, and is preferably HLA-DR, HLA-DQ or HLA-DP.
- the antigenic peptide is not particularly limited as long as it is a peptide presented by MHC class II.
- Antigen peptides presented to MHC class II include, for example, WT1, PSA, MAGE-3, CEA, survivin, tyrosinase or peptides derived from proteins derived from a group of viruses strongly associated with malignant tumor development, but are preferably Includes WT1-derived peptides.
- the MHC and / or antigen peptide may be a protein synthesized biochemically by chemical synthesis or a cell-free translation system, or may have a base sequence encoding MHC or the like. It may be a recombinant protein produced from a transformant into which a nucleic acid has been introduced.
- MHC or the like is produced according to a known peptide synthesis method, for example, any of a solid phase synthesis method and a liquid phase synthesis method may be used.
- Manufacture of target protein by condensing amino acid derivative with protecting group on carboxy group and side chain functional group and amino acid derivative with protecting amino group and side chain functional group and removing protecting group can do.
- the condensation and the elimination of the protecting group are performed according to a method known per se, for example, the methods described in the following (1) to (5). (1) M.
- the MHC and the like thus obtained can be purified and isolated by a known purification method.
- the purification method include solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, a combination thereof, and the like.
- the free form can be converted into an appropriate salt by a known method or a method analogous thereto, or when the MHC or the like is obtained as a salt.
- the salt can be converted to a free form or another salt by a known method or a method analogous thereto.
- MHC and the like can also be produced by culturing a transformant containing a nucleic acid encoding the same and separating and purifying the MHC and the like from the resulting culture.
- the nucleic acid encoding MHC or the like may be DNA or RNA, or may be a DNA / RNA chimera.
- DNA is used.
- the nucleic acid may be double-stranded or single-stranded. In the case of double-stranded, it may be double-stranded DNA, double-stranded RNA or DNA: RNA hybrid. In the case of a single strand, it may be a sense strand (ie, a coding strand) or an antisense strand (ie, a non-coding strand).
- DNA encoding MHC examples include genomic DNA, warm-blooded animals (eg, human, cow, monkey, horse, pig, sheep, goat, dog, cat, guinea pig, rat, mouse, rabbit, hamster, bird, etc.).
- Cell-derived cDNA, synthetic DNA and the like can be mentioned. If it is a cDNA encoding MHC or the like, any cell of the animal [for example, hepatocytes, spleen cells, nerve cells, glial cells, pancreatic ⁇ cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, epithelial cells, goblet cells, etc.
- Cells endothelial cells, smooth muscle cells, fibroblasts, fibrocytes, muscle cells, adipocytes, immune cells (eg, macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, Eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, osteocytes, osteoblasts, osteoclasts, mammary cells, hepatocytes or stromal cells, or precursors, stem cells or cancer cells of these cells Etc.] or any tissue in which those cells are present [eg, brain, various parts of the brain (eg, olfactory bulb, amygdala, basal sphere, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla, cerebellum), spinal cord, inferior Pituitary, stomach, Gut, kidney, liver, gonad, thyroid, gall bladder, bone marrow, adrenal gland, skin, lung, digestive tract (eg,
- cDNA encoding MHC or the like is cloned from a cDNA library prepared by inserting the above-described total RNA or mRNA fragment into an appropriate vector, by colony or plaque hybridization, PCR, or the like, respectively. You can also.
- the vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like.
- the DNA encoding the MHC or the like is amplified by PCR using a synthetic DNA primer having a part of the base sequence encoding the MHC or the like, or a DNA incorporated into an appropriate expression vector, a part of the MHC or the like.
- Cloning can also be performed by hybridization with a labeled DNA fragment or synthetic DNA encoding the entire region. Hybridization is performed according to a method known per se or a method analogous thereto, for example, the method described in Molecular Cloning, 2nd edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). Can be. When a commercially available library is used, hybridization can be performed according to the method described in the attached instruction manual. Hybridization can be performed preferably under stringent conditions.
- High stringency conditions include, for example, a hybridization reaction in 6 ⁇ SSC (sodium chloride / sodium citrate) at 45 ° C. followed by one or more washes in 0.2 ⁇ SSC / 0.1% SDS at 65 ° C. No. Those skilled in the art can appropriately change the salt concentration of the hybridization solution, the temperature of the hybridization reaction, the probe concentration, the length of the probe, the number of mismatches, the hybridization reaction time, the salt concentration of the washing solution, the washing temperature, etc. Thus, the desired stringency can be easily adjusted. When a commercially available library is used, hybridization can be performed according to the method described in the instruction manual attached to the library.
- An expression vector containing a DNA encoding MHC or the like can be produced, for example, by cutting out a DNA fragment of interest from DNA encoding MHC or the like, and ligating the DNA fragment downstream of a promoter in an appropriate expression vector. Can be.
- plasmids derived from Escherichia coli eg, pBR322, pBR325, pUC12, pUC13
- animal cell expression plasmids eg, pA1-11, pXT1, pRc / CMV, pRc / RSV, pcDNAI / Neo
- retroviruses Animal virus vectors such as vaccinia virus and adenovirus are used.
- the promoter may be any promoter as long as it is appropriate for the host used for gene expression.
- SR ⁇ promoter when the host is an animal cell, SR ⁇ promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney murine leukemia virus) LTR, HSV-TK (herpes simplex virus) (Virus thymidine kinase) promoter and the like.
- CMV promoter, SR ⁇ promoter and the like are preferable.
- the host is a bacterium belonging to the genus Escherichia, trp promoter, lac promoter, recA promoter, ⁇ PL promoter, lpp promoter, T7 promoter and the like are preferable.
- SV40 ori an SV40 origin of replication
- the selection marker include dihydrofolate reductase gene (hereinafter sometimes abbreviated as dhfr, methotrexate (MTX) resistance), the ampicillin resistance gene (hereinafter sometimes abbreviated as # 038 r), neomycin resistance gene ( hereinafter sometimes abbreviated as neo r, include G418 resistance) and the like.
- dhfr gene-deficient Chinese hamster cells are used and the dhfr gene is used as a selection marker
- the target gene can be selected using a thymidine-free medium.
- a base sequence (signal codon) encoding a signal sequence suitable for the host may be added (or replaced with a native signal codon) to the 5 ′ end of DNA encoding MHC or the like.
- a base sequence signal codon
- the host is a bacterium belonging to the genus Escherichia, a PhoA signal sequence, an OmpA signal sequence, and the like; when the host is an animal cell, an insulin signal sequence, an ⁇ -interferon signal sequence, an antibody molecule signal sequence, and the like are used.
- M MHC or the like can be produced by transforming a host with an expression vector containing a DNA encoding the MHC or the like and culturing the resulting transformant.
- Escherichia bacteria for example, Escherichia bacteria, animal cells and the like are used.
- Escherichia bacteria include K12 DH1 [Proc. Natl. Acad. Sci. USA, 60, 160 (1968)], JM103 [Nucleic Acids Research, 9, 309 (1981)], JA221 [Journal of Molecular]. Biology, 120, 517 (1978)], HB101 [Journal of Molecular Biology, 41, 459 (1969)], C600 [Genetics, 39, 440 (1954)] and the like are used.
- animal cells examples include monkey COS-7 cells, monkey Vero cells, Chinese hamster ovary cells (hereinafter abbreviated as CHO cells), dhfr gene-deficient CHO cells (hereinafter abbreviated as CHO (dhfr ⁇ ) cells), mouse L Cells, mouse AtT-20 cells, mouse myeloma cells, rat GH3 cells, human FL cells and the like are used.
- Transformation can be performed according to known methods according to the type of host.
- the Escherichia bacterium can be transformed, for example, according to the method described in Proc. @Natl. @Acad. @Sci. @USA, Vol. 69, # 2110 (1972) or Genee, Vol.
- ⁇ Animal cells can be transformed, for example, according to the method described in Cell Engineering Separate Volume 8, New Cell Engineering Experiment Protocol, 263-267 (1995) (published by Shujunsha), Virology, 52, 456 (1973).
- ⁇ Culture of the transformant can be carried out according to a known method depending on the type of host.
- a medium for culturing a transformant in which the host is a bacterium belonging to the genus Escherichia for example, glucose, M9 medium containing casamino acid (Miller, Journal of Experiments in Molecular Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York) 1972] is preferred. If necessary, an agent such as, for example, 3 ⁇ -indolylacrylic acid may be added to the medium to make the promoter work efficiently.
- ⁇ Cultivation of a transformant whose host is Escherichia is usually performed at about 15 to about 43 ° C. for about 3 to about 24 hours. If necessary, ventilation or stirring may be performed.
- Examples of a medium for culturing a transformant whose animal host is an animal cell include, for example, a minimum essential medium (MEM) containing about 5 to about 20% fetal bovine serum [Science, 122, 501 (1952)], Dulbecco's Modified Eagle Medium (DMEM) (Virology, Volume 8, 396 (1959)), RPMI 1640 Medium (The Journal of the American Medical Association, 199, 519 (1967)), 199 Medium (Proceeding of the Society for the Biological Medicine) , # 73, # 1 (1950)].
- MEM minimum essential medium
- DMEM Dulbecco's Modified Eagle Medium
- RPMI 1640 Medium The Journal of the American Medical Association, 199, 519 (1967)
- 199 Medium Proceeding of the Society for the Biological Medicine
- # 73, # 1 (1950) The pH of the medium is preferably from about 6 to about 8.
- the cultivation is usually performed at about 30 ° C. to about 40 ° C. for about 15
- MHC or the like can be produced inside or outside the cells of the transformant.
- M MHC and the like can be separated and purified from a culture obtained by culturing the transformant according to a method known per se.
- MHC or the like when MHC or the like is extracted from cultured cells or cytoplasm of cells, cells or cells collected from the culture by a known method are suspended in an appropriate buffer and subjected to ultrasonication, lysozyme, and / or freeze-thawing. After disrupting the cells or cells, a method of obtaining a crude extract of soluble protein by centrifugation or filtration is used as appropriate.
- the buffer may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 TM .
- a method such as collecting the culture supernatant from the culture by centrifugation or filtration is used.
- ⁇ Isolation and purification of MHC and the like contained in the thus obtained soluble fraction and culture supernatant can be performed according to a method known per se.
- Such methods include methods using solubility such as salting out and solvent precipitation; mainly using differences in molecular weight such as dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis.
- a method utilizing a difference in charge such as ion exchange chromatography; a method utilizing a specific affinity such as affinity chromatography; a method utilizing a difference in hydrophobicity such as reverse phase high performance liquid chromatography;
- a method utilizing a difference in isoelectric point such as point electrophoresis; and the like.
- the MHC / antigen peptide complex obtained as described above may be a multimer.
- the method of multimerizing the MHC / antigen peptide complex of the present invention is known, for example, via a tetramer of avidin or streptavidin, and tetramerizing the MHC / antigen peptide complex modified with biotin. can do.
- multimerization can be achieved by linking an MHC / antigen peptide complex to dextran.
- the MHC / superantigen complex is an MHC / superantigen complex. It is a complex of class II and superantigen. Examples of superantigens include staphylococcal enterotoxin, streptococcal pyrogenic exotoxin, and toxic shock syndrome toxin.
- the MHC or superantigen may be produced by the same method as described in the aforementioned MHC and the like. Further, the MHC / superantigen complex may be a multimer as in the case of the MHC / antigen peptide complex.
- the method of multimerizing the MHC / superantigen complex of the present invention is the same as the method of multimerizing the MHC / antigen peptide complex.
- the CD3 / TCR complex agonist used in step (I) of the present invention may be in any form as long as it can be brought into contact with the CD3 / TCR complex on the surface of CD3-positive cells during culture.
- it may be contained in the culture medium during culturing, or may be immobilized in the culture vessel, but is preferably immobilized in the culture vessel.
- the medium is not particularly limited as long as the medium can culture CD3-positive cells.
- the medium can culture CD3-positive cells.
- GMEM Glasgow's Minimal Essential Medium
- IMDM Medium 199 medium
- EMEM Eagle's Minimum Essential Medium
- DMEM Dulbecco's modified Eagle's Medium
- Ham's F12 medium Ham's F12 medium
- RPMI 1640 Fischer's medium
- Neurobasal Medium Life Technologies
- the medium may contain serum or may be serum-free.
- the concentration of serum for example, fetal bovine serum (FBS), human serum, etc.
- FBS fetal bovine serum
- human serum etc.
- the medium may be, for example, Knockout Serum Replacement (KSR) (a serum replacement for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), albumin, insulin, transferrin, selenium.
- KSR Knockout Serum Replacement
- One or more serum substitutes such as compounds (eg, sodium selenite), vitamin Cs (eg, ascorbic acid) apotransferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol And lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (eg, Glutamax®), non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics (eg, penicillin) , Streptomycin), antioxidants, pyruvate, buffers, inorganic salts, selenate, progesterone and putrescine It may also contain more of the substance.
- the concentration of the CD3 / TCR complex agonist is, as a lower limit, 0.3 ng / ml or more, preferably 3 ng / ml or more, and as an upper limit, It may be up to 10,000 ng / ml, preferably up to 1000 ng / ml.
- the concentration of the anti-CD3 agonist antibody in the medium is, for example, 10 ng / ml to 1000 ng / ml.
- the culturing can be carried out, for example, in a CO 2 incubator under an atmosphere with a CO 2 concentration of about 1 to about 10%, preferably about 2 to about 5%, at about 30 to about 40 ° C., preferably about 37 ° C. .
- a CO 2 concentration of about 1 to about 10%, preferably about 2 to about 5%, at about 30 to about 40 ° C., preferably about 37 ° C.
- those skilled in the art can appropriately determine the culture period in the medium containing the CD3 / TCR complex agonist while monitoring the number of CD3-positive cells and the like.
- the number of days is not particularly limited as long as CD3-positive cells can be obtained. For example, at least 6 hours or more, 12 hours or more, 16 hours or more, 24 hours or more, 48 hours or more, 72 hours or more, preferably 16 to 72 hours. It is. Further, it is preferably 14 days or less, more preferably 7 days or less.
- the vitamin Cs are present in the culture in an amount corresponding to 5 ng / ml to 500 ng / ml (eg, 5 ng / ml, 10 ng / ml, 25 ng / ml, 50 ng / ml). , 100 ng / ml, 200 ng / ml, 300 ng / ml, 400 ng / ml, 500 ng / ml).
- the vitamin Cs are present in the culture in an amount corresponding to 5 ⁇ g / ml to 500 ⁇ g / ml (eg, 5 ⁇ g / ml, 10 ⁇ g / ml, 25 ⁇ g / ml, 50 ⁇ g / ml). ml, 100 ⁇ g / ml, 200 ⁇ g / ml, 300 ⁇ g / ml, 400 ⁇ g / ml, 500 ⁇ g / ml).
- the medium used in the step (I) of the present invention may further contain a cytokine.
- the cytokine contained in the medium is not particularly limited, and includes at least one or more selected from IL-7, IL-15, IL-18, and IL-21, and includes IL-7, IL- It is preferable that all of 15, IL-18 and IL-21 are contained.
- the lower limit of the concentration of the cytokine may be at least 0.1 ng / mL, preferably at least 10 ng / mL, and the upper limit may be at most 1000 ng / mL, preferably at most 300 ng / mL.
- the concentration in the medium is, for example, 1 to 100 ng / ml for IL-7, 1 to 100 ng / ml for IL-15, and 5 to 500 ng for IL-18. / ml, and IL-21 is 2-200 ng / ml.
- the medium used in step (I) of the present invention may further contain TL1A and / or IL-12. At this time, the concentration of TL1A in the medium is 5 to 500 ng / ml, and the concentration of IL-12 in the medium is 5 to 500 ng / ml.
- the medium used in the step (I) of the present invention may contain a TNF family cytokine as a cytokine.
- TNF family cytokines include TNF- ⁇ , TNF- ⁇ , lymphotoxin ⁇ , Fas ligand, TRAIL, TWEAK, TL1A, RANK ligand, OX40 ligand, APRIL, AITRL, BAFF, 4-1BBL and CD40 ligand.
- TL1A is preferred.
- the concentration in the medium may be 5 to 500 ng / ml.
- examples of the apoptosis inhibitor used in the step (I) of the present invention include a protease inhibitor, for example, a caspase inhibitor.
- a protease inhibitor for example, a caspase inhibitor.
- the caspase inhibitor Pan ⁇ Caspase ⁇ FMK ⁇ inhibitor ⁇ Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp (O-Me) ⁇ fluoromethylketone) is preferable, and its concentration in the medium is 1 to 1000 ⁇ M. possible.
- the culture vessel is not particularly limited as long as it is a culture vessel capable of culturing CD3-positive cells, and the vessel, slide, beads, and a combination thereof are used. be able to.
- the culture vessel include a flask, a flask for tissue culture, a dish, a Petri dish, a dish for tissue culture, a multi-dish, a microplate, a microwell plate, a multiplate, a multiwell plate, a microslide, a chamber slide, a petri dish, and a tube. , Trays, culture bags, roller bottles, microbeads, and the like.
- the immobilization of the CD3 / TCR complex agonist on the culture vessel can be carried out by known means.
- a CD3 / TCR complex agonist is dissolved in a solvent (eg, PBS), added to a culture vessel, and allowed to stand at 4 ° C. overnight.
- a solvent eg, PBS
- concentration of the CD3 / TCR complex agonist solution when the CD3 / TCR complex agonist is immobilized on the culture vessel may be appropriately determined by those skilled in the art according to the type of the CD3 / TCR complex agonist.
- the CD3 / TCR complex agonist is an anti-CD3 agonist antibody or a binding fragment thereof
- a solution of 0.3 to 10,000 ng / ml of the anti-CD3 agonist antibody or a binding fragment thereof is usually cultured. It can be brought into contact with a container, preferably 3 to 5000 ng / ml, more preferably 3 to 3000 ng / ml, and particularly preferably 3 to 600 ng / ml.
- the concentration of the anti-CD3 agonist antibody or the binding fragment thereof in the solution is, for example, 10 ng / ml to 10,000 ng / ml, and preferably 50 ng / ml to 5000 ng / ml. Yes, more preferably from 200 ng / ml to 4000 ng / ml.
- the concentration of the anti-CD3 agonist antibody or the binding fragment thereof in the solution is, for example, 1 to 50 000 ng / ml, preferably 3 to 30 000 ng / ml, and more preferably 30 to 30 000 ng / ml.
- the concentration in the solution is, for example, 1 ng / ml to 50000 ng / ml, preferably Is 10 ng / ml ⁇ 10000 ng / ml, more preferably 50 ng / ml ⁇ 5000 ng / ml, even more preferably 200 ng / ml ⁇ 4000 ng / ml.
- the concentration in the solution is, for example, 1 ng / ml to 50000 ng / ml, preferably Is 3 ng / ml ⁇ 30000 ng / ml, more preferably 30 ng / ml ⁇ 30000 ng / ml, even more preferably 300 ng / ml ⁇ 30000 ng / ml.
- fibronectin is not particularly limited as long as it can bind to CD3-positive cells.
- the variant of fibronectin is not particularly limited as long as it is a molecule capable of binding to VLA-5 and VLA-4 on the surface of CD3-positive cells, and includes, for example, RetroNectin (registered trademark).
- the fibronectin or a variant thereof used in the step (I) of the present invention is not limited as long as it can be brought into contact with CD3-positive cells during culture, as in the case of the CD3 / TCR complex agonist.
- it may be contained in the culture medium during culturing, or may be immobilized in the culture vessel, but is preferably immobilized in the culture vessel.
- the medium When fibronectin or a variant thereof is contained in the medium, the medium may be the same as the medium containing the CD3 / TCR complex agonist. Further, the presence or absence of serum, additives, and the like may be the same as in the medium containing the CD3 / TCR complex agonist.
- the concentration of fibronectin or its variant is, as a lower limit, 10 ng / ml or more, preferably 100 ng / ml or more, and as an upper limit, 10,000 ⁇ g / ml. Or less, preferably 1000 ⁇ g / ml or less.
- the culture vessel When the fibronectin or its variant is immobilized on a culture vessel, the culture vessel may be the same as the culture vessel on which the CD3 / TCR complex agonist is immobilized.
- the immobilization of fibronectin or a variant thereof on a culture vessel may be the same as the immobilization of a CD3 / TCR complex agonist.
- the concentration of the solution of fibronectin or its variant when immobilizing fibronectin or its variant on a culture vessel may be appropriately determined by those skilled in the art according to fibronectin or its variant.
- fibronectin or its variant is RetroNectin (registered trademark)
- the concentration of the retronectin solution is more preferably 0.1 to 1000 ⁇ g / mL, further preferably 1 to 300 ⁇ g / mL, and particularly preferably 1 to 150 ⁇ g / mL.
- the CD30 agonist is not particularly limited as long as it is a molecule capable of transmitting a signal from CD30 into cells by specifically binding to CD30.
- the CD30 agonist include at least one selected from the group consisting of an anti-CD30 agonist antibody or a binding fragment thereof and a CD30 ligand or a binding fragment thereof.
- the anti-CD30 agonist antibody and the binding fragment thereof used in the step (I) of the present invention may be the same as the anti-CD3 agonist antibody or the anti-TCR antibody in kind, preparation method and the like.
- the CD30 ligand or a binding fragment thereof used in the step (I) of the present invention includes, for example, CD153.
- the CD30 ligand or a binding fragment thereof may be produced by a method similar to that for producing MHC and / or antigenic peptides.
- the CD30 agonist used in the step (I) of the present invention is not limited in its aspect, as long as it can be brought into contact with CD30 during culture, similarly to the CD3 / TCR complex agonist.
- it may be contained in the culture medium during culturing, or may be immobilized in a culture vessel, but is preferably contained in the culture medium.
- the medium When the CD30 agonist is contained in the medium, the medium may be the same as the medium containing the CD3 / TCR complex agonist. Further, the presence or absence of serum, additives, and the like may be the same as in the medium containing the CD3 / TCR complex agonist.
- a CD30 agonist When a CD30 agonist is contained in the medium, those skilled in the art may appropriately determine the concentration of the CD30 agonist in the medium according to the type of the CD30 agonist.
- the concentration of the anti-CD30 agonist antibody or the binding fragment thereof in the medium is usually 1 ng / ml to 10000 ng / ml, preferably 1 ng / ml. / ml-1000 ng / ml, more preferably 3 ng / ml-300 ng / ml, even more preferably 30 ng / ml-300 ng / ml.
- the culture vessel When the CD30 agonist is immobilized on the culture vessel, the culture vessel may be the same as the culture vessel on which the CD3 / TCR complex agonist is immobilized.
- the method of immobilizing a CD30 agonist on a culture vessel may be the same as the method of immobilizing a CD3 / TCR complex agonist.
- the concentration of the CD30 agonist solution when the CD30 agonist is immobilized on the culture vessel is, as a lower limit, 0.1 ng / ml or more, preferably 1 ng / ml or more, and as an upper limit, 10000 ng / ml or less, Preferably, it can be 1000 ng / ml or less.
- the production method or the expansion culture method of the present invention further comprises a CD3 / TCR complex agonist, and CD3 positive cultured in the step (I) of the present invention in the absence of fibronectin or a variant thereof, and in the presence of a CD30 agonist.
- the method may include a step of culturing cells (hereinafter, referred to as step (II) of the present invention).
- the medium used in the above step (I) can be used, and the medium may contain serum or may be serum-free.
- the concentration of serum for example, fetal bovine serum (FBS), human serum, etc.
- FBS fetal bovine serum
- human serum etc.
- the medium may be, for example, Knockout Serum Replacement (KSR) (a serum replacement for FBS during ES cell culture), N2 supplement (Invitrogen), B27 supplement (Invitrogen), albumin, insulin, transferrin, selenium.
- KSR Knockout Serum Replacement
- One or more serum substitutes such as compounds (eg, sodium selenite), vitamin Cs (eg, ascorbic acid) apotransferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol And may contain lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, growth factors, low molecular compounds, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, selenate , Progesterone and putrescine may also be included.
- the culturing can be carried out, for example, in a CO 2 incubator under an atmosphere with a CO 2 concentration of about 1 to about 10%, preferably about 2 to about 5%, at about 30 to about 40 ° C., preferably about 37 ° C. .
- a CO 2 concentration of about 1 to about 10%, preferably about 2 to about 5%, at about 30 to about 40 ° C., preferably about 37 ° C.
- those skilled in the art can appropriately determine the culture period while monitoring the number of CD3-positive cells and the like.
- the number of days is not particularly limited, for example, at least 3 days or more, 5 days or more, 7 days or more, 10 days or more, 14 days or more, 21 days or more, preferably 7 days or more 15 days It is as follows. Further, it is preferably 30 days or less, more preferably 21 days or less.
- the vitamin Cs are present in the culture in an amount corresponding to 5 ng / ml to 500 ng / ml (eg, 5 ng / ml, 10 ng / ml, 25 ng / ml, 50 ng / ml). , 100 ng / ml, 200 ng / ml, 300 ng / ml, 400 ng / ml, 500 ng / ml).
- the vitamin Cs are present in the culture in an amount corresponding to 5 ⁇ g / ml to 500 ⁇ g / ml (eg, 5 ⁇ g / ml, 10 ⁇ g / ml, 25 ⁇ g / ml, 50 ⁇ g / ml). ml, 100 ⁇ g / ml, 200 ⁇ g / ml, 300 ⁇ g / ml, 400 ⁇ g / ml, 500 ⁇ g / ml).
- the medium used in step (II) of the present invention may further contain a cytokine.
- the cytokine is not particularly limited, but includes at least one or more selected from IL-7, IL-15, IL-18, IL-21, and includes IL-7, IL-15, IL- Preferably, all of 18 and IL-21 are contained.
- the concentration of the cytokine may be, as a lower limit, 0.1 ng / ml or more, preferably 10 ng / ml or more, and as an upper limit, 1000 ng / ml or less, preferably 300 ng / ml or less. .
- the concentration in the medium may be, for example, 1 ng / ml to 100 ng / ml for IL-7 and 1 ng / ml to 100 ng / ml for IL-15.
- IL-18 may be from 5 ng / ml to 500 ng / ml, and IL-21 may be from 2 ng / ml to 200 ng / ml.
- the medium used in step (II) of the present invention may further contain TL1A and / or IL-12.
- the concentration of TL1A in the medium may be 5 ng / ml to 500 ng / ml, and the concentration of IL-12 in the medium may be 5 ng / ml to 500 ng / ml. .
- the medium used in step (II) of the present invention may further contain an apoptosis inhibitor.
- Apoptosis inhibitors include protease inhibitors, for example, caspase inhibitors.
- caspase inhibitors Pan
- Z-VAD N-benzyloxycarbonyl-Val-Ala-Asp (O-Me)
- the concentration in the medium may be 1 ⁇ M to 1000 ⁇ M, preferably 1 ⁇ M to 500 ⁇ M, more preferably 1 ⁇ M to 200 ⁇ M, and particularly preferably 1 ⁇ M to 50 ⁇ M.
- steps (I) and (II) may be repeated in this order.
- the present invention also provides CD3-positive cells (hereinafter, referred to as CD3-positive cells of the present invention) obtained by the production method or the expansion culture method of the present invention.
- CD3-positive cells of the present invention are the same as the CD3-positive cells obtained by the production method or the expansion culture method of the present invention.
- the present invention also provides a kit for expanding CD3-positive cells (hereinafter, referred to as a kit of the present invention), comprising: (1) a culture vessel in which a CD3 / TCR complex agonist and fibronectin or a variant thereof are immobilized, and (2) a medium containing a CD30 agonist
- CD3 / TCR complex agonist, fibronectin or its variant, CD30 agonist, culture vessel and medium contained in the kit of the present invention may be the same as those described in the production method or the expansion culture method of the present invention.
- the present invention also provides a method for maintaining CD3-positive cells as CD3-positive CD197-positive cells, which comprises a step of stimulating a CD30 signal in CD3-positive cells (hereinafter referred to as a maintenance method of the present invention).
- a maintenance method of the present invention Normally, when peripheral blood-derived na ⁇ ve T cells are stimulated by an antigen presented to dendritic cells, na ⁇ ⁇ ve T cells are activated by intracellular signals, repeat proliferation and maturation, and sequentially, stem cell memory T cells, Differentiates into central memory T cells, effector memory T cells, and effector T cells.
- Effector T cells produce cytokines in the case of CD3-positive CD4-positive CD8-negative cells (helper T cells), and CD3-positive CD4-negative CD8-positive cells (cytotoxic T cells) kill target cells through antigens, Cannot survive for a long time.
- self-proliferating naive or stem cell memory T cells CD197 positive, CD45RA positive
- central memory T cells CD197 positive, CD45RA negative
- the CD3-positive cells cultured may be the same as the CD3-positive cells cultured in the production method or the expansion culture method of the present invention.
- the CD3-positive cells are CD3-positive CD197-positive cells.
- the maintenance method of the present invention includes a step of stimulating a CD30 signal in CD3-positive cells.
- the method of stimulating the CD30 signal in CD3-positive cells is not particularly limited as long as the signal can be transmitted downstream via the intracellular domain of CD30. Examples of such a method include a method including a step of culturing CD3-positive cells in the presence of a CD30 agonist (hereinafter, referred to as a maintenance method (1) of the present invention).
- a maintenance method (1) of the present invention CD3-positive cells can be maintained as CD3-positive CD197-positive cells.
- CD3-positive cells can be maintained as CD3-positive CD197-positive CD45RA-negative cells.
- the CD30 agonist and culture conditions used in the maintenance method (1) of the present invention may be the same as the CD30 agonist and culture conditions used in the production method or the expansion culture method of the present invention.
- the present invention also provides a kit for maintaining CD3-positive cells as CD3-positive CD197-positive cells, which contains a CD30 agonist (hereinafter, referred to as a maintenance kit of the present invention).
- the CD30 agonist contained in the maintenance kit of the present invention may be the same as the CD30 agonist used in the maintenance method (1) of the present invention.
- a CD3-positive cell that expresses a chimeric antigen receptor containing the intracellular domain of CD30 As another method of stimulating a CD30 signal in CD3-positive cells, a CD3-positive cell that expresses a chimeric antigen receptor containing the intracellular domain of CD30, the chimeric antigen receptor A method including a step of culturing in the presence of a stimulating antigen (hereinafter, referred to as a maintenance method (2) of the present invention) may be mentioned.
- a maintenance method (2) of the present invention By stimulating the chimeric antigen receptor containing the intracellular domain of CD30, it becomes possible to transmit a signal downstream through the intracellular domain of CD30, and to express the chimeric antigen receptor containing the intracellular domain of CD30 CD3-positive cells can be maintained as CD3-positive CD197-positive cells.
- CD3-positive cells expressing a chimeric antigen receptor containing the intracellular domain of CD30 can be maintained as CD3-positive CD197-positive CD45RA-negative cells.
- the culture conditions used in the maintenance method (2) of the present invention may be the same as the culture conditions used in the production method or the expansion culture method of the present invention.
- the antigen that stimulates the chimeric antigen receptor used in the maintenance method (2) of the present invention is not particularly limited as long as a signal can be transmitted downstream via the intracellular domain of CD30 contained in the chimeric antigen receptor. .
- the antigen that stimulates the chimeric antigen receptor is, for example, the same as the antigen targeted by the chimeric antigen receptor of the CD3 positive cells expressing the chimeric antigen receptor expressing in the production method or the expansion culture method of the present invention. May be.
- the present invention also provides a chimeric antigen receptor comprising an antigen-binding domain, a transmembrane domain and an intracellular signaling domain, wherein the intracellular signaling domain comprises an intracellular domain of CD30 or a variant thereof. (Hereinafter referred to as the chimeric antigen receptor of the present invention).
- the antigen-binding domain contained in the chimeric antigen receptor of the present invention may be the same as the antigen-binding domain contained in the chimeric antigen receptor expressed in CD3-positive cells cultured in the production method or the expansion culture method of the present invention. .
- the transmembrane domain contained in the chimeric antigen receptor of the present invention may be the same as the transmembrane domain contained in the chimeric antigen receptor expressed in CD3-positive cells cultured in the production method or the expansion culture method of the present invention. .
- the intracellular signaling domain contained in the chimeric antigen receptor of the present invention includes the intracellular domain of CD30 or a variant thereof.
- the intracellular domain of CD30 is not particularly limited as long as the antigen-binding domain contained in the chimeric antigen receptor of the present invention recognizes the antigen and retains the function of transmitting a recognition signal into the cell.
- a peptide containing the amino acid sequence represented by SEQ ID NO: 6 is exemplified.
- the variant of the intracellular domain of CD30 is not limited as long as the above-mentioned function is maintained.
- the variant is about 90% or more, preferably about 95% or more, more preferably about 97% %, Particularly preferably about 98% or more, most preferably about 99% or more.
- “homology” may be the same as the homology in the amino acid sequence of “IL-15 / IL-15R ⁇ ”.
- Examples of the modified intracellular domain of CD30 include, for example, (1) 1 or 2 or more (preferably about 1 to 100, preferably 1 to 50) of the amino acid sequences represented by SEQ ID NO: 6. Degree, more preferably about 1 to 10, particularly preferably 1 to several (2, 3, 4 or 5) amino acids, and (2) the amino acid sequence represented by SEQ ID NO: 6 1 or 2 or more (preferably about 1 to 100, preferably about 1 to 50, more preferably about 1 to 10, and particularly preferably 1 to a number (2, 3, 4, or 5)) (3) 1 or 2 or more amino acids (preferably about 1 to 50, preferably about 1 to 10, more preferably 1 to a number of amino acid sequences represented by SEQ ID NO: 6) 2, 3, 4 or 5) amino acids, and (4) the amino acid sequence represented by SEQ ID NO: 6.
- the amino acid sequence is inserted, deleted or substituted as described above, the position of the insertion, deletion or substitution is not particularly limited as long as the function of the intracellular domain of CD30 is maintained.
- the intracellular signaling domain contained in the chimeric antigen receptor of the present invention may further contain an intracellular domain derived from another protein in addition to the intracellular domain of CD30 or a variant thereof. Furthermore, the contained intracellular domain is the same as the intracellular domain contained in the intracellular signaling domain contained in the chimeric antigen receptor expressed in CD3-positive cells cultured in the production method or the expansion culture method of the present invention. Good.
- the intracellular domain further included is not particularly limited, but is preferably an intracellular domain derived from CD28 or CD3 ⁇ chain.
- the chimeric antigen receptor of the present invention may incorporate a spacer between the antigen-binding domain and the transmembrane domain or between the intracellular signaling domain and the transmembrane domain.
- the spacer may be the same as the spacer contained in the chimeric antigen receptor expressed on CD3-positive cells cultured in the production method or the expansion culture method of the present invention.
- the chimeric antigen receptor of the present invention specifically, an scFv that recognizes CD19 as an antigen-binding domain, a transmembrane domain of CD8 as a transmembrane domain, an intracellular domain derived from CD28 as an intracellular signaling domain, CD30 And a chimeric antigen receptor containing an intracellular domain derived from CD3 ⁇ and an intracellular domain derived from the CD3 ⁇ chain.
- the order of the respective intracellular domains contained in the intracellular signaling domain is not particularly limited, for example, the order of the intracellular domain derived from CD28, the intracellular domain derived from CD30, the intracellular domain derived from the CD3 ⁇ chain include.
- the chimeric antigen receptor of the present invention comprises, for example, the amino acid sequence represented by SEQ ID NO: 7.
- the chimeric antigen receptor of the present invention may be a protein chemically synthesized or biochemically synthesized by a cell-free translation system, or a nucleic acid having a base sequence encoding the chimeric antigen receptor of the present invention is introduced. It may be a recombinant protein produced from the transformed transformant.
- the chimeric antigen receptor of the present invention can be similarly produced, isolated and purified according to the method for producing MHC and / or antigenic peptide used in the production method or the expansion culture method of the present invention.
- the present invention also provides a nucleic acid (hereinafter, referred to as the nucleic acid of the present invention) comprising a polynucleotide encoding the chimeric antigen receptor of the present invention.
- the nucleic acid of the present invention may be DNA or RNA, or may be a DNA / RNA chimera. Preferably, DNA is used. Further, the nucleic acid may be double-stranded or single-stranded. In the case of double-stranded, it may be double-stranded DNA, double-stranded RNA or DNA: RNA hybrid. In the case of a single strand, it may be a sense strand (ie, a coding strand) or an antisense strand (ie, a non-coding strand).
- the nucleic acid of the present invention can be obtained by Polymerase Chain Reaction (hereinafter abbreviated as “PCR method”).
- PCR method Polymerase Chain Reaction
- genomic DNA or cDNA encoding each of the antigen-binding domain, transmembrane domain and intracellular signaling domain contained in the chimeric antigen receptor of the present invention is obtained. If it is cDNA, it can also be directly amplified by PCR and Reverse Transcriptase-PCR (hereinafter abbreviated as “RT-PCR”) using the total RNA or mRNA fraction prepared from the cells as templates.
- RT-PCR Reverse Transcriptase-PCR
- PCR is performed using a synthetic DNA primer consisting of a part of the base sequence encoding each domain of the antigen-binding domain, transmembrane domain and intracellular signaling domain and a base sequence encoding the spacer.
- the nucleic acid encoding each domain can be amplified.
- the PCR method is repeated using each of the obtained domains as a template and the synthetic DNA primers to obtain the nucleic acid of the present invention.
- the present invention also provides a chimeric antigen receptor gene transfer vector (hereinafter, referred to as the gene transfer vector of the present invention) containing the nucleic acid of the present invention.
- a chimeric antigen receptor gene transfer vector hereinafter, referred to as the gene transfer vector of the present invention
- the gene transfer vector of the present invention can be produced, for example, by ligating the nucleic acid of the present invention downstream of a promoter in an appropriate gene transfer vector.
- the gene transfer vector, promoter, and other elements are the same as the vector, promoter, and other elements used when introducing an exogenous TCR into pluripotent stem cells in the production method or the expansion culture method of the present invention. It may be.
- the present invention also provides a chimeric antigen receptor-expressing cell (hereinafter, referred to as a chimeric antigen receptor-expressing cell of the present invention), comprising the gene transfer vector of the present invention.
- the cells expressing the chimeric antigen receptor of the present invention can be produced by introducing and culturing the gene transfer vector of the present invention into cells.
- Cells into which the gene transfer vector of the present invention is introduced include CD3-positive cells or progenitor cells thereof (hematopoietic stem cells, lymphoid common progenitor cells, lymphoblasts, etc.) or pluripotent stem cells. , ES cells, iPS cells, EC cells, and EG cells, preferably ES cells or iPS cells.
- the gene transfer vector of the present invention can be introduced by a technique such as lipofection, liposome, or microinjection.
- the chimeric antigen receptor-expressing cells of the present invention are preferably CD3-positive cells.
- the CD3-positive cells are preferably CD3-positive CD8-positive cells (CD3-positive CD8-positive CD4-positive cells or CD3-positive CD8-positive CD4-negative cells), more preferably CD3-positive CD8-positive CD4-negative cells.
- Another preferable example of the CD3-positive cell is a CD3-positive CD4-positive cell (CD3-positive CD4-positive CD8-positive cell or CD3-positive CD4-positive CD8-negative cell).
- the chimeric antigen receptor-expressing cell of the present invention is a cell produced by introducing the gene transfer vector of the present invention into a pluripotent stem cell
- the pluripotent stem cell is differentiated into a CD3-positive cell according to a method known per se. Can be done.
- the specific method for differentiating pluripotent stem cells into CD3-positive cells may be the same as the method for producing CD3-positive cells to differentiate pluripotent stem cells in the production method or the expansion culture method of the present invention.
- the chimeric antigen receptor-expressing cells of the present invention obtained as described above are given specificity for the target antigen by the chimeric antigen receptor, they exhibit cytotoxic activity against tumors that express the target antigen. obtain. Further, since the chimeric antigen receptor can directly recognize the antigen molecule without depending on HLA class I or class II, the expression of the chimeric antigen receptor of the present invention reduces the expression of the HLA class I or class II gene. It is possible to generate a high immune response even for tumors that have developed. Therefore, the present invention also provides a drug (hereinafter, referred to as the drug of the present invention) containing the cell expressing the chimeric antigen receptor of the present invention as an active ingredient.
- a drug hereinafter, referred to as the drug of the present invention
- the medicament containing the chimeric antigen receptor-expressing cell of the present invention can be used for the prevention or treatment of a tumor expressing an antigen recognized by the chimeric antigen receptor of the present invention.
- mammals eg, mice, Rats, hamsters, rabbits, cats, dogs, cows, sheep, monkeys, humans
- a medicament of the present invention for use in the prevention or treatment of a tumor that expresses an antigen recognized by the chimeric antigen receptor of the present invention.
- the prevention or treatment of a tumor expressing an antigen recognized by the chimeric antigen receptor of the present invention which comprises administering the cell expressing the chimeric antigen receptor of the present invention, preferably in the form of a medicament containing the cells.
- a method is provided.
- the tumor to be prevented or treated by the medicament of the present invention or the cell expressing the chimeric antigen receptor of the present invention is not particularly limited as long as it expresses an antigen recognized by the chimeric antigen receptor of the present invention.
- the tumor is described, for example, in "Daniel Baumhoer et al., Am J. Clin Pathol, 2008, 129, 899-906" and is a benign tumor, a malignant tumor (also referred to as "cancer"). ), And tumors that can be diagnosed or determined as benign or malignant.
- tumors include liver cancer (eg, hepatocellular carcinoma), ovarian cancer (eg, ovarian clear cell adenocarcinoma), childhood cancer, lung cancer (eg, squamous cell carcinoma, small cell lung cancer), testicular cancer (Eg, nonseminoma germ cell tumor), soft tissue tumor (eg, liposarcoma, malignant fibrous histiocytoma), uterine cancer (eg, cervical intraepithelial neoplasia, cervical squamous cell carcinoma), melanoma, adrenal tumor ( Examples: adenomas of the adrenal gland, neurological tumors (eg, Schwannoma), gastric cancer (eg, gastric adenocarcinoma), kidney cancer (eg, Gravitz tumor), breast cancer (eg, invasive lobular carcinoma, mucinous carcinoma) ), Thyroid cancer (eg, medullary carcinoma), laryngeal cancer (eg, squamous cell carcinoma), bladder cancer (
- the cells expressing the chimeric antigen receptor of the present invention may be cultured and / or stimulated using an appropriate medium and / or stimulating molecule before administration to a subject.
- Stimulatory molecules include, but are not limited to, cytokines, suitable proteins, other components, and the like.
- the cytokines include IL-2, IL-7, IL-12, IL-15, IFN- ⁇ , and the like, and preferably IL-2 can be used.
- the concentration of IL-2 in the medium is not particularly limited. For example, it is preferably 0.01 U / ml to 1 ⁇ 10 5 U / ml, more preferably 1 U / ml to 1 ⁇ 10 4 U / ml. ml.
- Suitable proteins include, for example, antigens recognized by chimeric antigen receptors, CD3 ligands, CD28 ligands, and anti-IL-4 antibodies.
- a lymphocyte stimulating factor such as lectin can also be added.
- serum or plasma may be added to the medium. The amount added to these media is not particularly limited, but is, for example, 0% by volume to 20% by volume, and the amount of serum or plasma used can be changed depending on the culture stage. For example, the serum or plasma concentration can be used stepwise reduced.
- the origin of serum or plasma may be either self or non-self, but from the viewpoint of safety, self-derived is preferred.
- the medicament of the present invention is preferably administered parenterally to a subject.
- Parenteral administration methods include methods such as intravenous, intraarterial, intramuscular, intraperitoneal, and subcutaneous administration.
- the dose is appropriately selected depending on the condition, body weight, age, etc. of the subject. Usually, the number of cells is usually 1 ⁇ 10 6 to 1 ⁇ 10 10 cells / time for a subject weighing 60 kg.
- the dose is preferably 1 ⁇ 10 7 to 1 ⁇ 10 9 , more preferably 5 ⁇ 10 7 to 5 ⁇ 10 8 . In addition, it may be administered once or may be administered multiple times.
- the medicament of the present invention can be in a known form suitable for parenteral administration, for example, injection or infusion.
- the medicament of the present invention may contain physiological saline, phosphate buffered saline (PBS), a medium, and the like in order to stably maintain cells.
- the medium include, but are not limited to, RPMI, AIM-V, and X-VIVO10.
- a pharmaceutically acceptable carrier eg, human serum albumin
- a preservative e.g., a preservative, and the like may be added to the medicament for the purpose of stabilization.
- the cells expressing the chimeric antigen receptor of the present invention can kill cells expressing the antigen recognized by the chimeric antigen receptor of the present invention, and thus can be used as a killing agent for cells expressing the antigen.
- a killing agent can be prepared and used in the same manner as the above-mentioned medicine.
- the present invention provides a method for producing a prophylactic or therapeutic agent for a tumor that expresses an antigen recognized by the chimeric antigen receptor of the present invention, according to a medicament containing the cell expressing the chimeric antigen receptor of the present invention.
- a medicament containing the cell expressing the chimeric antigen receptor of the present invention Embodiments of the use of the cells expressing the chimeric antigen receptor of the invention are also included.
- the preventive or therapeutic agent for tumors can be produced by a method known per se. For example, similarly to the above-mentioned method for preparing the medicament of the present invention, it can be produced in a known form suitable for parenteral administration, for example, injection or infusion.
- Example 1 Preparation of iPS cells As the iPS cells, the Ff-I01s04 strain donated by Kyoto University iPS Cell Research Institute (CiRA) was used. The iPS cell culture was performed according to the protocol “Culture of human iPS cells without feeder” distributed by CiRA.
- T cell receptor (TCR) gene is derived from TAK1 and provided by HLA-A * 24: 02 restricted WT1-specific TCR (WT1- TCR) gene was used.
- Gene transfer into iPS cells was performed by incorporating the gene into a CS-UbC-RfA-IRES2-hKO1 lentiviral vector provided by RIKEN and infecting the iPS cells.
- CTL Differentiation of iPS cells into which WT1-TCR gene has been introduced into CD8-positive T cells
- CTL CD8-positive T cells
- antibody RetroNectin (registered trademark) was purchased from Takara Bio Inc.
- anti-CD3 agonist antibody an anti-human CD3 functional grade purified (Clone: OKT3) purchased from eBioscience or a CD3 antibody (Clone: UCHT1) purchased from GeneTex was used. OKT3 was used unless otherwise noted.
- an anti-CD30 agonist antibody a CD30 agonist antibody purchased from R & D was used.
- ELISA for detecting immobilized anti-CD3 agonist antibody and Immobilized RetroNectin®
- HRP Conjugated Goat anti-Mouse IgG2a Detection Antibody contained in Mouse IgG2a ELISA Quantitation Set purchased from Bethyl Laboratorie was used.
- immobilized RetroNectin registered trademark
- 1-Step TM Ultra TMB-ELISA Substrate Solution (ThermoFisher) was added. After standing at room temperature for 15 minutes, 1 M sulfuric acid was added to stop the reaction, and the absorbance at 450 nm was measured using a plate reader.
- iPS cell-derived T cells prepared at 100,000 cells / 200 ⁇ L in an ⁇ -MEM medium containing 15% FBS and the cytokines shown in Table 1 were added to an anti-CD3 agonist antibody (3, 30, 300, 3000 ng / cell).
- ml) and RetroNectin (0, 1.85, 2.25, 16.7, 50, 150 ⁇ g / ml) were seeded in immobilized plates were incubated under 5% CO 2/37 °C 3 days.
- the cells are collected from the plate, the number of cells is counted using TC20 (Bio-Rad), and suspended in an appropriate amount in a medium obtained by adding the cytokines and the like shown in Table 2 to an ⁇ -MEM medium containing 15% FBS. Nigoshi, was added to 96-well plates that are not immobilized, and incubated under 5% CO 2/37 °C. Thereafter, the cells are collected from the plate 4 to 7 times once at each of the timings of the culture 5, 6, 7, 8, 9, 10, 12, 14, and 16 days, and the number of cells is counted. They were cultured under 5% CO 2/37 °C was added to the plate that is not immobilized and suspended in an appropriate amount.
- ATP test The ATP in the cells and the culture supernatant on the 12th day of the culture in the proliferation test was measured according to a standard protocol using a CellTiter-Glo (R) Luminescent Cell Viability Assay purchased from Promega.
- HLA-A * 24 02 positive LCL cells were purchased from RIKEN BioResource Center. The cells were cultured in RPMI1640 medium containing 10% FBS. The synthesis of the WT1 antigen peptide (CMTWNQMNL: SEQ ID NO: 3) was commissioned to Scrum Corporation. The cytotoxicity test was evaluated using a DELFIA immunoassay purchased from PerkinElmer according to a standard protocol.
- Test Example 1 1. Measurement of concentration of anti-CD3 agonist antibody and retronectin (registered trademark) suitable for immobilization on culture plate For immobilization of anti-CD3 agonist antibody and retronectin (registered trademark) on culture plate using ELISA method The appropriate concentration was determined (FIG. 1). The concentration-dependent solid-phase immobilization of the anti-CD3 agonist antibody was confirmed between 3 ng / mL and 3000 ng / mL. Retronectin (registered trademark) was confirmed to have a concentration-dependent solid phase immobilization between 16.7 ⁇ g / mL and 150 ⁇ g / mL.
- iPS cell-derived T cells stimulated by immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) .IPS cell-derived T cells prepared at 100,000 cells / 200 ⁇ L were treated with an anti-CD3 agonist antibody (3000 ng / mL) and Anti-CD3 / CD28 added on a 96-well plate on which Retronectin (registered trademark) (150 ⁇ g / mL) is immobilized, or added so that the number of iPS cell-derived T cells and the number of bead particles are 1: 1. After stimulation with beads (Dynabeads) for 3 days, the number of cells when cultured without stimulation was counted over time (FIG. 3). The iPS cell-derived T cells proliferated more when stimulated with the immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) than the anti-CD3 / CD28 beads.
- Proliferation test of iPS cell-derived T cells by anti-CD30 agonist antibody stimulation Add anti-CD30 agonist antibody (0, 30, 100, 300 ng / mL) at the time of stimulation with immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) Thus, it was examined whether or not it affected the proliferation of iPS cell-derived T cells.
- the immobilized 96-well plate used was one on which an anti-CD3 agonist antibody (3000 ng / ml) and RetroNectin (registered trademark) (150 ⁇ g / ml) were immobilized.
- the iPS cell-derived T cells proliferated by adding the anti-CD30 agonist antibody. Proliferation occurred in a concentration-dependent manner with the added anti-CD30 agonist antibody (FIG. 6).
- the cells are collected from the plate, the number of cells is counted using TC20 (Bio-Rad), and suspended in an appropriate amount in a medium obtained by adding the cytokines and the like shown in Table 2 to an ⁇ -MEM medium containing 15% FBS. Nigoshi, was added to the plate which has not been immobilized, and incubated under 5% CO 2/37 °C. After that, cells are collected from the plate once at the timing of culture days 6, 7, 9, 10, 14, and 16, and the number of cells is counted, and the cells are suspended in an appropriate amount and added to the unimmobilized plate. They were cultured under 5% CO 2/37 °C with.
- the culture solution to which the anti-CD30 agonist antibody diluted to the final concentration of 100 ng / mL was added and the one to which no anti-CD30 agonist antibody was added were used.
- the above stimulation from day 0 to day 16 of culture was repeated twice.
- the iPS cell-derived T cells also showed an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) and an anti-CD30 as compared to stimulation with only the immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark). Proliferated more by stimulation with an agonist antibody (FIG. 7).
- CD197 and CD45RA on iPS cell-derived T cell membrane surface after stimulation with immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody Stimulation with immobilized anti-CD3 agonist antibody / RetroNectin® After stimulation with an immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) and an anti-CD30 agonist antibody, the expression of CD197 and CD45RA on the surface of the iPS cell-derived T cell membrane was measured on the 7th day using a flow cytometer.
- the WT1-TCR gene-introduced iPS cell-derived T cells had almost no nonspecific cytotoxic activity and showed only WT1 antigen-specific cytotoxic activity (FIG. 9). In addition, the WT1 antigen-specific cytotoxic activity was maintained even after proliferation by the second stimulation (FIG. 9).
- Example 2 Preparation of human peripheral blood-derived CD8-positive T cells Human peripheral blood was purchased from Precision Bioservices as peripheral blood mononuclear cells derived from healthy individuals. CD8 + T cells were isolated using a CD8 + T cell isolation kit, human (Milteny).
- the cells were collected from the plate, the number of cells was counted, and the cells were suspended in an appropriate amount and administered to mice.
- days 6, 10, 13, and 17 of the culture the cells were collected from the plate, suspended in an appropriate amount, and subjected to a CD197 expression experiment.
- a culture medium containing 15 / anti-CD30 antibody CD197 expression on the cell membrane surface of the CD8-positive T cells derived from human peripheral blood stimulated with anti-CD3 / CD28 beads was measured by a flow cytometer on days 6, 10, 13, and 17 of culture. .
- CD197 expression was confirmed in all groups on day 6, but CD197 expression almost disappeared on day 13 in the IL-2 containing medium group and on day 17 in the IL-7 / IL-15 containing medium group.
- the medium group containing IL-7 / IL-15 / anti-CD30 antibody CD197 expression was maintained even on day 17 (FIG. 11).
- Example 3 Proliferation test of anti-CD19-CART cells derived from iPS cells.
- Anti-CD19-CART cells derived from iPS cells prepared at 100,000 cells / 200 ⁇ L in a medium obtained by adding the cytokines and the like shown in Table 1 to ⁇ -MEM medium containing 15% FBS, It was seeded in CD3 antibody and RetroNectin plate which is (R) immobilized, and incubated under 5% CO 2/37 °C 3 days. On the third day of the culture, collect the cells from the plate, count the number of cells using TC20 (biorat), suspend the cells in an appropriate amount in a medium containing 15% FBS and add the cytokines in Table 2 to ⁇ -MEM medium.
- Nigoshi was added to the plate which has not been immobilized, and incubated under 5% CO 2/37 °C. Thereafter, cells were collected from the plate 4-7 times on days 5, 6, 7, 8, 9, 10, 12, 14, and 16 of the culture, the number of cells was counted, and the cells were suspended in an appropriate amount and immobilized. They were cultured under 5% CO 2/37 °C was added to non plates.
- Anti-CD19-CAR Gene For the anti-CD19-CAR gene, an oligo DNA encoding a polypeptide (SEQ ID NO: 5) designed to be arranged in the order shown in Table 6 from the N-terminus was artificially synthesized.
- CD197 on iPS cell-derived anti-CD19-CART cell membrane surface after stimulation with immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody Immobilized anti-CD3 antibody / RetroNectin® after stimulation
- the expression of CD197 on the surface of the iPS cell-derived anti-CD19-CART cell membrane on days 3 and 7 after stimulation with the immobilized anti-CD3 antibody / RetroNectin (registered trademark) / anti-CD30 agonist antibody was measured using a flow cytometer. On the third day, CD197 expression was confirmed in both groups.
- Example 4 Anti-CD19-CAR Gene Containing CD30-Derived Intracellular Domain
- an oligo DNA encoding a polypeptide (SEQ ID NO: 7) designed to be arranged in the order of Table 7 from the N-terminus was artificially synthesized.
- retroviral vector carrying anti-CD19-CAR gene containing CD30-derived intracellular domain [Example 4]
- the artificial oligo DNA synthesized in the above was incorporated into a multicloning site of a pMY retrovirus vector.
- a virus vector was prepared using FRY-RD18 cells for producing a retrovirus vector.
- iPS cell-derived anti-CD19-CART cell iCD19-CD30-CART
- the retrovirus vector carrying the anti-CD19-CAR gene prepared in [1] was used in [Example 1] 3.
- the iPS cell-derived T cells prepared in the above were infected to prepare iPS cell-derived anti-CD19-CART cells (iCD19-CD30-CART) containing a CD30-derived intracellular domain.
- Example 5 Preparation of iPS cells As in [Example 1], the Ff-I01s04 strain donated by Kyoto University iPS Cell Research Institute (CiRA) was used as iPS cells. The iPS cell culture was performed according to the protocol “Culture of human iPS cells without feeder” distributed by CiRA.
- iPS cell-derived ⁇ T cells iPS cell-derived ⁇ T cells
- Expansion culture of iPS cell-derived ⁇ T cells [Example 5] 2.
- the i ⁇ T cells obtained in the above were suspended at 2,000,000 cells / mL in an ⁇ -MEM medium containing 15% FBS to which the cytokines in Table 8 were added, and the anti-CD3 antibody (UCHT1) and RetroNectin (registered trademark) were immobilized. It was seeded in of the plates, and cultured under 5% CO 2/37 °C 3 days.
- the cells are collected from the plate, the number of cells is counted using a NucleoCounter NC-200 (ChemoMetec), and an appropriate amount is added to an ⁇ -MEM medium containing 15% FBS plus a cytokine shown in Table 9 suspended, was added to the immobilized non G-Rex 6-well plates (WILSONWOLF), they were cultured under 5% CO 2/37 °C to. Thereafter, some of the cells were collected from the plate 4 to 6 times on days 5, 6, 7, 8, 9, 10, 11, 14, and 17 of culture, and the number of cells was counted.
- the anti-CD3 antibody and RetroNectin (registered trademark) were immobilized on a culture plate by the following method.
- Anti-CD3 antibody (UCHT1, final concentration 3000 ng / mL) and RetroNectin (registered trademark) (final concentration 150 ⁇ g / mL) dissolved in PBS at the required concentrations were added to the plate, and the plate was allowed to stand at 4 ° C. overnight. . After washing with PBS, it was used for the test.
- Example 5 Proliferation test of iPS cell-derived ⁇ T cells stimulated with anti-CD30 agonist antibody
- Example 5 The effect of adding an anti-CD30 agonist antibody (300 ng / ml) to the stimulation method using immobilized anti-CD3 agonist antibody / RetroNectin (registered trademark) on the proliferation of iPS cell-derived ⁇ T cells Verified. The iPS cell-derived T cells proliferated by adding the anti-CD30 agonist antibody (FIG. 18).
- IL-15R ⁇ / IL-15 Gene for the IL-15R ⁇ / IL-15 gene, an oligo DNA encoding a polypeptide (SEQ ID NO: 8) designed to be arranged in the order shown in Table 10 from the N-terminus was artificially synthesized.
- retroviral vector carrying IL-15R ⁇ / IL-15 gene [Example 6]
- the artificial oligo DNA synthesized in the above was incorporated into a multicloning site of a pMY retrovirus vector.
- a virus vector was prepared using FRY-RD18 cells for producing a retrovirus vector.
- iPS cell-derived anti-CD19-CAR / IL-15 ⁇ T cells [Example 3] Retrovirus vector carrying the anti-CD19-CAR gene prepared in [1] and [Example 6] Using the retrovirus vector carrying the IL-15R ⁇ / IL-15 gene prepared in [5], [Example 5] The iPS cell-derived ⁇ T cells (i ⁇ T cells) prepared in the above were infected to prepare iPS cell-derived anti-CD19-CAR / IL-15 ⁇ T cells (iCD19CAR / IL-15 ⁇ T cells).
- Example 5 Expansion culture of anti-CD19-CAR / IL-15 ⁇ T cells derived from iPS cells [Example 5] Except that IL-2 was not added. Expansion culture of iCD19CAR / IL-15 ⁇ T cells was carried out in the same manner as described above.
- ICD19CAR / IL-15 ⁇ T cells The cytotoxic activity of iCD19CAR / IL-15 ⁇ T cells was evaluated based on the later target cell death.
- ICD19CAR / IL-15 ⁇ T cells expanded in a medium containing an anti-CD30 agonist antibody were shown to have cytotoxic activity against CD19-positive Raji cells and not against CD19-negative CCRF-CEN cells. (FIG. 20).
- IPS cell-derived anti-CD19-CAR / IL-15 ⁇ T cells after stimulation with immobilized anti-CD3 agonist antibody / RetroNectin® and anti-CD30 agonist antibody prolong the survival days NOD / Shi-scid, IL-2R ⁇ KO (NOG 5) 10 ⁇ 10 5 Nalm6 cells (ATCC) were implanted in the tail vein of a mouse (Central Laboratory Animal, female, 7-8 weeks old) to prepare a Nalm6 xenograft mouse. Four days after transplantation, [Example 6] 4.
- Example 7 1. 3. Production of anti-CD19-CAR / IL-15 ⁇ T cells derived from iPS cells [Example 3] [Example 6] to iPS cell-derived anti-CD19-CART cells produced by the method of [1].
- iPS cell-derived anti-CD19-CAR / IL-15 ⁇ T cells iCD19CAR / IL-15 ⁇ T cells
- the suspension obtained by suspending the iCD19CAR / IL-15 ⁇ T cells (5 ⁇ 10 6 cells) obtained in the above in 0.1 mL of HBSS-buffer or an equivalent amount of HBSS-buffer was administered to the tail vein.
- Luciferin was administered to the tail vein every week after administration, and the activity of luciferase expressed by Nalm6 cells was measured using IVIS.
- luminescence derived from Nalm6 cells was confirmed systemically 2 weeks after administration, and all cases died by 3 weeks after administration, whereas in the iCD19CAR / IL-15 ⁇ T cell administration group, 6 weeks after administration. No luminescence was detected until later (FIG. 22).
- Example 8 Production of iPS cell-derived ⁇ T cells [Example 5] And 2. IPS cell-derived ⁇ T cells (i ⁇ T cells) were produced in the same manner as described above.
- concentration-dependent solid-phase immobilization was confirmed between 3 ng / mL and 30000 ng / ml (0.003 ⁇ g / ml to 30 ⁇ g / ml).
- concentration of RetroNectin registered trademark
- concentration-dependent solid-phase immobilization was confirmed between 16.7 ⁇ g / mL and 150 ⁇ g / mL.
- T cells By culturing CD3-positive cells in the presence of a CD3 / TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist, T cells can be efficiently and repeatedly expanded.
- the cultured CD3-positive cells are CD3-positive CD8-positive cells or CD3-positive CD8-positive CD30-positive cells, the cells produced or expanded are easily shifted to effector T cells and exert cytotoxic activity. Therefore, it can be applied to T cell therapy.
- This application is filed with Japanese Patent Application No. 2018-151580 (filing date: August 10, 2018), Japanese Patent Application No. 2019-042666 (filing date: March 8, 2019), and Japanese Patent Application No. 2019-117878. (Filing date: June 25, 1980), the entire contents of which are incorporated herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
従来の治療法が奏功しないがんに対しても強い延命効果を示すことが明らかとなった免疫療法は、がん治療の主役になろうとしている。抗CD19キメラ抗原受容体(CAR)遺伝子を導入した自己T細胞を移入するCART療法は、B細胞悪性腫瘍に対して高い完全寛解率を示し、2017年にB細胞性急性リンパ芽球性白血病とびまん性大細胞型B細胞リンパ腫を対象とした2つのCART療法がFDAより承認された。また、がん細胞抗原を認識するT細胞受容体(TCR)遺伝子を導入したTCR-T細胞療法も、多くの臨床試験が進行中である。これらの患者自身(自己)のT細胞を利用した遺伝子改変T細胞療法は、非常に優れた臨床成績を示す一方で、T細胞の輸送と遺伝子改変、細胞培養などを含み、数週間以上かかる煩雑なプロセスがコスト抑制と品質管理を難しくしている上に、進行の早いがん患者の治療機会喪失を招くため、オフザシェルフ(既製品)同種T細胞療法の開発が強く求められている。患者から回収したT細胞の拡大培養方法としては、これまでに、T細胞集団に抗CD3アゴニスト抗体および抗CD30アゴニスト抗体を接触させることにより、CD8陽性Tc1リンパ球またはCD8陽性Tc2リンパ球を製造する方法(特許文献1)や、がん患者からT細胞集団を取得し、該T細胞集団に抗CD3アゴニスト抗体、抗CD28抗体およびVEGF阻害剤を接触させることにより、腫瘍特異的T細胞を拡大培養する方法(特許文献2)が報告されている。しかしながら、健常人もしくは患者由来のT細胞は増殖能が限られており、一回のアフェレシスで回収可能なT細胞から製造可能な遺伝子改変T細胞数は限定されている。また、TCRの刺激によりT細胞を拡大培養した場合、ナイーブ細胞、メモリーT細胞の細胞表面マーカーであるCCR7 (CD197)の発現が一過的に上昇するものの、その後数日で消失していくことが報告されている(非特許文献1)。また、メモリーT細胞であること(“T cell persistence”)が、in vivo抗腫瘍活性において重要であること、メモリーT細胞であるCARTの投与細胞数を上げることにより、高いin vivo抗腫瘍効果が認められたことが報告されている(非特許文献2)。従って、T細胞を拡大培養した結果得られる細胞集団のCD197発現が低い場合は、がん治療に好適ではなかった。
[1]CD3/TCR複合体アゴニスト、フィブロネクチンまたはその改変体、およびCD30アゴニストの存在下、CD3陽性細胞を培養する工程(I)を含む、CD3陽性細胞の製造方法。
[2]CD3/TCR複合体アゴニストおよびフィブロネクチンまたはその改変体の非存在下、かつCD30アゴニストの存在下、工程(I)で培養されたCD3陽性細胞を培養する工程(II)をさらに含む、[1]に記載の方法。
[3]前記CD3陽性細胞が、多能性幹細胞由来である、[1]または[2]に記載の方法。
[4]前記多能性幹細胞が、iPS細胞である、[3]に記載の方法。
[5]前記CD3陽性細胞が、キメラ抗原受容体発現CD3陽性細胞である、[1]~[4]のいずれか1つに記載の方法。
[6]前記CD3陽性細胞が、CD3陽性CD8陽性細胞である、[1]~[5]のいずれか1つに記載の方法。
[7]前記CD3陽性CD8陽性細胞が、CD3陽性CD8陽性CD4陰性細胞である、[6]に記載の方法。
[8]前記CD3陽性細胞が、γTCR陽性および/またはδTCR陽性細胞である、[1]~[7]のいずれか1つに記載の方法。
[9]前記CD3/TCR複合体アゴニストが、CD3アゴニストおよび/またはTCRアゴニストである、[1]~[8]のいずれか1つに記載の方法。
[10]前記CD3アゴニストが、抗CD3アゴニスト抗体またはその結合断片である、[9]に記載の方法。
[11]前記抗CD3アゴニスト抗体またはその結合断片が、UCHT1クローンから産生される抗CD3アゴニスト抗体またはその結合断片である、[10]に記載の方法。
[12]前記TCRアゴニストが、抗TCR抗体またはその結合断片、HLA/ペプチド複合体またはその多量体、およびHLA/スーパー抗原複合体またはその多量体からなる群より選択される少なくとも一つである、[9]に記載の方法。
[13]前記抗CD3アゴニスト抗体またはその結合断片が、培養容器に固相化されている、[10]または[11]に記載の方法。
[14]前記抗CD3アゴニスト抗体またはその結合断片の固相化が、1 ng/ml~50000 ng/mlの該抗CD3アゴニスト抗体またはその結合断片を培養容器に接触させることによって行われる、[13]に記載の方法。
[15]前記フィブロネクチンまたはその改変体が、レトロネクチン(登録商標)である、[1]~[14]のいずれか1つに記載の方法。
[16]前記レトロネクチン(登録商標)が、培養容器に固相化されている、[15]に記載の方法。
[17]前記レトロネクチン(登録商標)の固相化が、1~150 μg/mLの該レトロネクチン(登録商標)を培養容器に接触させることによって行われる、[16]に記載の方法。
[18]前記CD30アゴニストが、抗CD30アゴニスト抗体またはその結合断片およびCD30リガンドまたはその結合断片からなる群より選択される少なくとも一つである、[1]~[17]のいずれか1つに記載の方法。
[19]前記抗CD30アゴニスト抗体またはその結合断片が、培地に含有されている、[18]に記載の方法。
[20]前記培地中の前記抗CD30アゴニスト抗体またはその結合断片の濃度が、1 ng/ml~1000 ng/mlである、[19]に記載の方法。
[21]培地が、IL-7、IL-15、IL-18およびIL-21から選択される少なくとも1つ以上を含む、[1]~[20]のいずれか1つに記載の方法。
[22]培地が、IL-7、IL-15、IL-18およびIL-21を含む、[21]に記載の方法。
[23]培地が、さらにTL1Aおよび/またはIL-12を含む、[21]または[22]に記載の方法。
[24]前記製造されたCD3陽性細胞が、さらにCD197陽性である、[1]~[23]のいずれか1つに記載の方法。
[25][1]~[24]のいずれか1つに記載の方法によって得られるCD3陽性細胞。
[26]CD3/TCR複合体アゴニスト、フィブロネクチンまたはその改変体、およびCD30アゴニストの存在下、CD3陽性細胞を培養する工程を含む、CD3陽性細胞の拡大培養方法。
[27]以下を含む、CD3陽性細胞の拡大培養用キット。
(1)CD3/TCR複合体アゴニスト、および
フィブロネクチンまたはその改変体
が固相化された培養容器、ならびに
(2)CD30アゴニストを含有する培地。
[28]CD3陽性細胞中のCD30シグナルを刺激する工程を含む、CD3陽性細胞をCD3陽性CD197陽性細胞に維持する方法。
[29]前記CD3陽性細胞が、CD3陽性CD8陽性細胞である、[28]に記載の方法。
[30]前記CD3陽性CD8陽性細胞が、CD3陽性CD8陽性CD4陰性細胞である、[29]に記載の方法。
[31]刺激する工程で用いられる培地が、IL-7、IL-15、IL-18およびIL-21から選択される少なくとも1つ以上を含む、[28]~[30]のいずれか1つに記載の方法。
[32]刺激する工程で用いられる培地が、IL-7、IL-15、IL-18およびIL-21を含む、[31]に記載の方法。
[33]刺激する工程で用いられる培地が、さらにTL1Aおよび/またはIL-12を含む、[31]または[32]に記載の方法。
[34]CD30アゴニストを含む、CD3陽性細胞をCD3陽性CD197陽性細胞に維持用キット。
[35]抗原結合ドメイン、膜貫通ドメインおよび細胞内シグナル伝達ドメインを含むキメラ抗原受容体であって、該細胞内シグナル伝達ドメインがCD30の細胞内シグナル伝達ドメインまたはその改変体を含む、キメラ抗原受容体。
[36][35]に記載のキメラ抗原受容体をコードするポリヌクレオチドを含む、核酸。
[37][36]に記載の核酸を含む、キメラ抗原受容体発現ベクター。
[38][37]に記載のキメラ抗原受容体発現ベクターを含む、キメラ抗原受容体発現細胞。
[39]前記キメラ抗原受容体発現細胞が、CD3陽性細胞である、[38]に記載の細胞。
[40][38]または[39]に記載の細胞を含む医薬。
[41][35]に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療に使用するための、[40]に記載の医薬。
[42][38]または[39]に記載の細胞を含有してなる、[35]に記載のキメラ抗原受容体によって認識される抗原を発現する細胞の殺傷剤。
[43][35]に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療に使用するための、[38]または[39]に記載の細胞。
[44][35]に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防剤又は治療剤を製造するための、[38]または[39]に記載の細胞の使用。
[45][38]または[39]に記載の細胞を投与することを含む、[35]に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療方法。
本明細書において、「遺伝子の発現」には、該遺伝子の特定のヌクレオチド配列からmRNAが合成されること(転写又はmRNAの発現ともいう)及び該mRNAの情報に基づきタンパク質が合成されること(翻訳又はタンパク質の発現ともいう)の両方が包含されるものであるが、特に断らない限り、「遺伝子の発現」又は単なる「発現」はタンパク質の発現を意味するものとする。
CD3/TCR複合体アゴニストおよびCD30アゴニストにより、それぞれCD3/TCR複合体およびCD30を刺激することができる。
さらに、本発明の製造方法または拡大培養方法において、培養されるCD3陽性細胞は、培養前においてCD30陽性であってもよいし、培養中にCD30陽性に分化してもよい。従って、前記CD3陽性細胞が培養前においてCD30陽性である場合は、前記CD3陽性細胞は、好ましくは、CD3陽性CD8陽性CD30陽性細胞(CD3陽性CD8陽性CD4陽性CD30陽性細胞またはCD3陽性CD8陽性CD4陰性CD30陽性細胞)、より好ましくは、CD3陽性CD8陽性CD4陰性CD30陽性細胞である。また、別の好ましい前記CD3陽性細胞としては、CD3陽性CD4陽性CD30陽性細胞(CD3陽性CD4陽性CD8陽性CD30陽性細胞またはCD3陽性CD4陽性CD8陰性CD30陽性細胞)が挙げられる。
前記製造または拡大培養されたCD3陽性細胞は、好ましくは、さらにCD197陽性CD45RA陰性である。前記製造または拡大培養されたCD3陽性細胞がさらにCD197陽性CD45RA陰性である場合、当該細胞は、具体的には、CD3陽性CD8陽性CD197陽性CD45RA陰性細胞(CD3陽性CD8陽性CD4陽性CD197陽性CD45RA陰性細胞またはCD3陽性CD8陽性CD4陰性CD197陽性CD45RA陰性細胞)、より好ましくは、CD3陽性CD8陽性CD4陰性CD197陽性CD45RA陰性細胞である。あるいは、当該細胞は、CD3陽性CD4陽性CD30陽性CD197陽性CD45RA陰性細胞(CD3陽性CD4陽性CD8陽性CD30陽性CD197陽性CD45RA陰性細胞またはCD3陽性CD4陽性CD8陰性CD30陽性CD197陽性CD45RA陰性細胞)である。CD3陽性細胞のうち、CD197陽性CD45RA陰性細胞は、特にセントラルメモリーT細胞とも呼ばれる。
このほか、公開されているすべての論文(例えば、Shi Y., Ding S., et al., Cell Stem Cell, (2008) Vol3, Issue 5,568-574;、Kim JB., Scholer HR., et al., Nature, (2008) 454, 646-650;Huangfu D., Melton, DA., et al., Nature Biotechnology, (2008) 26, No 7, 795-797)、あるいは特許(例えば、特開2008-307007号、特開2008-283972号、US2008-2336610、US2009-047263、WO2007-069666、WO2008-118220、WO2008-124133、WO2008-151058、WO2009-006930、WO2009-006997、WO2009-007852)に記載されている当該分野で公知のiPSCのいずれも用いることができる。
人工多能性幹細胞株としては、NIH、理研、京都大学等が樹立した各種iPSC株が利用可能である。例えば、ヒトiPSC株であれば、理研のHiPS-RIKEN-1A株、HiPS-RIKEN-2A株、HiPS-RIKEN-12A株、Nips-B2株等、京都大学の253G1株、253G4株、1201C1株、1205D1株、1210B2株、1383D2株、1383D6株、201B7株、409B2株、454E2株、606A1株、610B1株、648A1株、1231A31株、FfI-01s04株等が挙げられ、1231A3株が好ましい。
本明細書において、「外因性のTCR」とは、外因性のTCRαと外因性のTCRβからなるヘテロダイマー、外因性のTCRγと外因性のTCRδからなるヘテロダイマー、および/または外因性の同一のTCR鎖からなるホモダイマーである。
TCRが、内因性のTCRαおよび内因性のTCRβを含む二量体である場合は、多能性幹細胞が、内因性のTCRαをコードする塩基配列を含む核酸および内因性のTCRβをコードする塩基配列を含む核酸を含む細胞から作製された多能性幹細胞であってよい。そのような細胞としては、例えば、T細胞(CD8陽性CD4陰性細胞、CD8陰性CD4陽性細胞、CD4陽性CD8陽性細胞など)が挙げられる。また、TCRが、外因性のTCRαおよび外因性のTCRβを含む二量体である場合は、多能性幹細胞が、外因性のTCRαをコードする塩基配列を含む核酸および外因性のTCRβをコードする塩基配列を含む核酸を含む細胞であってよい。
本明細書において、「外因性のTCR核酸」とは、外因性のTCRαをコードする塩基配列を含む核酸、外因性のTCRβをコードする塩基配列を含む核酸、外因性のTCRγをコードする塩基配列を含む核酸、および/または外因性のTCRδをコードする塩基配列を含む核酸である。
工程(1)において、造血前駆細胞(Hematopoietic Progenitor Cell(s)(HPC))とは、CD34陽性細胞を意味し、好ましくは、CD34陽性CD43陽性細胞である。本工程(1)において、造血前駆細胞と造血幹細胞は、区別されるものではなく、特に断りがなければ同一の細胞を示す。
造血前駆細胞からCD3陽性細胞への分化方法としては、造血前駆細胞をCD3陽性細胞へ分化できる限り特に制限されないが、例えば、国際公開第2016/076415号または国際公開第2017/221975号などに記載されているような、造血前駆細胞からT細胞を誘導する方法と同様の培養条件で、造血前駆細胞を培養する方法が挙げられる。
接着培養の場合であって、培養容器をコーティングする場合のコーティング剤としては、例えば、マトリゲル(Niwa A, et al. PLos One, 6(7):e22261, 2011))、コラーゲン、ゼラチン、ラミニン、ヘパラン硫酸プロテオグリカン、レトロネクチン、DLL4若しくはDLL1、あるいはDLL4若しくはDLL1と抗体のFc領域(以下、Fcと称することがある)等との融合タンパク質(例:DLL4/Fc chimera)、エンタクチン、および/またはこれらの組み合わせが挙げられ、レトロネクチンおよびDLL4とFc等との融合タンパク質の組み合わせが好ましい。
CD3陽性CD8陽性CD4陰性細胞(またはCD3陽性CD8陽性CD4陰性CD30陽性細胞)を取得する方法としては、例えば、国際公開第2016/076415号および国際公開第2017/221975号などに記載されているような方法が挙げられる。また同様の方法を用いてCD3陽性細胞を富化してもよい。
ここで、縮合や保護基の脱離は、自体公知の方法、例えば、以下の(1)~(5)に記載された方法に従って行われる。
(1) M. BodanszkyおよびM.A. Ondetti, Peptide Synthesis, Interscience Publishers, New York (1966年)
(2) SchroederおよびLuebke, The Peptide, Academic Press, New York (1965年)
(3) 泉屋信夫他、ペプチド合成の基礎と実験、丸善(株) (1975年)
(4) 矢島治明および榊原俊平、生化学実験講座 1、タンパク質の化学IV 205 (1977年)
(5) 矢島治明監修、続医薬品の開発、第14巻、ペプチド合成、広川書店
上記方法で得られるMHC等が遊離体である場合には、該遊離体を公知の方法あるいはそれに準じる方法によって適当な塩に変換することができるし、逆にMHC等が塩として得られた場合には、該塩を公知の方法あるいはそれに準じる方法によって遊離体または他の塩に変換することができる。
エシェリヒア属菌としては、例えば、K12 DH1〔Proc. Natl. Acad. Sci. USA, 60巻,160(1968)〕, JM103〔Nucleic Acids Research, 9巻,309(1981)〕, JA221〔Journal of Molecular Biology,120巻,517(1978)〕, HB101〔Journal of Molecular Biology,41巻,459(1969)〕, C600〔Genetics,39巻,440(1954)〕などが用いられる。
本発明の工程(I)において使用される前記培地は、さらにTL1Aおよび/またはIL-12が含まれていてもよい。このとき、TL1Aの培地中の濃度としては5~500 ng/mlであり、IL-12の培地中の濃度としては5~500 ng/mlである。
本発明の工程(II)において使用される前記培地は、さらにTL1Aおよび/またはIL-12が含まれていてもよい。このとき、TL1Aの培地中の濃度としては5 ng/ml~500 ng/mlであってもよく、IL-12の培地中の濃度としては5 ng/ml~500 ng/mlであってもよい。
(1)CD3/TCR複合体アゴニスト、および
フィブロネクチンまたはその改変体
が固相化された培養容器、ならびに
(2)CD30アゴニストを含有する培地
通常、末梢血由来のナイーブT細胞が樹状細胞に提示された抗原によって刺激された場合、ナイーブT細胞は、細胞内シグナルが活性化され、増殖と成熟を繰り返し、順次、ステムセルメモリーT細胞、セントラルメモリーT細胞、エフェクターメモリーT細胞、エフェクターT細胞に分化していく。エフェクターT細胞は、CD3陽性CD4陽性CD8陰性細胞(ヘルパーT細胞)の場合サイトカインを産生し、CD3陽性CD4陰性CD8陽性細胞(細胞傷害性T細胞)は抗原を介して標的細胞を殺傷するが、長期間生存できない。しかし、T細胞中のCD30シグナルを刺激することによって、エフェクターT細胞に分化できる自己増殖可能なナイーブT細胞あるいはステムセルメモリーT細胞(CD197陽性、CD45RA陽性)またはセントラルメモリーT細胞(CD197陽性、CD45RA陰性)として維持することが可能である。
また、本発明の維持方法(1)の一実施形態においては、CD3陽性細胞をCD3陽性CD197陽性CD45RA陰性細胞に維持することができる。
本発明の維持方法(1)で使用されるCD30アゴニスト、培養条件は、本発明の製造方法または拡大培養方法において使用されるCD30アゴニスト、培養条件と同一であってよい。
また、本発明の維持方法(2)の一実施形態においては、CD30の細胞内ドメインを含むキメラ抗原受容体を発現するCD3陽性細胞をCD3陽性CD197陽性CD45RA陰性細胞に維持することができる。
本発明の維持方法(2)で使用される培養条件は、本発明の製造方法または拡大培養方法において使用される培養条件と同一であってよい。
従って、本発明はまた、本発明のキメラ抗原受容体発現細胞を有効成分として含む医薬(以下、本発明の医薬と記載する)を提供する。本発明のキメラ抗原受容体発現細胞を含む医薬は、本発明のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防または治療のために用いることができ、例えば哺乳動物(例:マウス、ラット、ハムスター、ウサギ、ネコ、イヌ、ウシ、ヒツジ、サル、ヒト)、好ましくはヒトに投与することができる。従って、本発明の一態様において、本発明のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療に使用するための、本発明の医薬が提供される。また、本発明のキメラ抗原受容体発現細胞を、好ましくは該細胞を含む医薬の形態で、投与することを含む、本発明のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療方法が提供される。
1.iPS細胞の準備
iPS細胞には、京都大学iPS細胞研究所(CiRA)から供与されたFf-I01s04株を使用した。iPS細胞培養は、CiRAが配布するプロトコール「フィーダーフリーでのヒトiPS 細胞の培養」に準じて行った。
TCR遺伝子は、愛媛大学大学院医学研究科安川正貴教授から供与されたTAK1由来、HLA-A*24:02拘束性WT1特異的TCR(WT1-TCR)遺伝子を用いた。iPS細胞への遺伝子導入は、理化学研究所から供与されたCS-UbC-RfA-IRES2-hKO1レンチウイルスベクターに組込み、iPS細胞に感染させることで行った。
WT1-TCR遺伝子が導入されたiPS細胞のCD8陽性T細胞(CTL)への分化は、公知の方法(WO2017/221975)に準じて行った。本細胞は、CD3陽性、CD8陽性であった。以下においては、該細胞をiPS細胞由来T細胞として使用した。
レトロネクチン(登録商標)は、タカラバイオ社から購入した。抗CD3アゴニスト抗体には、eBioscience社から購入したanti-human CD3 functional grade purified (Clone: OKT3)またはGeneTex社から購入したCD3 antibody (Clone: UCHT1)を用いた。特に言及しない限りは、OKT3を使用した。抗CD30アゴニスト抗体には、R&D社から購入したCD30 agonist antibodyを用いた。
必要な濃度でPBSに溶解した抗CD3アゴニスト抗体およびレトロネクチン(登録商標)を50μL/wellで96穴プレートに添加した後、4℃下一晩静置した。PBSで洗浄した後に試験に供した。
固相化抗CD3アゴニスト抗体の検出には、Bethyl Laboratorie社から購入したMouse IgG2a ELISA Quantitation Setに含まれるHRP Conjugated Goat anti-Mouse IgG2a Detection Antibodyを使用した。固相化レトロネクチン(登録商標)の検出には、タカラバイオ社から購入したRetroNectin EIA kitに含まれるペルオキシダーゼ標識抗RetroNectin 抗体を用いた。固相化プレートに各検出用抗体を添加後、1時間室温で静置した。0.05%のTween-20を含むPBSで洗浄した後、1-StepTM Ultra TMB-ELISA Substrate Solution (ThermoFisher)を添加した。15分間、室温で静置した後、1M硫酸を加えて反応を停止し、プレートリーダを用いて450 nmの吸光度を測定した。
15% FBSを含むα-MEM培地に表1のサイトカインなどを加えた培地で100,000細胞/200μLに調製したiPS細胞由来T細胞を、抗CD3アゴニスト抗体(3, 30, 300, 3000 ng/ml)とレトロネクチン(登録商標)(0, 1.85, 2.25, 16.7, 50, 150 μg/ml)を固相化したプレートに播種して、5% CO2/37℃下で3日間培養した。
培養3日目にプレートから細胞を回収し、TC20(バイオラッド)を用いて細胞数を計測すると共に、15% FBSを含むα-MEM培地に表2のサイトカインなどを加えた培地で適量に懸濁し、固相化されていない96穴プレートに添加し、5% CO2/37℃下で培養した。その後、培養5、6、7、8、9、10、12、14および16日目のいずれかのタイミングで各1回、計4~7回細胞をプレートから回収して細胞数を計測すると共に適量に懸濁して固相化されていないプレートに添加して5% CO2/37℃下で培養した。
増殖試験の培養12日目の細胞及び培養上清中のATPは、Promega社から購入したCellTiter-Glo(R) Luminescent Cell Viability Assayを用い、標準プロトコールに準じて測定した。
HLA-A*24:02陽性LCL細胞は、理化学研究所バイオリソースセンターから購入した。10% FBSを含むRPMI1640培地で培養した。WT1抗原ペプチド(CMTWNQMNL:配列番号:3)は、株式会社スクラムに合成を委託した。細胞傷害性試験は、パーキンエルマー社から購入したDELFIAイムノアッセイを用いて、標準プロトコールに準じて評価した。
細胞懸濁時の培養液に最終濃度0, 30, 100, 300 ng/mLに希釈した抗CD30アゴニスト抗体を添加した。それ以外は「7.増殖試験」と同じ方法で行った。
また、複数回の固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体による刺激に対するiPS細胞由来T細胞の増殖試験としては、細胞懸濁時の培養液に最終濃度100 ng/mLに希釈した抗CD30アゴニスト抗体を添加した。それ以外は「7.増殖試験」と同じ方法で行った。
培養7日目の細胞を回収して表3の抗体で染色した後、LSRFortessaTM X-20 (BD Bioscience社)フローサイトメトリーを用いて検出した。
1.培養プレートへの固相化に適した抗CD3アゴニスト抗体の濃度およびレトロネクチン(登録商標)の濃度の測定
ELISA法を用いて抗CD3アゴニスト抗体およびレトロネクチン(登録商標)の培養プレートへの固相化に適した濃度を測定した(図1)。抗CD3アゴニスト抗体は3 ng/mLから3000 ng/mLの間で濃度依存的な固相化が確認された。レトロネクチン(登録商標)は、16.7μg/mLから150 μg/mLの間で濃度依存的な固相化が確認された。
抗CD3アゴニスト抗体(0, 3,30,300, 3000 ng/mL)とレトロネクチン(登録商標)(0, 1.85,5.56,16.7,50,150 μg/mL)でそれぞれ固相化したプレート上でiPS細胞由来T細胞を3日間刺激後、9日間非固相化プレート上で培養した後、ATP量を測定した(図2)。
100,000細胞/200μLに調製したiPS細胞由来T細胞を、抗CD3アゴニスト抗体(3000 ng/mL)及びレトロネクチン(登録商標)(150 μg/mL)が固相化された96穴プレート上、またはiPS細胞由来T細胞数とビーズ粒子数が1:1の割合になるように添加された抗CD3/CD28ビーズ(Dynabeads)で3日間刺激後、刺激無しで培養した時の細胞数を経時的に計測した(図3)。iPS細胞由来T細胞は、抗CD3/CD28ビーズよりも、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)で刺激した方がより増殖した。
固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)による複数回の刺激に対する、iPS細胞由来T細胞の細胞増殖反応を確認した。1回の増殖試験は、固相化したプレート上でiPS細胞由来T細胞を3日間刺激後、11-15日間非固相化プレート上での培養を行うことで実施した。試験終了後、細胞数を調整して次の試験に供した。iPS細胞由来T細胞は、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)による4回目の刺激にも反応して、増殖した(図4)。
固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)による刺激によって増殖したWT1-TCR遺伝子導入iPS細胞由来T細胞の、WT1抗原特異的細胞傷害活性を評価した。WT1抗原特異的細胞傷害活性は、WT1抗原ペプチドを添加したLCLに対する傷害活性と、非添加のLCLに対する傷害活性の差によって評価した。WT1-TCR遺伝子導入iPS細胞由来T細胞は、非特異的な細胞傷害活性をほとんど有さず、WT1抗原特異的細胞傷害活性だけを示した(図5)。
固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)刺激時に、抗CD30アゴニスト抗体を添加(0, 30, 100, 300 ng/mL)することで、iPS細胞由来T細胞の増殖に影響があるか検証した。固相化96穴プレートは、抗CD3アゴニスト抗体(3000 ng/ml)とレトロネクチン(登録商標)(150 μg/ml)が固相化されたものを用いた。iPS細胞由来T細胞は、抗CD30アゴニスト抗体を添加することでより増殖した。また、添加した抗CD30アゴニスト抗体の濃度依存的に増殖した(図6)。
複数回の固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体による刺激に対して、iPS細胞由来T細胞が増殖反応を示すか検証した。抗CD3アゴニスト抗体(3000 ng/ml)及びレトロネクチン(登録商標)(150 μg/ml)が固相化されたプレートに播種して、5% CO2/37℃下で3日間培養した。
培養3日目にプレートから細胞を回収し、TC20(バイオラッド)を用いて細胞数を計測すると共に、15% FBSを含むα-MEM培地に表2のサイトカインなどを加えた培地で適量に懸濁し、固相化されていないプレートに添加し、5% CO2/37℃下で培養した。その後、培養6、7、9、10、14および16日目のタイミングで各1回、細胞をプレートから回収して細胞数を計測すると共に適量に懸濁して固相化されていないプレートに添加して5% CO2/37℃下で培養した。培養液には最終濃度100 ng/mLに希釈した抗CD30アゴニスト抗体を添加したもの、および抗CD30アゴニスト抗体を添加しないものを用いた。上記の培養0~16日目までの刺激を2回繰り返し実施した。2回目の刺激においてもiPS細胞由来T細胞は、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)のみによる刺激に比して、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体による刺激によってより増殖した(図7)。
固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)による刺激、または固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体による刺激後、7日目のiPS細胞由来T細胞膜表面上のCD197とCD45RAの発現をフローサイトメーターで測定した。抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体によって刺激された細胞群において、CD197陽性CD45RA陰性のセントラルメモリー様のiPS細胞由来T細胞が過半数を占めた(図8)。
固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)および抗CD30アゴニスト抗体による刺激によって増殖させた、WT1-TCR遺伝子導入iPS細胞由来T細胞を、WT1抗原ペプチドの存在又は非存在下でHLA-A*24:02陽性LCL細胞に適用し、WT1抗原特異的細胞傷害活性を評価した。WT1-TCR遺伝子導入iPS細胞由来T細胞は、非特異的な細胞傷害活性をほとんど有さず、WT1抗原特異的細胞傷害活性だけを示した(図9)。また、そのWT1抗原特異的細胞傷害活性は、2回目の刺激による増殖後も維持されていた(図9)。
1.ヒト末梢血由来CD8陽性T細胞の準備
ヒト末梢血は、健常人由来末梢血単核球としてPrecision Bioservices社から購入した。CD8+ T cell isolation kit, human(Milteny社)を用いてCD8陽性T細胞を単離した。
[実施例1]7.増殖試験と同様の方法で、試験を実施した。
15% FBSを含むα-MEM培地に表4に示す添加物加えた3種類の培地で最終濃度100,000細胞/mLに懸濁したヒト末梢血由来CD8陽性T細胞に、細胞数の3倍量になるよう調整したDynabeads T-Activator CD3/CD28(gibco社)を加えて、5%CO2/37℃下で3日間培養した。培養3日目にプレートから細胞を回収し、15%FBSを含むα-MEM培地に表5のサイトカインなどを加えた培地で適量に懸濁し5%CO2/37℃下で培養した。その後培養10日目に細胞をプレートから回収して細胞数を計測すると共に適量に懸濁してマウスに投与した。また培養6、10、13、17日目に細胞をプレートから回収して適量に懸濁してCD197発現実験に供した。
細胞投与の同日投与前に2Gyのガンマ線照射を行った、8週齢雄性のNSGマウス(日本チャールスリバー)を用いた。[実施例2]3.のマウス生着試験に用いるヒト末梢血由来CD8陽性T細胞の培養で調整した、5,000,000細胞をマウス静脈から投与しその後4週間飼育した。その後安楽死させてマウスから骨髄細胞および脾細胞、血液中の白血球を回収した。
回収した細胞を表3の抗体で染色した後、LSRFortessaTM X-20 (BD Bioscience社)フローサイトメトリーを用いて検出した。
1.抗CD30アゴニスト抗体刺激によるヒト末梢血由来CD8陽性T細胞の増殖試験
固相化抗CD3抗体/レトロネクチン(登録商標)刺激時に、抗CD30アゴニスト抗体を添加することで、ヒト末梢血由来CD8陽性T細胞の増殖に影響があるか確認した。抗CD30アゴニスト抗体の添加により、ヒト末梢血中のCD8陽性T細胞の増殖が亢進した(図10)。
IL-2含有培地もしくはIL-7/IL-15含有培地、IL-7/IL-15/抗CD30抗体含有培地において、抗CD3/CD28ビーズで刺激したヒト末梢血由来CD8陽性T細胞の、培養6、10、13、17日目における細胞膜表面上CD197発現をフローサイトメーターで測定した。6日目では全群でCD197発現が確認されたが、IL-2含有培地群においては13日目に、IL-7/IL-15含有培地群においては17日目にCD197発現がほとんど消失したのに対して、IL-7/IL-15/抗CD30抗体含有培地群では、17日目においてもCD197発現が維持されていた(図11)。
IL-2含有培地もしくはIL-7/IL-15含有培地、IL-7/IL-15/抗CD30抗体含有培地において、抗CD3/CD28ビーズで刺激した培養10日目のヒト末梢血由来CD8陽性T細胞を免疫不全マウスの静脈に投与し、血液中及び免疫組織での生着を確認した。投与後28日目にマウスから血液および脾臓および骨髄を採取し、含まれるヒトCD8陽性T細胞をフローサイトメトリーで検出した。いずれの臓器においてもIL-2含有培地群ではほとんどヒトCD8陽性T細胞は検出されなかったのに対して、IL-7/IL-15含有培地群およびIL-7/IL-15/抗CD30抗体含有培地群においてはヒトCD8陽性T細胞が検出された。またIL-7/IL-15/抗CD30抗体含有培地群においてより多数のヒトCD8陽性T細胞が検出された。従って、IL-7/IL-15/抗CD30抗体を含む培地で培養したヒト末梢血由来CD8陽性T細胞は、培養中にCD197の発現を長期にわたって維持できるだけでなく、生体内においても長期にわたって生存可能であることが示された(図12)。
1.iPS細胞由来抗CD19-CART細胞の増殖試験
15% FBSを含むα-MEM培地に表1のサイトカインなどを加えた培地で100,000細胞/200 μLに調製したiPS細胞由来抗CD19-CART細胞を、抗CD3抗体とレトロネクチン(登録商標)が固相化されたプレートに播種して、5% CO2/37℃下で3日間培養した。培養3日目にプレートから細胞を回収し、TC20(バイオラット)を用いて細胞数を計測すると共に、15% FBSを含むα-MEM培地に表2のサイトカインなどを加えた培地で適量に懸濁し、固相化されていないプレートに添加し、5% CO2/37℃下で培養した。その後培養5、6、7、8、9、10、12、14、16日目のいずれか4-7回細胞をプレートから回収して細胞数を計測すると共に適量に懸濁して固相化されていないプレートに添加して5% CO2/37℃下で培養した。
抗CD19-CAR遺伝子は、N末から表6の順番で並ぶように設計したポリペプチド(配列番号5)をコードするオリゴDNAを人工合成した。
[実施例3]2.で合成した人工オリゴDNAをpMEI-5レトロウイルスベクターのマルチクローニングサイトに組込んだ。ウイルスベクター作製は、ユニーテック社に委託した。
[実施例3]3.で作製した抗CD19-CAR遺伝子を搭載したレトロウイルスベクターを、[実施例1]3.で作製したiPS細胞由来T細胞に感染させて、iPS細胞由来抗CD19-CART細胞を作製した。
1.固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)によって刺激されたiPS細胞由来抗CD19-CART細胞の増殖試験
[実施例1]3.で作製したiPS細胞由来T細胞および[実施例3]4.で作製したiPS細胞由来抗CD19-CART細胞を、固相化抗CD3抗体/レトロネクチン(登録商標)で3日間刺激後、刺激無しで培養した時の細胞数を経時的に計測した。iPS細胞由来抗CD19-CART細胞は、iPS細胞由来T細胞と同程度に、固相化抗CD3抗体/レトロネクチン(登録商標)による刺激で増殖した(図13)。
固相化抗CD3抗体/レトロネクチン(登録商標)刺激時に、抗CD30アゴニスト抗体を添加することで、iPS細胞由来抗CD19-CART細胞の増殖に影響があるか確認した。抗CD30アゴニスト抗体の添加により、iPS細胞由来抗CD19-CART細胞の増殖が亢進した(図14)。
固相化抗CD3抗体/レトロネクチン(登録商標)刺激後、もしくは固相化抗CD3抗体/レトロネクチン(登録商標)/抗CD30アゴニスト抗体刺激後3日目および7日目のiPS細胞由来抗CD19-CART細胞膜表面上のCD197発現をフローサイトメーターで測定した。3日目では両群でCD197発現が確認されたが、7日目には、抗CD3抗体/レトロネクチン(登録商標)刺激群においてはCD197発現がほとんど消失したのに対して、抗CD3抗体/レトロネクチン(登録商標)+抗CD30アゴニスト抗体刺激群においては、CD197発現が維持されていることが確認された(図15)。
[試験例3]1.の増殖によって得られた、iPS細胞由来抗CD19-CART細胞のCD19陽性がん細胞に対する細胞傷害活性は、CD19陽性Raji細胞に対する傷害活性により評価した。iPS細胞由来抗CD19-CART細胞は、CD19発現Raji細胞に対して細胞傷害活性を示した(図16)。
1.CD30由来細胞内ドメインを含む抗CD19-CAR遺伝子
抗CD19-CAR遺伝子は、N末から表7の順番で並ぶように設計したポリペプチド(配列番号7)をコードするオリゴDNAを人工合成した。
[実施例4]1.で合成した人工オリゴDNAをpMYレトロウイルスベクターのマルチクローニングサイトに組込んだ。レトロウイルスベクター産生用のFRY-RD18細胞を用いてウイルスベクターを作製した。
[実施例4]2.で作製した抗CD19-CAR遺伝子を搭載したレトロウイルスベクターを、[実施例1]3.で作製したiPS細胞由来T細胞に感染させて、CD30由来細胞内ドメインを含むiPS細胞由来抗CD19-CART細胞(iCD19-CD30-CART)を作製した。
[実施例4]3.で得たiCD19-CD30-CARTのCD19陽性がん細胞に対する細胞傷害活性を、CD19陽性Raji細胞に対する傷害活性により評価した。iCD19-CD30-CARTは、CD19発現Raji細胞に対して細胞傷害活性を示した(図17)。
1.iPS細胞の準備
iPS細胞には、[実施例1]と同様に、京都大学iPS細胞研究所(CiRA)から供与されたFf-I01s04株を使用した。iPS細胞培養は、CiRAが配布するプロトコール「フィーダーフリーでのヒトiPS 細胞の培養」に準じて行った。
iPS細胞のγδTCR陽性T細胞(γδT細胞)への分化は、[実施例1]と同様に、公知の方法(WO2017/221975)に準じて行った。分化の工程において使用する抗CD3抗体としては、3000 ng/mL UCHT1(GeneTex社製)を用いた。得られたCD3陽性細胞はγδT細胞であった(以下、「iPS細胞由来γδT細胞(iγδT細胞)」と称する)。
[実施例5]2.で得たiγδT細胞を、15% FBSを含むα-MEM培地に表8のサイトカインなどを加えた培地で2,000,000細胞/mLで懸濁し、抗CD3抗体(UCHT1)とレトロネクチン(登録商標)が固相化されたプレートに播種して、5% CO2/37℃下で3日間培養した。培養3日目にプレートから細胞を回収し、NucleoCounter NC-200(ChemoMetec)を用いて細胞数を計測すると共に、15% FBSを含むα-MEM培地に表9のサイトカインなどを加えた培地で適量に懸濁し、固相化されていないG-Rex 6穴プレート(WILSONWOLF)に添加し、5% CO2/37℃下で培養した。その後培養5、6、7、8、9、10、11、14、17日目のいずれか4-6回、一部の細胞をプレートから回収して細胞数を計測した。抗CD3抗体およびレトロネクチン(登録商標)の培養プレートへの固相化は、以下の方法で行った。必要な濃度でPBSに溶解した抗CD3抗体(UCHT1、最終濃度3000 ng/mL)およびレトロネクチン(登録商標)(最終濃度150 μg/mL)をプレートに添加した後、4℃下一晩静置した。PBSで洗浄した後に試験に供した。
1.抗CD30アゴニスト抗体刺激によるiPS細胞由来γδT細胞の増殖試験
[実施例5]3.において、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)を用いた刺激方法に、抗CD30アゴニスト抗体を添加(300 ng/ml)することで、iPS細胞由来γδT細胞の増殖に影響があるか検証した。iPS細胞由来T細胞は、抗CD30アゴニスト抗体を添加することでより増殖した(図18)。
1.IL-15Rα/IL-15遺伝子
IL-15Rα/IL-15遺伝子は、N末から表10の順番で並ぶように設計したポリペプチド(配列番号8)をコードするオリゴDNAを人工合成した。
[実施例6]1.で合成した人工オリゴDNAをpMYレトロウイルスベクターのマルチクローニングサイトに組込んだ。レトロウイルスベクター産生用のFRY-RD18細胞を用いてウイルスベクターを作製した。
[実施例3]3.で作製した抗CD19-CAR遺伝子を搭載したレトロウイルスベクターおよび[実施例6]1.で作製したIL-15Rα/IL-15遺伝子を搭載したレトロウイルスベクターを、[実施例5]2.で作製したiPS細胞由来γδT細胞(iγδT細胞)に感染させて、iPS細胞由来抗CD19-CAR/IL-15γδT細胞(iCD19CAR/IL-15γδT細胞)を作製した。
IL-2を添加しなかったことを除き、[実施例5]3.と同様の方法で、iCD19CAR/IL-15γδT細胞の拡大培養を実施した。
1.抗CD30アゴニスト抗体刺激によるiPS細胞由来抗CD19-CAR/IL-15γδT細胞の増殖試験
[実施例6]4.において、固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)刺激時に、抗CD30アゴニスト抗体を添加(300 ng/mL)することで、iCD19CAR/IL-15γδT細胞の増殖に影響があるか検証した。抗CD30アゴニスト抗体を添加することでより増殖した(図19)。
[実施例6]4.で得られたiCD19CAR/IL-15γδT細胞の細胞傷害活性を評価した。CD19陽性Raji細胞およびCD19陰性CCRF-CEN細胞を標的細胞として、iCD19CAR/IL-15γδT細胞を、標的細胞に対して0.5, 1, 2, 4, 8, 16倍の割合で混和して、2時間後における標的細胞死をもとに、iCD19CAR/IL-15γδT細胞の細胞傷害活性を評価した。抗CD30アゴニスト抗体を含む培地で拡大培養したiCD19CAR/IL-15γδT細胞は、CD19陽性Raji細胞に対して細胞傷害活性を有し、CD19陰性CCRF-CEN細胞に対しては有さないことが示された(図20)。
NOD/Shi-scid,IL-2RγKO (NOG) マウス(実験動物中央研究所、雌性、7-8週齢)に5x105個のNalm6細胞(ATCC)を尾静脈移植してNalm6ゼノグラフトマウスを作製した。移植後4日目に、[実施例6]4.で得られたiCD19CAR/IL-15γδT細胞(5x106個(cells))を0.1 mLのHBSS-緩衝液に懸濁した懸濁液または等量のHBSS-緩衝液を尾静脈投与した後、生存日数を確認した。CD19陽性Nalm6がん細胞を経尾静脈移植したマウスは、コントロール投与群では3週間以内に全例死亡したのに対して、抗CD30アゴニスト抗体を含む培地で拡大培養したiCD19CAR/IL-15γδT細胞投与群では、少なくとも6週間後まで全例において生存していた(図21)。
1.iPS細胞由来抗CD19-CAR/IL-15αβT細胞の製造
[実施例3]4.の方法で製造したiPS細胞由来抗CD19-CART細胞に、[実施例6]2.で作製したIL15Rα/IL-15遺伝子を搭載したレトロウイルスベクターを感染させて、iPS細胞由来抗CD19-CAR/IL-15αβT細胞(iCD19CAR/IL-15αβT細胞)を作製した。
[実施例7]1.で得たiCD19CAR/IL-15αβT細胞を、[実施例6]4.と同様の方法で、7日目まで培養した。ただし、抗ヒトCD30抗体は添加していない。
1.固相化抗CD3アゴニスト抗体/レトロネクチン(登録商標)による刺激後のiCD19CAR/IL-15αβT細胞によるin vivo抗腫瘍効果
NOD/Shi-scid,IL-2RγKO (NOG) マウス(実験動物中央研究所、雌性、7-8週齢)に5x105個のルシフェラーゼ発現Nalm6細胞(ATCC)を尾静脈移植してルシフェラーゼ発現Nalm6ゼノグラフトマウスを作製した。移植後4日目に、[実施例7]2.で得られたiCD19CAR/IL-15αβT細胞(5x106個(cells))を0.1 mLのHBSS-緩衝液に懸濁した懸濁液または等量のHBSS-緩衝液を尾静脈投与した。投与後1週間毎にルシフェリンを尾静脈投与して、Nalm6細胞が発現するルシフェラーゼの活性をIVISを用いて測定した。コントロール投与群では、投与2週間後に全身にNalm6細胞由来の発光が確認され、投与後3週目までに全例死亡したのに対して、iCD19CAR/IL-15αβT細胞投与群では、投与6週目後まで発光は検出されなかった(図22)。
1.iPS細胞由来γδT細胞の製造
[実施例5]1.および2.と同様にしてiPS細胞由来γδT細胞(iγδT細胞)を製造した。
1.培養プレートへの固相化に適した抗CD3アゴニスト抗体(UCHT1)の濃度およびレトロネクチン(登録商標)の濃度の測定
抗CD3アゴニスト抗体(UCHT1)およびレトロネクチン(登録商標)を混合し、[実施例1]5.と同様にして培養プレートへ固相化した。その後、ELISA法を用いて培養プレート上の固相化量を測定した(図23)。レトロネクチン(登録商標)と混合しなかった抗CD3アゴニスト抗体は3 ng/mLから30000 ng/ml(0.003 μg/mlから30 μg/ml)の間で濃度依存的な固相化が確認されたが、混合するレトロネクチン(登録商標)濃度を上げるに従って抗CD3アゴニスト抗体の固相化量は低下した。一方、レトロネクチン(登録商標)は、16.7μg/mLから150 μg/mLの間で濃度依存的な固相化が確認された。
15% FBSを含むIMDM培地に表1のサイトカインなどと、最終濃度0, 3, 30, 300 ng/mlに希釈した抗CD30アゴニスト抗体を加えた培地で100,000細胞/200μLに調整したiγδT細胞を、抗CD3アゴニスト抗体(0, 300, 3000, 30000 ng/ml(0, 0.3, 3, 30 μg/ml))とレトロネクチン(登録商標)(0, 2,15, 150 μg/mL)を固相化したプレートに播種して、5% CO2/37℃下で3日間培養した。
培養3日目にプレートから細胞を回収し、15% FBSを含むIMDM培地に表2のサイトカインなどを加えた適量の培地に懸濁し、非固相化96穴プレートに播種し、5% CO2/37℃下で培養した。その後、培養5、6、7、8、9、10、12日目のいずれかのタイミングで各1回、計4~7回細胞をプレートから回収し、適量の培地に懸濁し、非固相化プレートに播種して5% CO2/37℃下で培養した。培養13日目に、血球計数板を用いて細胞数を計測し、培養0日目の細胞数と比較した増殖率を測定した(図24)。抗CD3アゴニスト抗体およびレトロネクチン(登録商標)をそれぞれ0.3 μg/mLと2 μg/mL、3 μg/mLと15 μg/mL、30 μg/mLと150 μg/mLで混合して固相化したプレートにおいて、同等のiγδT細胞の増殖誘導が観察された。また抗CD30アゴニスト抗体添加濃度依存的な細胞増殖が確認された。
本出願は、日本で出願された特願2018-151580(出願日:平成30年8月10日)、特願2019-042666(出願日:平成31年3月8日)および特願2019-117878(出願日:令和元年6月25日)を基礎としており、その内容はすべて本明細書に包含されるものとする。
Claims (45)
- CD3/TCR複合体アゴニスト、フィブロネクチンまたはその改変体、およびCD30アゴニストの存在下、CD3陽性細胞を培養する工程(I)を含む、CD3陽性細胞の製造方法。
- CD3/TCR複合体アゴニストおよびフィブロネクチンまたはその改変体の非存在下、かつCD30アゴニストの存在下、工程(I)で培養されたCD3陽性細胞を培養する工程(II)をさらに含む、請求項1に記載の方法。
- 前記CD3陽性細胞が、多能性幹細胞由来である、請求項1または2に記載の方法。
- 前記多能性幹細胞が、iPS細胞である、請求項3に記載の方法。
- 前記CD3陽性細胞が、キメラ抗原受容体発現CD3陽性細胞である、請求項1~4のいずれか1項に記載の方法。
- 前記CD3陽性細胞が、CD3陽性CD8陽性細胞である、請求項1~5のいずれか1項に記載の方法。
- 前記CD3陽性CD8陽性細胞が、CD3陽性CD8陽性CD4陰性細胞である、請求項6に記載の方法。
- 前記CD3陽性細胞が、γTCR陽性および/またはδTCR陽性細胞である、請求項1~7のいずれか1項に記載の方法。
- 前記CD3/TCR複合体アゴニストが、CD3アゴニストおよび/またはTCRアゴニストである、請求項1~8のいずれか1項に記載の方法。
- 前記CD3アゴニストが、抗CD3アゴニスト抗体またはその結合断片である、請求項9に記載の方法。
- 前記抗CD3アゴニスト抗体またはその結合断片が、UCHT1クローンから産生される抗CD3アゴニスト抗体またはその結合断片である、請求項10に記載の方法。
- 前記TCRアゴニストが、抗TCR抗体またはその結合断片、HLA/ペプチド複合体またはその多量体、およびHLA/スーパー抗原複合体またはその多量体からなる群より選択される少なくとも一つである、請求項9に記載の方法。
- 前記抗CD3アゴニスト抗体またはその結合断片が、培養容器に固相化されている、請求項10または11に記載の方法。
- 前記抗CD3アゴニスト抗体またはその結合断片の固相化が、1 ng/ml~50000 ng/mlの該抗CD3アゴニスト抗体またはその結合断片を培養容器に接触させることによって行われる、請求項13に記載の方法。
- 前記フィブロネクチンまたはその改変体が、レトロネクチン(登録商標)である、請求項1~14のいずれか1項に記載の方法。
- 前記レトロネクチン(登録商標)が、培養容器に固相化されている、請求項15に記載の方法。
- 前記レトロネクチン(登録商標)の固相化が、1~150 μg/mLの該レトロネクチン(登録商標)を培養容器に接触させることによって行われる、請求項16に記載の方法。
- 前記CD30アゴニストが、抗CD30アゴニスト抗体またはその結合断片およびCD30リガンドまたはその結合断片からなる群より選択される少なくとも一つである、請求項1~17のいずれか1項に記載の方法。
- 前記抗CD30アゴニスト抗体またはその結合断片が、培地に含有されている、請求項18に記載の方法。
- 前記培地中の前記抗CD30アゴニスト抗体またはその結合断片の濃度が、1 ng/ml~1000 ng/mlである、請求項19に記載の方法。
- 培地が、IL-7、IL-15、IL-18およびIL-21から選択される少なくとも1つ以上を含む、請求項1~20のいずれか1項に記載の方法。
- 培地が、IL-7、IL-15、IL-18およびIL-21を含む、請求項21に記載の方法。
- 培地が、さらにTL1Aおよび/またはIL-12を含む、請求項21または22に記載の方法。
- 前記製造されたCD3陽性細胞が、さらにCD197陽性である、請求項1~23のいずれか1項に記載の方法。
- 請求項1~24のいずれか1項に記載の方法によって得られるCD3陽性細胞。
- CD3/TCR複合体アゴニスト、フィブロネクチンまたはその改変体、およびCD30アゴニストの存在下、CD3陽性細胞を培養する工程を含む、CD3陽性細胞の拡大培養方法。
- 以下を含む、CD3陽性細胞の拡大培養用キット。
(1)CD3/TCR複合体アゴニスト、および
フィブロネクチンまたはその改変体
が固相化された培養容器、ならびに
(2)CD30アゴニストを含有する培地。 - CD3陽性細胞中のCD30シグナルを刺激する工程を含む、CD3陽性細胞をCD3陽性CD197陽性細胞に維持する方法。
- 前記CD3陽性細胞が、CD3陽性CD8陽性細胞である、請求項28に記載の方法。
- 前記CD3陽性CD8陽性細胞が、CD3陽性CD8陽性CD4陰性細胞である、請求項29に記載の方法。
- 刺激する工程で用いられる培地が、IL-7、IL-15、IL-18およびIL-21から選択される少なくとも1つ以上を含む、請求項28~30のいずれか1項に記載の方法。
- 刺激する工程で用いられる培地が、IL-7、IL-15、IL-18およびIL-21を含む、請求項31に記載の方法。
- 刺激する工程で用いられる培地が、さらにTL1Aおよび/またはIL-12を含む、請求項31または32に記載の方法。
- CD30アゴニストを含む、CD3陽性細胞をCD3陽性CD197陽性細胞に維持用キット。
- 抗原結合ドメイン、膜貫通ドメインおよび細胞内シグナル伝達ドメインを含むキメラ抗原受容体であって、該細胞内シグナル伝達ドメインがCD30の細胞内シグナル伝達ドメインまたはその改変体を含む、キメラ抗原受容体。
- 請求項35に記載のキメラ抗原受容体をコードするポリヌクレオチドを含む、核酸。
- 請求項36に記載の核酸を含む、キメラ抗原受容体発現ベクター。
- 請求項37に記載のキメラ抗原受容体発現ベクターを含む、キメラ抗原受容体発現細胞。
- 前記キメラ抗原受容体発現細胞が、CD3陽性細胞である、請求項38に記載の細胞。
- 請求項38または39に記載の細胞を含む医薬。
- 請求項35に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療に使用するための、請求項40に記載の医薬。
- 請求項38または39に記載の細胞を含有してなる、請求項35に記載のキメラ抗原受容体によって認識される抗原を発現する細胞の殺傷剤。
- 請求項35に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療に使用するための、請求項38または39に記載の細胞。
- 請求項35に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防剤又は治療剤を製造するための、請求項38または39に記載の細胞の使用。
- 請求項38または39に記載の細胞を投与することを含む、請求項35に記載のキメラ抗原受容体によって認識される抗原を発現する腫瘍の予防又は治療方法。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021002365-8A BR112021002365A2 (pt) | 2018-08-10 | 2019-08-08 | métodos para produzir uma célula cd3-positiva, para prevenção ou tratamento de um tumor e para manter uma célula cd3-positiva como uma célula cd3-positiva cd197-positiva, célula cd3-positiva, método de cultura para expansão de uma célula cd3-positiva, kits para cultura de expansão de uma célula cd3-positiva e para manter uma célula cd3-positiva como uma célula cd3-positiva cd197-positiva, receptor de antígeno quimérico, ácido nucleico, vetor de expressão do receptor de antígeno quimérico, célula expressando o receptor de antígeno quimérico, medicamento, agente para eliminar uma célula, e, uso da célula. |
SG11202100829SA SG11202100829SA (en) | 2018-08-10 | 2019-08-08 | Method for producing cd3-positive cell |
CA3107421A CA3107421A1 (en) | 2018-08-10 | 2019-08-08 | Method for producing cd3-positive cell |
US17/263,675 US20210301260A1 (en) | 2018-08-10 | 2019-08-08 | Method for producing cd3-positive cell |
EA202190439A EA202190439A1 (ru) | 2019-06-25 | 2019-08-08 | Способ продуцирования cd3-позитивных клеток |
JP2020535880A JP7382603B2 (ja) | 2018-08-10 | 2019-08-08 | Cd3陽性細胞の製造方法 |
AU2019318021A AU2019318021A1 (en) | 2018-08-10 | 2019-08-08 | Method for producing CD3-positive cell |
KR1020217005452A KR20210044231A (ko) | 2018-08-10 | 2019-08-08 | Cd3 양성 세포의 제조 방법 |
MX2021001528A MX2021001528A (es) | 2018-08-10 | 2019-08-08 | Metodo para la produccion de celulas positivas para cd3. |
EP19847695.4A EP3835415B1 (en) | 2018-08-10 | 2019-08-08 | Method for producing cd3-positive cell |
CN201980052874.2A CN112567025A (zh) | 2018-08-10 | 2019-08-08 | Cd3阳性细胞的制造方法 |
IL280323A IL280323A (en) | 2018-08-10 | 2021-01-21 | A method for preparing a cd3-positive cell |
CONC2021/0001701A CO2021001701A2 (es) | 2018-08-10 | 2021-02-11 | Método para la producción de células positivas para cd3 |
JP2023184978A JP2024012413A (ja) | 2018-08-10 | 2023-10-27 | Cd3陽性細胞の製造方法 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018151580 | 2018-08-10 | ||
JP2018-151580 | 2018-08-10 | ||
JP2019-042666 | 2019-03-08 | ||
JP2019042666 | 2019-03-08 | ||
JP2019117878 | 2019-06-25 | ||
JP2019-117878 | 2019-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020032179A1 true WO2020032179A1 (ja) | 2020-02-13 |
Family
ID=69413594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/031390 WO2020032179A1 (ja) | 2018-08-10 | 2019-08-08 | Cd3陽性細胞の製造方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210301260A1 (ja) |
EP (1) | EP3835415B1 (ja) |
JP (2) | JP7382603B2 (ja) |
KR (1) | KR20210044231A (ja) |
CN (1) | CN112567025A (ja) |
AU (1) | AU2019318021A1 (ja) |
BR (1) | BR112021002365A2 (ja) |
CA (1) | CA3107421A1 (ja) |
CO (1) | CO2021001701A2 (ja) |
IL (1) | IL280323A (ja) |
MX (1) | MX2021001528A (ja) |
SG (1) | SG11202100829SA (ja) |
TW (1) | TW202016293A (ja) |
WO (1) | WO2020032179A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048275A1 (ja) | 2021-09-27 | 2023-03-30 | 国立大学法人京都大学 | T細胞の製造方法 |
WO2023149555A1 (ja) | 2022-02-04 | 2023-08-10 | 国立大学法人京都大学 | T細胞の製造方法 |
WO2024071411A1 (ja) * | 2022-09-30 | 2024-04-04 | 国立大学法人京都大学 | iPS細胞から誘導された免疫細胞 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024020365A1 (en) * | 2022-07-18 | 2024-01-25 | The Children's Medical Center Corporation | Methods of t cell differentiation and compositions thereof |
WO2024091676A1 (en) * | 2022-10-28 | 2024-05-02 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for accelerated production of thymic cells from pluripotent stem cells |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003038062A2 (en) | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
JP2005124568A (ja) * | 2003-10-01 | 2005-05-19 | Junichi Masuyama | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 |
WO2007040105A1 (ja) * | 2005-09-30 | 2007-04-12 | Takara Bio Inc. | T細胞集団の製造方法 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP2008035864A (ja) * | 2001-08-15 | 2008-02-21 | Takara Bio Inc | 抗原特異的細胞傷害性t細胞拡大培養方法 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2008118220A2 (en) | 2006-11-28 | 2008-10-02 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
US20080236610A1 (en) | 2004-04-10 | 2008-10-02 | Holger Bartels | Hair Rollers |
WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2008151058A2 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US20090047263A1 (en) | 2005-12-13 | 2009-02-19 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
WO2013075222A1 (en) | 2011-11-21 | 2013-05-30 | University Health Network | Populations of hematopoietic progenitors and methods of enriching stem cells therefor |
US20140255368A1 (en) | 2013-03-11 | 2014-09-11 | Case Western Reserve University | Method of generating tumor-specific t cells |
WO2016076415A1 (ja) | 2014-11-13 | 2016-05-19 | 国立大学法人京都大学 | 多能性幹細胞からt細胞への誘導方法 |
WO2017221975A1 (ja) | 2016-06-23 | 2017-12-28 | 国立大学法人京都大学 | Cd4cd8両陽性t細胞の製造方法 |
JP2018506983A (ja) * | 2015-03-02 | 2018-03-15 | ユーシーエル ビジネス ピーエルシー | レトロウイルスおよびレンチウイルスベクター |
JP2018514204A (ja) * | 2015-04-30 | 2018-06-07 | ユーシーエル ビジネス ピーエルシー | ガンマデルタt細胞受容体(tcr)とキメラ抗原受容体(car)とを発現するt細胞 |
JP2018151580A (ja) | 2017-03-14 | 2018-09-27 | 富士ゼロックス株式会社 | 定着装置及び画像形成装置 |
JP2019042666A (ja) | 2017-08-31 | 2019-03-22 | 日立造船株式会社 | 汚泥濃縮装置の運転方法及び、汚泥濃縮システム |
JP2019117878A (ja) | 2017-12-27 | 2019-07-18 | 株式会社豊田自動織機 | 半導体装置 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6043934B2 (ja) * | 2008-10-31 | 2016-12-14 | 国立大学法人名古屋大学 | 抗原特異的細胞傷害性t細胞の調製キット |
CA2959141A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
EP4091616A1 (en) * | 2015-02-27 | 2022-11-23 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (car) targeting hematologic malignancies, compositions and methods of use thereof |
WO2018135646A1 (ja) * | 2017-01-20 | 2018-07-26 | 国立大学法人京都大学 | CD8α+β+細胞傷害性T細胞の製造方法 |
-
2019
- 2019-08-08 JP JP2020535880A patent/JP7382603B2/ja active Active
- 2019-08-08 CN CN201980052874.2A patent/CN112567025A/zh active Pending
- 2019-08-08 BR BR112021002365-8A patent/BR112021002365A2/pt unknown
- 2019-08-08 MX MX2021001528A patent/MX2021001528A/es unknown
- 2019-08-08 CA CA3107421A patent/CA3107421A1/en active Pending
- 2019-08-08 EP EP19847695.4A patent/EP3835415B1/en active Active
- 2019-08-08 US US17/263,675 patent/US20210301260A1/en active Pending
- 2019-08-08 AU AU2019318021A patent/AU2019318021A1/en active Pending
- 2019-08-08 TW TW108128295A patent/TW202016293A/zh unknown
- 2019-08-08 WO PCT/JP2019/031390 patent/WO2020032179A1/ja unknown
- 2019-08-08 SG SG11202100829SA patent/SG11202100829SA/en unknown
- 2019-08-08 KR KR1020217005452A patent/KR20210044231A/ko unknown
-
2021
- 2021-01-21 IL IL280323A patent/IL280323A/en unknown
- 2021-02-11 CO CONC2021/0001701A patent/CO2021001701A2/es unknown
-
2023
- 2023-10-27 JP JP2023184978A patent/JP2024012413A/ja active Pending
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008035864A (ja) * | 2001-08-15 | 2008-02-21 | Takara Bio Inc | 抗原特異的細胞傷害性t細胞拡大培養方法 |
WO2003038062A2 (en) | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
JP2005124568A (ja) * | 2003-10-01 | 2005-05-19 | Junichi Masuyama | 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物 |
US20080236610A1 (en) | 2004-04-10 | 2008-10-02 | Holger Bartels | Hair Rollers |
WO2007040105A1 (ja) * | 2005-09-30 | 2007-04-12 | Takara Bio Inc. | T細胞集団の製造方法 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP2008283972A (ja) | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
US20090047263A1 (en) | 2005-12-13 | 2009-02-19 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
WO2008118220A2 (en) | 2006-11-28 | 2008-10-02 | Veritainer Corporation | Radiation detection unit for mounting a radiation sensor to a container crane |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2008124133A1 (en) | 2007-04-07 | 2008-10-16 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
WO2008151058A2 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
WO2009006997A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells and their medical use |
WO2009007852A2 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc | Multipotent/pluripotent cells and methods |
WO2009006930A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
WO2013075222A1 (en) | 2011-11-21 | 2013-05-30 | University Health Network | Populations of hematopoietic progenitors and methods of enriching stem cells therefor |
US20140255368A1 (en) | 2013-03-11 | 2014-09-11 | Case Western Reserve University | Method of generating tumor-specific t cells |
WO2016076415A1 (ja) | 2014-11-13 | 2016-05-19 | 国立大学法人京都大学 | 多能性幹細胞からt細胞への誘導方法 |
JP2018506983A (ja) * | 2015-03-02 | 2018-03-15 | ユーシーエル ビジネス ピーエルシー | レトロウイルスおよびレンチウイルスベクター |
JP2018514204A (ja) * | 2015-04-30 | 2018-06-07 | ユーシーエル ビジネス ピーエルシー | ガンマデルタt細胞受容体(tcr)とキメラ抗原受容体(car)とを発現するt細胞 |
WO2017221975A1 (ja) | 2016-06-23 | 2017-12-28 | 国立大学法人京都大学 | Cd4cd8両陽性t細胞の製造方法 |
JP2018151580A (ja) | 2017-03-14 | 2018-09-27 | 富士ゼロックス株式会社 | 定着装置及び画像形成装置 |
JP2019042666A (ja) | 2017-08-31 | 2019-03-22 | 日立造船株式会社 | 汚泥濃縮装置の運転方法及び、汚泥濃縮システム |
JP2019117878A (ja) | 2017-12-27 | 2019-07-18 | 株式会社豊田自動織機 | 半導体装置 |
Non-Patent Citations (56)
Title |
---|
"GenBank", Database accession no. NP _ 954637 |
"Manipulating the Mouse Embryo: A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS |
AKIRA IRIYA ET AL., PROTEIN NUCLEIC ACID ENZYME, vol. 44, 1999, pages 892 |
BAGUISI ET AL., NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 456 |
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310 |
CELL RESEARCH, 2008, pages 600 - 603 |
CELL STEM CELL, DOI:10.1016/J.STEM.2009.05.005, 2009 |
CELL STEM CELL, vol. 4, 2009, pages 381 - 384 |
CIBELLI ET AL., SCIENCE, vol. 280, 1998, pages 1256 |
DANIEL BAUMHOER ET AL., AM J. CLIN PATHOL, vol. 129, 2008, pages 899 - 906 |
GENEE, vol. 17, 1982, pages 107 |
GENETICS, vol. 39, 1954, pages 440 |
HARUAKI YAJIMASHUNPEI SAKAKIBARA: "Seikagaku Jikken Koza (Biochemical Experiment) 1", TANPAKUSHITSU NO KAGAKU (CHEMISTRY OF PROTEINS, vol. IV, 1977, pages 205 |
HUANGFU D.MELTON, DA. ET AL., NATURE BIOTECHNOLOGY, vol. 26, no. 7, 2008, pages 795 - 797 |
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
JOURNAL OF MOLECULAR BIOLOGY, vol. 120, 1978, pages 517 |
JOURNAL OF MOLECULAR BIOLOGY, vol. 41, 1969, pages 459 |
KAARTINEN ET AL., CYTOTHERAPY, vol. 19, 2017, pages 689 - 702 |
KIM JB.SCHOLER HR. ET AL., NATURE, vol. 454, 2008, pages 646 - 650 |
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
LIU S. ET AL., CYTOTHERAPY, vol. 17, 2015, pages 344 - 358 |
M. BODANSZKYM.A. ONDETTI: "Peptide Synthesis", vol. 14, 1966, INTERSCIENCE PUBLISHERS, article "Zoku Iyakuhin no Kaihatsu (A sequel to Development of Pharmaceuticals" |
MILLER: "Journal of Experiments in Molecular Genetics", 1972, COLD SPRING HARBOR LABORATORY, pages: 431 - 433 |
MOL THER, vol. 17, 2009, pages 1453 - 1464 |
NAT. CELL BIOL., vol. 11, 2009, pages 197 - 203 |
NIWA A ET AL., PLOS ONE, vol. 6, no. 7, 2011, pages e22261 |
NOBUO IZUMIYA ET AL.: "Peptide Gosei-no-Kiso to Jikken (Basics and experiments of peptide synthesis", 1975, MARUZEN CO. |
NUCLEIC ACIDS RESEARCH, vol. 9, 1981, pages 309 |
OKITA K ET AL., NAT. METHODS, vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 12 |
OKITA K ET AL., STEM CELLS, vol. 31, no. 3, pages 458 - 66 |
OKITA, K.ICHISAKA, T.YAMANAKA, S., NATURE, vol. 451, 2007, pages 141 - 146 |
PODACK, ECKHARD R. ET AL.: "CD30-Governor of Memory T Cells?", ANNALS NEW YORK ACADEMY OF SCIENCES, vol. 975, no. 1, December 2002 (2002-12-01), pages 101 - 113, XP055685070 * |
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 160 |
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110 |
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1 |
R.K. LINDEMANN ET AL., MOL. CANCER, vol. 2, 2003, pages 20 |
RIDEOUTIII ET AL., NATURE GENETICS, vol. 24, 2000, pages 109 |
SAIBO KOGAKU: "Shin Saibo Kogaku Jikken Protocol", 1995, SHUJUNSHA, pages: 263 - 267 |
SALLUSTO ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 2037 - 2045 |
SCHROEDERLUEBKE: "The Peptide", 1965, ACADEMIC PRESS |
SCIENCE, vol. 122, 1952, pages 501 |
SCIENCE, vol. 324, 2009, pages 797 - 801 |
See also references of EP3835415A4 |
SHI Y.DING S. ET AL., CELL STEM CELL, vol. 3, 2008, pages 568 - 574 |
STEM CELLS, vol. 26, 2008, pages 1998 - 2005 |
TAKAHASHI KYAMANAKA S. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI KYAMANAKA S., CELL, vol. 126, 2006, pages 663 - 676 |
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
VIROLOGY, vol. 52, 1973, pages 456 |
VIROLOGY, vol. 8, 1959, pages 396 |
WAKAYAMA ET AL., NATURE GENETICS, vol. 22, 1999, pages 127 |
WAKAYAMA ET AL., NATURE, vol. 394, 1998, pages 369 |
WAKAYAMA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 14984 |
WEI X. ET AL., J. IMMUNOL., vol. 167, 2001, pages 277 - 282 |
WILMUT ET AL., NATURE, vol. 385, 1997, pages 810 |
YU J.THOMSON JA. ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048275A1 (ja) | 2021-09-27 | 2023-03-30 | 国立大学法人京都大学 | T細胞の製造方法 |
WO2023149555A1 (ja) | 2022-02-04 | 2023-08-10 | 国立大学法人京都大学 | T細胞の製造方法 |
WO2024071411A1 (ja) * | 2022-09-30 | 2024-04-04 | 国立大学法人京都大学 | iPS細胞から誘導された免疫細胞 |
Also Published As
Publication number | Publication date |
---|---|
SG11202100829SA (en) | 2021-03-30 |
AU2019318021A1 (en) | 2021-03-04 |
TW202016293A (zh) | 2020-05-01 |
EP3835415B1 (en) | 2024-09-25 |
CO2021001701A2 (es) | 2021-02-26 |
EP3835415A1 (en) | 2021-06-16 |
MX2021001528A (es) | 2021-04-19 |
JPWO2020032179A1 (ja) | 2021-08-26 |
US20210301260A1 (en) | 2021-09-30 |
JP7382603B2 (ja) | 2023-11-17 |
JP2024012413A (ja) | 2024-01-30 |
KR20210044231A (ko) | 2021-04-22 |
CN112567025A (zh) | 2021-03-26 |
IL280323A (en) | 2021-03-25 |
EP3835415A4 (en) | 2022-10-05 |
BR112021002365A2 (pt) | 2021-05-11 |
CA3107421A1 (en) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7479635B2 (ja) | γδT細胞の製造方法 | |
JP7382603B2 (ja) | Cd3陽性細胞の製造方法 | |
JP7287990B2 (ja) | 治療用分子のt細胞送達のための組成物および方法 | |
JP7450892B2 (ja) | Nk細胞のための人工hla陽性フィーダー細胞株及びその使用 | |
WO2021244486A1 (zh) | 信号转换受体及其用途 | |
TW202122574A (zh) | 含有nef的t細胞及其產生方法 | |
US20230183645A1 (en) | Method for producing regenerated t cells via ips cells | |
US20230000915A1 (en) | T-cell master cell bank | |
JP2022546675A (ja) | 細胞治療の方法 | |
WO2022220146A1 (ja) | T細胞受容体遺伝子を導入するためのiPS細胞により構成される細胞バンク | |
TW202434719A (zh) | Cd3陽性細胞的製造方法 | |
WO2023249071A1 (ja) | T細胞受容体 | |
EA046950B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ γδT-КЛЕТОК | |
WO2024071411A1 (ja) | iPS細胞から誘導された免疫細胞 | |
US20240197872A1 (en) | Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof | |
WO2024022509A1 (en) | Methods for promoting persistence of cell therapy | |
KR20240055714A (ko) | 돌연변이 il-15 조성물 및 이의 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19847695 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020535880 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3107421 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217005452 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021002365 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019318021 Country of ref document: AU Date of ref document: 20190808 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019847695 Country of ref document: EP Effective date: 20210310 |
|
ENP | Entry into the national phase |
Ref document number: 112021002365 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210208 |